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Abstract 
Hypertrophic cardiomyopathy (HCM) is characterised by myocardial hypertrophy, 
fibrosis and abnormal vascular pathology and is usually caused by mutations in 
sarcomeric protein genes. Histological studies and in vivo imaging with cardiac 
magnetic resonance imaging (CMRI) have shown that myocardial fibrosis is an 
important entity that contributes to disease progression. However, little is known 
about the regulation of genes involved in collagen synthesis and metabolism, the 
pathways that contribute to the development of myocardial fibrosis and whether this 
is an early pathological process which ultimately leads to the development of the overt 
phenotype in genetic mutation carriers. Furthermore, the contribution of fibrosis on 
myocardial function has been poorly defined.  
 
In this thesis, I identified that myocardial genetic expression of collagen is upregulated 
in patients with HCM and this is paralleled by elevated levels of procollagen in plasma. 
The genetic expression of transforming growth factor beta (TGF-β) and its 
downstream mediator connective tissue growth factor was also enhanced in HCM and 
correlated with collagen I and III RNA levels, suggesting a central role of TGF-β in 
mediating fibrosis. Plasma markers of collagen synthesis and metabolism were also 
increased in sarcomeric mutation carriers without hypertrophy, suggesting that 
fibrosis may be an early process that contributes to the development of the overt 
phenotype.  
 
Plasma levels of procollagen I were higher in patients with non-sustained ventricular 
tachycardia and focal fibrosis identified by CMRI was associated with impaired systolic 
deformation.  Diffuse fibrosis beyond that seen in healthy controls also correlated 
with a reduction in systolic function.  
 
Together, the findings of this thesis support the hypothesis that myocardial fibrosis is an 
active process in HCM that precedes clinical phenotype. Myocardial fibrosis is at least in 
part mediated by the TGF- β pathway and associated with impaired systolic performance 
and may contribute to arrhythmic risk in HCM.  
	 3	
Impact statement 
 
The findings of this thesis provide further insight into the pathways that drive 
myocardial fibrosis in hypertrophic cardiomyopathy and the impact of fibrosis on 
myocardial dysfunction. The evidence presented in this thesis also lends further 
support to the hypothesis that plasma markers of myocardial fibrosis are elevated in 
patients with HCM and that myocardial fibrosis is an early entity which may precede 
and subsequently contribute to the development of the overt clinical phenotype in 
sarcomeric mutation carriers.  
 
Together these findings could aid in the development of therapies targeted against 
pathways which promote myocardial fibrosis at an early or preclinical stage of the 
disease. The findings of this study may also point to a future role for the measurement 
of plasma collagen biomarkers as a potential screening tool in family members of 
those affected by the disease and also in the monitoring of disease activity, 
progression, response to treatment and potentially risk stratification.   
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1. Introduction 
 
1.1 Definition of hypertrophic cardiomyopathy 
Cardiomyopathies are defined by structural and functional abnormalities of the 
ventricular myocardium that are unexplained by flow-limiting coronary artery disease 
or abnormal loading conditions.1  The European Society of Cardiology (ESC) Working 
Group on Myocardial and Pericardial Diseases proposed an updated classification of 
cardiomyopathies based on morphological and functional phenotypes and 
subcategories of familial/genetic and non-familial/non-genetic disease.1 Hypertrophic 
cardiomyopathy (HCM) is defined by the presence of increased left ventricular (LV) 
wall thickness that is not explained solely by abnormal loading conditions. 2 
1.2 History of disease 
Descriptions of a hypertrophied myocardium in association with sudden death date back 
to the 18th century.3 In the 19th century physicians such as Vulpian and colleagues 
provided clinico-pathological reports of hypertrophic cardiomyopathy and descriptions 
of clinical features that would be compatible with left ventricular outflow tract 
obstruction (LVOTO).4 It was not however until Donald Teare’s landmark paper in 1958, 
that the first modern description of HCM was presented. Eight cases of ‘‘asymmetrical 
hypertrophy (ASH) or muscular hamartoma’’ in young adults were described with 
seven experiencing sudden death. The paper was relevant for both the association of 
left ventricular hypertrophy (LVH) and sudden death (SCD) but also because he 
identified a familial pattern of disease.5  
1.3 Epidemiology and genetic basis of the disease 
 
Hypertrophic cardiomyopathy is the commonest inherited cardiac disease with 
prevalence of 1 in 500 of the general population.6 In most cases, HCM is inherited in an 
autosomal dominant manner and is secondary to mutations in one of 11 genes that 
encode proteins of the cardiac sarcomere: specifically, β-myosin heavy chain (MYH7, 
chromosome 14); myosin-binding protein C (MYBPC3, chromosome 11); cardiac 
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troponin T (TNNT2, chromosome 1); cardiac troponin I (TNNI3, chromosome 19); a-
tropomyosin (TPM1, chromosome 15); a-cardiac actin (ACTC, chromosome 15); 
essential myosin light chain (MYL3, chromosome 3); regulatory myosin light chain 
(MYL2, chromosome 12); cardiac troponin C (TNNC1, chromosome 3); a-myosin heavy 
chain (MYH6, chromosome 14).7 Mutations in contiguous Z -disks and calcium handling 
proteins account for less than 1% of cases.7-9  
 
To date over 1000 mutations in genes encoding sarcomeric proteins have been reported 
in patients with the disease. Mutations in MYH7 and MYBPC3 account for the majority 
of mutation positive cases, whilst mutations in TNNT2, TNNI3, TPM1, ACTC and myosin 
light chains and are thought to account for 10 – 15% of cases.7-10. The combination of 
genetic diversity, heterogeneous clinical phenotypes and inconsistent study design has 
precluded the establishment of precise genotype–phenotype relationships.11 
 
Phenocopies of HCM caused by other genetic and acquired disorders can be broadly 
classified into those associated with metabolic disorders, mitochondrial myopathies, 
neuromuscular disease and infiltrative processes.12 These phenocopies are often 
associated with extra-cardiac manifestations, abnormalities in the conduction 
pathway and cardiac imaging may also demonstrate distinct morphological 
abnormalities. 
 
1.4 Pathological findings 
 
Hypertrophic cardiomyopathy is characterised by distinct histological and morphological 
abnormalities.  
1.4.1 Histology 
 
Histologically, HCM is distinguished by a triad of myocyte hypertrophy, myocyte disarray 
and fibrosis.13 Another common feature is the presence of morphologically distinct 
intramural coronary arteries.14 
 
Myocyte hypertrophy is the hallmark of HCM which is greatest in layers closest to the 
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left ventricular cavity.15 Cardiomyocytes exhibit nuclear enlargement and pleomorphism 
with hyperchromasia with disorganized myofibrillar architecture.13  
 
Myocyte disarray is the loss of normal parallel alignment of myocytes. Although, this is 
not specific to HCM, the presence of more than 5 – 10% by volume is considered specific 
to HCM.16-20  
 
The observed pattern of myocardial fibrosis in HCM is complex and the literature is 
confusing as terminology is not consistent across pathological, imaging and clinical 
studies. Four distinct patterns have been described in HCM including diffuse 
interstitial expansion, perivascular fibrosis, replacement fibrosis following myocyte 
death and plexiform fibrosis associated with myocyte disarray commonly found in the 
septum and at insertion points.21-25 The entity of myocardial fibrosis in HCM is 
explored further in subsequent sections of the introduction.  
 
At necropsy, 83% of individuals with HCM who experienced SCD have morphologically 
distinct intramural coronary arteries characterised by a thickened vascular wall and 
decreased luminal area.14 The vascular wall is characterised by expansion of the 
intimal and medial compartment secondary to proliferation of smooth muscle cells 
and the collagen network.14 26 These vascular changes are not specific to HCM but are 
20 times more prevalent in HCM than in normal controls and their prevalence is similar 
in those with and without a history of chest pain.14 Abnormal small vessels are 
significantly more common in areas of extensive fibrosis and the extent of 
replacement fibrosis has been shown to correlate with small vessel disease.14 27 
 
1.4.2 Left ventricular hypertrophy  
 
The distribution of hypertrophy in HCM is not uniform. The most common distribution 
of hypertrophy is asymmetrical septal hypertrophy (ASH) but other distributions of 
hypertrophy include apical LVH, symmetrical concentric and eccentric hypertrophy.28 29 
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1.4.3 Myocardial architecture 
 
Abnormalities of the myocardial architecture and mitral valve apparatus have been 
associated with HCM. These include the presence of myocardial crypts,30 31 anterior 
mitral valve leaflet elongation,32 33 and abnormal LV apical trabeculae.32 These 
morphological abnormalities may precede the expression of LVH and predict the 
presence of sarcomeric mutation carriage.34  
 
1.5 Pathophysiology of disease 
 
Symptoms in HCM are explained by arrhythmias and exercise intolerance secondary to 
a complex interaction of LVOTO, myocardial dysfunction, and myocardial ischaemia.35 
Figure 1. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
1.5.1 Systolic anterior motion of the mitral valve and left ventricular 
outflow tract obstruction  
 
Systolic anterior motion of the mitral valve (SAM) is the anterior displacement of the 
mitral valve and its supporting structures into the left ventricular outflow tract. The 
extent of SAM is dynamic and can be enhanced by manoeuvres that increase 
Symptoms
Systolic	impairment
Atrial fibrilation
Diastolic	impairment
Left	ventricular	outflow	tract	obstructionIschaemia
Ventricular 
arrhythmias
Energy	metabolism	abnormalities
Figure 1: Mechanisms of symptoms in hypertrophic cardiomyopathy.  
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contractility or reduce afterload and preload. Left ventricular outflow tract 
obstruction is the result of complete SAM resulting in contact between the mitral 
valve and the inter-ventricular septum. Outflow tract obstruction is present in 
approximately one third of patients under resting conditions, with a further one third 
demonstrating latent or provocable obstruction.  
 
Left ventricular outflow tract obstruction is defined as a pressure gradient across the 
left ventricular outflow tract of ≥ 30 millimetre of mercury (mmHg) at rest or 
≥50mmHg with physiological provocation with Valsalva and exercise.12 Systolic 
anterior motion of the mitral valve is often associated with a degree of mitral 
regurgitation, which is posteriorly directed and secondary to a failure of leaflet 
apposition.   
 
Patients with LVOTO describe huge variations in their symptomatic status. Common 
symptoms include dyspnoea, chest pain and syncope, whilst and others with 
obstruction may not describe functional limitations.36 37 The association between 
LVOTO and SCD has been widely debated. Some studies have shown no association 
between obstruction and SCD, whilst others have shown a positive correlation. The 
presence or severity of outflow tract gradient has historically not been considered an 
independent risk factor for SCD. However, the recent 2014 ESC guidelines for 
hypertrophic cardiomyopathy now includes outflow tract gradient in their SCD risk 
stratification model.12 38  
1.5.2 Systolic dysfunction  
 
LV systolic performance is often considered to be hyperdynamic as the measured 
ejection fraction is ‘supra-normal’. However, this partly relates to small internal cavity 
dimensions rather than a true increase in LV contractility. A proportion of individuals 
develop progressive disease characterized by the development of systolic dysfunction 
(ejection fraction (EF) <50%). The prevalence of severe systolic impairment or ‘burnt 
out’ HCM using conventional echocardiographic criteria ranges from 2% to nearly 10% 
39 40. However, the incidence of systolic LV impairment may be much higher as clinically 
	 16	
significant reductions in systolic performance may occur while the measured ejection 
fraction remains within the normal range.41. Regional myocardial performance 
assessed using tissue Doppler and strain imaging is usually reduced and precedes the 
development of overt systolic failure 42 43. End-stage HCM with progressive systolic 
dysfunction develops at all ages, but in the majority of patients the time from onset 
of heart failure symptoms to diagnosis of severe systolic impairment is about 10-15 
years 39. The development of severe systolic heart failure is associated with a poor 
prognosis, with rapid progression to death or transplantation and an overall mortality 
rate of up to 11% per year 39.  
1.5.3 Diastolic dysfunction  
 
In clinical practice, surrogates for diastolic dysfunction include left atrial (LA) 
dilatation, abnormal Doppler indices and raised left ventricular end diastolic (LVED) 
pressures upon invasive assessment.  
 
Diastolic dysfunction is a contributory factor in exercise limitation in HCM 44-46  but 
conventional Doppler indices of left ventricular diastolic function do not correlate with 
symptoms or exercise capacity 47 48 or invasively measured diastolic parameters 49. 
This may be because Doppler velocities are affected by variables independent of 
diastolic function, such as volume loading 50 Characteristically, patients with HCM 
have left ventricular diastolic impairment demonstrated by reduced early diastolic 
(Ea) velocities in the mitral annulus and septum and reversal of the ratio of early to 
late diastolic velocities (Ea/Aa) 51 The transmitral E to lateral Ea ratio has a modest 
correlation with New York Heart Association (NYHA) functional class and exercise 
capacity51 suggesting that other factors including reduced stroke volume response to 
exercise, ventilation/perfusion mismatch, and abnormal peripheral oxygen utilisation 
may also influence exercise capacity. A recent study using magnetic resonance in 64 
patients showed that LV chamber stiffness (determined as the ratio of pulmonary 
capillary wedge pressure (derived from the transmitral E/Ea ratio) to LVED volume) 
was associated with exercise capacity, and was the only significant variable on 
multivariable analysis 52.   
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1.5.4 Myocardial ischaemia 
 
Exertional chest pain is a common symptom in individuals with HCM 53. Individuals 
with HCM also have morphologically distinct intramural coronary arteries which are 
characterised by a thickened vascular wall secondary to proliferation of smooth 
muscle cells 14 26. Several studies have shown that patients with HCM have abnormal 
myocardial perfusion although the exact clinical significance of this remains unclear.54-
59 60-62 
1.5.5 Energy metabolism 
 
The myocardium depends on oxygen for high-energy phosphate production by 
oxidative phosphorylation. In the normal heart, adenosine triphosphate (ATP) is 
produced mostly by the metabolism of free fatty acids (FFA) and carbohydrates, with 
FFA accounting for approximately 70% of total ATP production. In health, FFA 
oxidation is directly related to plasma FFA concentration, whereas glucose and lactate 
uptake are inversely related to plasma FFA levels. When oxygen delivery to the 
myocardium is insufficient to meet the requirements of mitochondrial respiration, 
high-energy phosphate production falls and lactate, the end product of anaerobic 
glycolysis, accumulates. This phenomenon is familiar in ischaemic heart disease, but 
evidence from animal and human studies suggest that HCM is also characterised by a 
reduction in the concentration of high-energy phosphates in the myocardium 63. One 
possible explanation is myocardial ischaemia caused by microvascular dysfunction as 
described earlier. Alternatively it may be the direct consequence of sarcomere protein 
gene mutations on myocardial contractile efficiency 64 
 
Skeletal muscle metabolism and uptake of oxygen are fundamental determinants of 
exercise capacity. Phosphocreatine, is a phosphorylated creatine molecule that can 
anaerobically donate a phosphate group to ADP to form ATP during the initial part of 
intense muscular effort. It has been shown using 31P magnetic resonance that patients 
with HCM carrying a mutation in β myosin heavy chain had elevated 
phosphocreatine:ATP ratio at rest compared to controls and HCM patients with 
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troponin T mutations.65 During exercise both HCM patient groups had a greater 
depletion of phosphocreatine. Furthermore, the recovery of phosphocreatine, a 
marker oxidative metabolic capacity was reduced in the β myosin heavy chain group. 
This data suggests that individuals with HCM have increased dependence on non-
oxidative synthesis of ATP and reduced oxidative capacity 65.  
1.5.6 Atrial fibrillation and thromboembolism 
 
Atrial fibrillation (AF) is common in patients with HCM. Studies have demonstrated a 
prevalence of 22% with a reported annual incidence of 2 – 2.6%. The presence of AF 
is associated with a high burden of thromboembolic complications.66 In a recent study 
of 4,821 patients, 3.6% experienced a thromboembolic complication within 10 years. 
This was strongly associated with the presence of AF and increasing LA dimensions. 
Other associations with AF include age, heart failure symptoms, maximal LV wall 
thickness (MWT) and vascular disease.  
1.5.7 Ventricular arrhythmia and sudden cardiac death 
 
The incidence of SCD in non-athletic individuals with HCM is very low (less than 1% 
per annum).67 Despite the low incidence, the effects of SCD can be devastating with a 
peak incidence in adolescence and young childhood, frequently in the absence of 
warning signs or symptoms. 68  
 
The mechanisms triggering ventricular arrhythmias in HCM is poorly understood. 
However, intraventricular dispersion of myocardial conduction secondary to variable 
cardiomyocyte size, fibrosis and disarray alongside increased myofilament calcium 
sensitivity and abnormal calcium handling are likely to promote electrophysiological 
dysfunction and re-entrant pathways.69-73 Furthermore, myocardial ischaemia 
secondary to abnormal intramural coronary arteries, systolic compression of 
epicardial arteries and an inadequate capillary density relative to muscle mass may 
promote ventricular arrhythmias and in part may explain the association between 
exercise and SCD.74 75  
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1.6 Clinical assessment 
1.6.1 Electrocardiogram 
 
Characteristic changes on the 12-lead surface electrocardiogram (ECG) include LVH, 
repolarization abnormalities and pathological Q waves. Patients with an apical 
distribution of LVH demonstrate characteristic giant T wave inversion in the mid pre-
cordial leads.76 The ECG may also assist in the identification of non-sarcomeric disease; 
for example, low QRS voltage and conduction abnormalities may be a marker of 
amyloid heart disease.77 
 
During ambulatory ECG monitoring, The prevalence of NSVT has been shown to be 
between 20 – 31%, whilst the prevalence of paroxysmal atrial arrhythmias is 37%.68 78 
1.6.2 Echocardiogram 
 
Current diagnostic criteria are based upon the demonstration of LVH with a maximal 
end diastolic LV wall thickness of ≥15mm, which cannot be explained by abnormal 
loading conditions. The presence of mild LVH (≥ 13 – 14mm) may be considered 
diagnostic in the presence of supporting features such as a family history, abnormal 
ECG changes or a pathogenic mutation.12 Right ventricular hypertrophy may be 
observed in up to 30% of affected individuals. 
 
The 2D echocardiogram is used to detect SAM of the mitral valve and Doppler 
echocardiography is used to quantify the left ventricular outflow tract gradient 
(LVOTG) at rest and during provocation manoeuvres. Further assessment in the 
upright position or following exercise should be performed in individuals with 
symptoms but no evidence of LVOTG at rest.79 Associated mitral regurgitation, which 
is often posteriorly directed, can be further assessed.  
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LA dimensions are frequently increased and are an adverse prognostic marker. Most 
individuals demonstrate small LV internal dimensions. The ejection fraction is a 
suboptimal measure of systolic performance in the presence of hypertrophy, and 
deformation imaging using Doppler and speckle tracking frequently demonstrate 
impairment in longitudinal function despite a preserved ejection fraction. Patients 
with progressive myocardial systolic dysfunction may exhibit myocardial thinning, LV 
cavity dilatation and impairment of systolic function with a spontaneous loss of 
LVOTO.39 41 Conventional parameters of diastolic performance and filling pressures 
including assessment of the mitral inflow E:A ratio, deceleration time and transmitral 
E to early diastolic velocity of the lateral wall are routinely performed and often 
demonstrate abnormal filling patterns.  
 
Features such as the presence of biventricular hypertrophy, myocardial speckling and 
thickening of valves and interatrial septum can help in identifying non sarcomeric 
disease such as amyloid heart disease or mitochondrial cytopathy.12  
1.6.3 Cardiopulmonary exercise testing 
 
Cardiopulmonary exercise testing is performed at baseline and is advocated with any 
change in functional status.  HCM is associated with impaired exercise tolerance and 
reduced peak oxygen consumption independently of symptomatic status.80 81 Up to 
one third of individuals may demonstrate an abnormal blood pressure response to 
exercise which has previously been shown to be an adverse prognostic marker.82 83 
Exercise testing may also provide a useful tool in differentiating HCM from an athletes 
heart with physiological hypertrophy.84  
1.6.4 Cardiac magnetic resonance imaging 
 
Cardiac magnetic resonance imaging allows for detailed assessment of myocardial 
morphology and systolic performance. Gadolinium contrast enhanced CMRI also 
allows in vivo estimation of myocardial fibrosis. Late gadolinium enhancement (LGE) 
imaging identifies areas of focal myocardial replacement fibrosis.85-88 Pre-and post-
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contrast T1 mapping provide a method for accurate quantification of extracellular 
volume (ECV). The distribution of LGE, gadolinium (Gd) kinetics and native T1 
relaxation time may help to identify clinical phenocopies of sarcomeric disease 
including cardiac amyloidosis and Anderson-Fabry disease.89-92 The development of 
interstitial fibrosis and expansion of extracellular volume (ECV) alongside subtle 
morphological abnormalities may precede the development of hypertrophy and may 
identify early expression of disease amongst gene carriers and family members. 32 34 93  
 
1.7 General principles of disease management  
1.7.1 Medical management  
 
In patients with symptoms caused by LVOTO, the aim of treatment is to reduce the 
outflow tract gradient. Options include negatively inotropic drugs (β-blockers, 
disopyramide and verapamil), atrio-ventricular sequential pacing, percutaneous 
alcohol ablation of the inter-ventricular septum and surgery. Approximately 60 to 70% 
of patients improve with medical therapy but high doses are frequently required and 
side effects are common 94. Similarly, diastolic characteristics and myocardial 
ischaemia may be improved by reducing heart rate and improving filling time.  
 
At present, pharmacological therapy of systolic heart failure in HCM is initiated only 
when patients develop symptoms or have a reduced ejection fraction. The drugs used 
(angiotensin converting enzyme (ACE) inhibitors (or angiotensin receptor blockers), β-
adrenoceptor blockers, diuretics and digoxin) are identical to those employed in 
patients with dilated cardiomyopathy (DCM), although the effect on prognosis is 
unknown. In patients with paroxysmal nocturnal dyspnoea and chronically raised 
pulmonary pressures diuretics can be effective, but the dose and duration of therapy 
should be minimised particularly in patients with severe diastolic impairment or labile 
obstruction.  
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Anticoagulation 
 
The data supporting the efficacy of anticoagulation with vitamin K antagonism in 
preventing stroke in those with HCM and AF is largely limited to non-randomised 
observational studies. Several studies have demonstrated that anticoagulation lowers 
the incidence of stroke in individuals with HCM and AF. 95-97 In a recent study, patients 
who were found to be in AF at presentation experienced a relative risk reduction of 
55% with VKA treatment. The study found that at an exploratory threshold of 4% risk 
of a thrombo-embolic event over 5 years, the absolute risk reduction and number 
needed to treat for patients in AF was 13% (95% CI 2.1 –24%) and 7.7, respectively. 98 
The role of novel anticoagulants in stroke prevention has yet to be evaluated.  
1.7.2 Management of cardiac dysrhythmia 
 
Implantable cardiac defibrillators (ICD) are indicated for secondary prevention and 
primary prevention of sudden cardiac death in high-risk individuals. Current 
ACCF/AHA and previous ESC guidelines used the presence of the following binary 
clinical parameters to define a risk algorithm: MWT >30mm, the presence of NSVT, 
unexplained syncope, abnormal blood pressure response to exercise (failure to 
augment systolic BP by at least 20mmHg) and a family history of sudden or aborted 
sudden cardiac death.99 100 The presence of multiple risk factors equates with higher 
risk and it is accepted practice to consider the implantation of an ICD in people with 2 
or more risk factors.99-101  
 
This strategy has proved useful in differentiating low and high risk individuals although 
with limited power.101 Additional challenges of this approach also relate to difficulties 
in managing individuals with a solitary risk factor (up to 40%) and inability to provide 
an individualized patient risk.101 To overcome this the ESC has advocated the use of a 
validated risk algorithm based upon age, MWT, LA diameter, peak LVOTG, family 
history of SCD, unexplained syncope and NSVT to provide individualized 5 year risk.12 
38  
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The guidance categorises an individual’s risk as low (<4%, 5 year risk of SCD), 
intermediate (4-6%) and high (>6%). ICD implantation is generally not indicated in 
those with low risk but may be considered in the presence of intermediate risk and 
should be considered in those identified as high risk.12 The insertion of an ICD requires 
close consideration of the life-style, socio-economic status and psychological health. 
Individuals should be counselled regarding potential complications as ICD related 
complication rates are high in HCM with one dataset demonstrating 16% of patients 
received inappropriate therapy and 18% experienced device related complications.102  
 
Symptomatic bradycardia and AV block may be treated with anti-bradycardia pacing. 
However, the development of progressive conduction in HCM should prompt the 
consideration of non-sarcomeric disease such as Anderson Fabry disease or amyloid.77 
The role of cardiac resynchronization therapy has not been systematically evaluated 
in HCM but is often considered in those with a broad QRS and systolic impairment.  
1.7.3 Invasive management of left ventricular outflow tract obstruction 
 
Invasive strategies for the management of LVOTO is indicated in symptomatic 
individuals whose symptoms are refractory to medical therapy. There is no evidence 
to support invasive septal reduction therapy in asymptomatic individuals. 
Right ventricular pacing  
 
Several small trials have shown that sequential atrio-ventricular (AV) pacing with a 
short AV delay may be useful in treating LVOTO by promoting cardiac dyssynchrony.103 
104 The evidence in support of this practice remains inconclusive and the use of 
sequential AV pacing for the management of LVOTO is generally reserved for those 
who are considered unsuitable for other forms of septal reduction therapy, those who 
have concurrent indication for device insertion or to facilitate medical optimization 
with beta blockers or calcium channel antagonist.12 105 
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Surgery 
 
Surgical septal reduction therapy to treat LVOTO involves resection of septal muscle 
distal to the mitral leaflet septal contact point through a retracted aortic valve. The 
surgical resection can be extended to the distal septum in the presence of mid-cavity 
obstruction and concomitant mitral valve surgery can be performed in the presence 
of residual outflow tract obstruction or mitral regurgitation. Long term symptomatic 
improvement can be achieved in above 70% of cases with low mortality and 
complications rates when performed in experienced centres.106-111  
Alcohol Septal Ablation  
 
Alcohol septal ablation (ASA) was developed in the 1990s and involves the selective 
injection of alcohol into an appropriate septal perforator to create a localized 
infarct.112 A meta-analysis of 42 published studies demonstrated that ASA is an 
effective treatment for the management of LVOTO resulting in improved functional 
class and exercise capacity.113 There are no randomized control trial data comparing 
surgical myectomy vs. ASA, but recent meta-analyses have demonstrated that ASA 
and surgical myectomy are comparable in improving functional class and mortality.114 
115 ASA is associated with higher incidence of high degree conduction disease requiring 
the insertion of a pacemaker and residual LVOTG.114 115 
1.7.4 Cardiac transplantation 
 
Cardiac transplantation can be considered in patients with HCM with refractory 
symptoms in the absence of LVOTO. In one case series HCM accounted for 
approximately 5% of cardiac transplants with comparable outcomes to those with 
alternate indications.116 The primary indication for heart transplant is refractory heart 
failure symptoms and evolution to end-stage disease with only a small proportion 
(approx. 5%) requiring intervention for refractory ventricular arrhythmias.116 117  
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2. Myocardial fibrosis in hypertrophic cardiomyopathy   
 
Fibrous connective tissue is formed as part of a reparative or reactive process and 
regardless of the organ involved, common molecular pathways are activated. 
Myocardial fibrosis is influenced by ischaemia, haemodynamic load and 
neurohumoral activation. Although fibrosis is not specific to HCM, histopathological 
studies consistently support a central role in the disease pathogenesis. Fibrosis may 
occur early in the disease and is associated with a worse prognosis but the degree of 
fibrosis in HCM cannot be explained by hypertrophy or disarray alone.  
 
2.1 The extracellular matrix 
 
The cardiac extracellular matrix (ECM) is a complex and dynamic entity composed of 
proteoglycans, glycoproteins, proteases, collagens, growth factors and cytokines, 
cardiac fibroblasts, blood vessels, lymphatic vessels and nerve endings. Modulation of 
these various components facilitates proper mechanical, chemical and electrical 
signalling between cells.118 119 The cardiac ECM provides a structural scaffold to cardiac 
myocytes and vascular structures as well as maintaining normal chamber geometry 
and ventricular function. Beyond its structural role, the ECM facilitates mechanical, 
electrical and chemical signals during homeostasis and cardiac development. Cell 
proliferation, migration, adhesion and changes in gene expression during occur in 
response to physiological stress or injury.118 120 
 
Cardiac myocytes are surrounded by a basement membrane which is composed of 
type IV collagen, alongside laminins, entactin, fibrillin and fibronectin.120 121 The 
interstitial matrix is a network comprised primarily of structural fibrillar collagens I and 
III. The network of collagen fibres is organised in 3 distinct layers: endomysium, 
perimysium and epimysium. The endomysium surrounds individual muscle fibres, 
while the perimysium surrounds groups of muscle fibres; the epimysium encloses 
groups of perimysial bundles.120 Non-collagenous glycoproteins (including fibronectin 
and laminin) and proteoglycans are important in cellular adhesion, cell-cell interaction 
and signal transduction.120  
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The ECM is linked via integrins to the cellular cytoskeleton. Integrins are 
transmembrane receptors, composed of α and β subunits, which serve important 
roles in cellular adhesions, ECM organisation, cellular signalling, proliferation and 
survival.122  In mammals there are 18 α subunits and 8 β subunits, with 24 different 
integrin combinations.123 In myocytes integrin subunits α1, α3, α5, α6, α7, α9, and 
α10 are expressed, while β1 is the cardiac-specific sub-isoform, with some authors also 
detecting expression of β3 and β5 subunits on myocytes. Cardiac fibroblasts (CF), also 
express the integrins α1 β1, α3 β1, α4 β1, α5 β1 and α6β1, but also uniquely express the 
subunits α2 and αv which associates with β1, β3 and β5.124 125  
 
Altered expression of integrins is observed in animal models of myocardial fibrosis, 
infarction and hypertrophy.124-126 In patients with ischaemic cardiomyopathy, levels of 
integrin β1D were reduced compared to controls whilst alterations in the expression of 
cardiac integrins have been demonstrated pre and post device therapy.127-130 The 
diversity of combinations in cardiac integrins and the varied expression through 
development, health, ageing and disease is likely to reflect varied functional roles for 
integrins.125 
 
Cardiac integrins may also play a role in angiotensin II (Ang II) and TGF- β mediated 
fibrosis. Exposure of CF to Ang II results in increased expression of integrins αVβ3 and 
α8β1.131 132 Furthermore, Ang II is a potent inducer of Osteopontin (OPN) which binds 
to a variety of integrins and β1 integrins regulate the angiotensinogen gene in CFs, in 
response to mechanical stretch124 133 Integrin dependent mechanical activation of 
TGF- β has been well described in epithelial cells which contains the αVβ6 integrin 
receptor.124 Epithelial cells are not expressed in the heart, but elevated levels of the 
mesenchymal integrins αVβ5 and αVβ3 have been identified in animal models of fibrotic 
cardiac disease and have been shown to play an important role in controlling human 
myofibroblast differentiation via TGF- β activation.134 Integrin αVβ8, has also been 
shown to activate in a proteinase dependent manner, although its role in cardiac 
fibrosis is yet to be established.135  
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2.2 Fibroblasts and regulation of the extracellular matrix  
 
Cardiac fibroblasts are the major cellular component of the human myocardium. CFs 
are critical in maintaining 
homeostasis of the ECM by 
regulating collagen 
synthesis and degradation. 
Collagen I and III is 
synthesised by CF as a 
procollagen precursor, 
maturation of this precursor 
results in the formation of 
mature collagen and the 
release of amino- and 
carboxy-terminal propeptide 
(PINP/PIIINP and 
PICP/PIIICP) by-products into 
the interstitium and plasma. 
Degradation of mature 
collagen is regulated by matrix metalloproteinases (MMP) which are inhibited by 
tissue inhibitors of metalloproteinases (TIMP). The by-products of collagen 
degradation are carboxy-terminal telopeptides (ICTP/IIICTP), Figure 2.  
 
In response to stress and pro-fibrotic mediators, resident CF undergo transition to the 
active myofibroblast phenotype promoting ECM turnover and collagen synthesis.136 
In addition to resident CF, during periods of cardiac remodelling myofibroblasts can 
also be derived from other cell types including smooth muscle cells, epithelial and 
endothelial cells and circulating bone marrow derived progenitor cells, monocytes and 
fibrocytes.137 138  
 
Figure 2 Collagen metabolism 
Abbreviations: PINP Aminoterminal propeptide of type I 
procollagen, PIIINP Aminoterminal propeptide of type III 
procollagen, PICP Carboxyterminal propeptide of type I 
procollagen, PIIICP Carboxyterminal propeptide of type III 
procollagen, MMP Matrix metalloproteinase, TIMP Tissue 
inhibitors of metalloproteinases, ICTP Carboxyterminal 
telopeptide of type I collagen, IIICTP Carboxyterminal 
telopeptide of type III collagen 
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2.3 Driving factors of myocardial fibrosis in hypertrophic 
cardiomyopathy 
 
Cardiac fibroblasts are under external influence and in response to a variety of stimuli 
including mechanical stretch, ischaemia, oxidative stress and inflammatory mediators 
can undergo transformation to express the myofibroblast phenotype and promote 
collagen accumulation. These stimuli are particularly relevant to the HCM disease 
model and are likely in some part to drive the development of myocardial fibrosis. 
2.3.1 Mechanical stretch 
 
Plasma levels of B-natriuretic peptides (BNP) are markers of myocardial stretch. 
Elevated levels of BNP have been demonstrated in both endomyocardial samples and 
serum of patients with HCM.139-144 The causative mechanism of myocardial stretch 
may relate to raised left ventricular filling pressures and also outflow tract obstruction. 
Furthermore, mutations involving the intrinsic myocardial stretch receptor, the Z 
discs, have been linked to the development of the HCM phenotype.145 146  
2.3.2 Oxidative stress  
 
Markers of oxidative stress are increased in individuals with HCM. Right ventricular 
septal endomyocardial samples from individuals with HCM have shown increased 
expression of major lipid peroxidation product, 4-hydroxy-2-nonenal-modified 
protein - when compared to normal controls and levels correlate with LV dimensions 
and inversely with systolic function.147 Serum levels of 8-isoprostaglandin F, a stable 
marker of oxidative stress, has also been shown to elevated in HCM and highest in 
those with LVOTO.148  
2.3.3 Ischaemia 
 
Myocardial ischaemia is another putative driver of myocardial fibrosis. Myocardial 
ischaemia is likely to be a result of increased myocardial metabolic demands and the 
presence of morphologically distinct and abnormal blood vessels. Histological 
examination may demonstrate features consistent with subacute and chronic 
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ischaemic injury including areas of coagulative necrosis, neutrophilic infiltrate, 
myocytolysis, granulation tissue healing and replacement fibrosis.27 149 150. 
 
Studies examining changes in coronary sinus pH have demonstrated that a proportion 
of patients produce lactate under stress.151-153 In vivo perfusion imaging techniques 
have also demonstrated myocardial ischaemia as a prominent feature in HCM.54-59 
Using positron emission tomography patients with HCM have shown a failure to 
augment myocardial blood flow during coronary vasodilatation, which is most marked 
in the sub-endocardium.60-62 Several studies have also demonstrated an association 
between replacement myocardial fibrosis, impaired myocardial blood flow and 
perfusion defects using CMRI. 62 154-157 
2.3.4 Inflammation 
 
Several markers of inflammation have been shown to be elevated in individuals with 
HCM. The acute inflammatory cytokine interleukin-6 is elevated in patients with HCM 
compared with controls.158 159 Circulating levels of pro-inflammatory cytokine, tumour 
necrosis factor alpha (TNF-a) are also higher in patients with HCM when compared to 
healthy controls, and were found to be highest (although not significantly so) in 
patients with end-stage HCM.159  In a study of patients with obstructive HCM, 
myocardial TNF-a levels were increased at baseline and decreased following non-
surgical septal reduction therapy.160  
 
In a recent study, elevated plasma levels of high sensitivity CRP, interleukin 1β, 
interleukin 1 receptor antagonist, interleukin 6 and interleukin 10 were observed in 
HCM compared to controls. Histological assessment of endomyocardial biopsies 
demonstrated the presence of inflammatory cell infiltrate in 37% of patients and 
correlated with histological fibrosis. Nuclear factor kβ activity was also identified in 
half of the endomyocardial biopsies. Plasma levels of TNFα, high sensitivity CRP and 
interleukin 1 receptor antagonist were shown to correlate with levels of late 
enhancement.161 
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2.3.5 Energy depletion 
 
Myocardial phosphocreatine to adenosine triphosphate (PCr:ATP) ratio is a marker of 
myocardial energy metabolism and can be measured by 31P magnetic resonance 
spectroscopy.  The PCr:ATP ratio has been shown to be reduced in individuals with 
HCM and may precede the development of hypertrophy.162-164 These findings support 
the hypothesis that energy deficiency may be an early driver of the clinical phenotype. 
A recent study evaluating the role of myocardial energy deficiency in HCM suggested 
that energy deficiency contributes to diastolic function and also exercise capacity.165  
 
2.4 Mediators of myocardial fibrosis 
 
Myocardial fibrosis is mediated by a complex interaction of hormones, growth factors 
and proteins, figure 3. Potentially mediators of myocardial fibrosis in HCM are 
discussed in more detail.  
 
Figure 3: Putative mediators of myocardial fibrosis. 
Abbreviations: TGF-β Transforming growth factor beta, ET-1 Endothelin 1, PDGF Platelet derived growth 
factor, BMP-7 Bone morphogenetic protein 7 
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2.4.1 Matricellular proteins 
 
Matricellular proteins are a group macromolecules that are secreted into the 
extracellular matrix that primarily modulate cellular function without serving a 
structural role.166   Although a diverse group of proteins, they share several 
characteristics which include: i) high levels of expression only during development and 
in response to injury; ii) ability to bind to a variety of cell-surface receptors, 
components of the extracellular matrix, growth factors, cytokines, and proteases; iii) 
ability to induce de-adhesion or counter-adhesion and iv) limited involvement in tissue 
homeostasis.166-168 Members of the matricellular protein family include TSP-1, 2 and 
4, secreted protein acidic and rich in cysteine (SPARC or Osteonectin), tenascin C (TN-
C) and X (TN-X), OPN, periostin and members of the CCN family.  
 
Osteopontin 
 
Osteopontin is an arginine–glycine–aspartate-containing adhesive glycoprotein. It is 
not expressed in the healthy myocardium but is upregulated in response to hypoxia, 
injury and volume/pressure overload.169 Transcription is up-regulated by Ang II and by 
other growth factors including TGF-β and fibroblast growth factor-basic (bFGF).170 171 
Osteopontin expression has been shown to be markedly increased in the infarcted 
myocardium.172 In animal models of cardiac hypertrophy and fibrosis, OPN expression 
is markedly upregulated and mediates a cardiac hypertrophy and fibrosis.173 174 Knock 
out animal models have shown a reduction in myocardial fibrosis, hypertrophy and 
accelerated systolic dysfunction in response to stress.169 173 175 In humans, increased 
myocardial expression of OPN in DCM correlates with myocyte hypertrophy, LV 
dilatation, impairment of systolic function and increased levels of type I collagen.176 
Elevated levels of OPN have also been identified in individuals with HCM relative to 
controls and patients with ischaemic heart disease (IHD).177 Plasma levels of OPN have 
been shown to correlate with the severity of heart failure and predict mortality.178  
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CCN Family 
 
The CCN gene family (Cyr61/CTGF/NOV) consists of six members: CCN-1 – 6. Of this 
group, the matricellular protein CCN2 has been most studied and implicated in cardiac 
disease. CCN2 expression is strongly driven by TGF-β partially through Smad 
dependent signalling.179 180  Ang II and ET-1 are also regarded potent inducers of 
CCN2.181 182 Ang II induction of CCN2 appears to be partially dependent on TGF-β and 
treatment of cultured cardiomyocytes and microvascular endothelial cells with anti-
TGF-β neutralizing antibody inhibited Ang II driven CCN2 expression.183 Elevated RNA 
and protein levels of CCN2 have been demonstrated in fibrotic disease in both animal 
models of cardiac disease and humans, including myocardial infarction, diabetes and 
heart failure.180 184 Despite its association with myocardial fibrosis, CCN2 on its own is 
considered a weak promotor of fibrosis, and requires TGF-β and other fibrogenic 
stimuli to produce a sustained and profound fibrotic response.180 185 
SPARC 
 
SPARC (osteonectin/BM-40) is a highly conserved, multifunctional glycoprotein. 
Induction of SPARC is mediated by TGF-β and other members of its family.186 SPARC 
shares a synergistic relationship with TGF-β and can promote TGF-β expression and 
signalling.187 SPARC has also been shown to have an inhibitory role in PDGF, vascular 
endothelial growth factor (VEGF) and fibroblast growth factor (FGF) signalling.188 
SPARC levels in the myocardium are significantly elevated in response to infarction 
and in models of hypertrophy and fibrosis.189-191 SPARC loss has been associated with 
disorganised granulation tissue, impaired scar maturation and with an increased 
incidence of cardiac rupture and heart failure.192 SPARC null mice had reduced 
collagen content in models of hypertrophy and fibrosis.191 
 
Periostin 
 
Periostin is a 90-kDa secreted protein involved in cell adhesion and contains four 
repetitive fasciclin domains. Periostin is expressed in the neonatal heart where it  has 
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a role in fibroblast recruitment and modulation, resulting in maturation of the 
collagenous system.193 194 In the adult myocardium, increased expression of periostin 
in  response to insult is driven by TGF- and bone morphogenetic protein (BMP).195 In 
the infarcted myocardium, periostin has been shown to play an important role in early 
scar formation and protection against acute myocardial rupture but may contribute 
to long term adverse remodelling.196-198 In animal models of hypertrophy, periostin 
was associated with myocardial hypertrophy with loss of function being associated 
with reduced hypertrophy and fibrosis.199-201  Overexpression of perostin has been 
associated with myocardial hypertrophy and also progressive ventricular failure and 
myocardial fibrosis.196 202 203  
Tenascin 
 
Tenascins are a family of highly conserved oligomeric glycoproteins with 4 paralogs 
labelled C, R, X and Win mammals. Tenascin C is the founding member and most 
implicated in cardiac pathophysiology. Tenascin C synthesis can be upregulated by 
environmental factors including hypoxia, mechanical stretch and in response to 
inflammatory cytokines and growth factors including TGF-β and Ang II.204 205 In animal 
models TN-C has been shown to play an important role in myofibroblast recruitment, 
ECM deposition and angiogenesis.167 206-209 Increased expression has been shown in 
human infarcted myocardium, myocarditis and dilated cardiomyopathy.210-213  
Thrombospondins 
 
The thombospondin (TSP) family consist of 5 multifunctional proteins that can be 
divided into 2 subgroups. Subgroup A, contains TSP-1 and TSP-2 which form trimers 
and subgroup B containing TSP -3, -4 and - 5, which are homopentamers. Each 
thrombospondin has a distinct pattern of expression but TSP 1, -2 and -4 have been 
shown to play roles in cardiac fibrosis.214-217 Thrombospondin-1 expression is 
enhanced by the pro-inflammatory cytokines and growth factors including TGF-β, 
PDGF, bFGF, Ang II, tumour necrosis factor (TNF) and interleukin-1 (IL-1).188 218 219 
Thrombospondin-1, is a angiostatic mediator that also plays an important role in TGF-
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β activation and inhibition of MMP activation.220 221 It is upregulated in the infarcted 
and pressure overloaded ventricle and is considered an important mediator of matrix 
preservation and preventing progressive ventricular dilatation.215 222 
Thrombospondin-2 has also been shown to play a role in matrix preservation by 
inhibiting MMPs whilst TSP-4 null animal models have shown accelerated fibrosis 
suggests an anti-fibrotic role.217 223 
2.4.2 Angiotensin II 
 
Angiotensin II is an oligopeptide that is elevated in fibrotic heart disease. Angiotensin 
II has been shown to promote fibroblast proliferation, collagen synthesis, myocardial 
fibrosis and TGF-β synthesis via activation of the angiotensin receptor type 1 (AT-1).214 
224-227 Transforming growth factor-β has been identified as a critical downstream 
mediator of Ang II which via TGF-β/Smad 3 signalling mediates collagen synthesis in 
response.228 Antagonism of AT-1 inhibits the expression of TGF-β1 in models of fibrotic 
heart disease.229 230 In the absence of TGF-β, Ang II does not result in myocardial 
fibrosis and hypertrophy.231 Angiotensin II may further promote myocardial fibrosis by 
promoting the expression of Interleukin-6 (IL-6) and suppression of microRNAs 29b 
and 33a.232-234 
 
In a Troponin T animal model of HCM, treatment with Losartan was shown to reduce 
the collagen volume fraction by 49% which was paralleled by a 50% reduction in the 
expression of collagen 1a(I) and TGF-B1.235 In another aMHC model of HCM chronic 
and early treatment was shown to prevent the development of LVH and fibrosis, 
although in this study the use of Losartan did not reverse established pathological 
remodelling as seen in the previous study.200  
 
The benefits for angiotensin antagonism in human studies have unfortunately been 
conflicting and underwhelming. In a small study involving 23 patients with HCM, the 
addition of valsartan was shown to reduced levels of procollagen I but with no 
differences seen in levels of BNP and procollagen III.236 In another study Losartan 
treatment in patients with non-obstructive HCM resulted in improvement in markers 
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of diastolic function and also a reduction in NT-pro BNP.237 In another study using 
Losartan therapy in HCM identified a signal demonstrating attenuation and even 
regression in some patients of both LV mass and the extent of LGE although no 
differences in the levels of PICP between the control and losartan group were 
noted.238   Other small pilot studies have also conferred a benefit of angiotensin 
antagonism using a angiotensin II receptor antagonist on LV mass, systolic 
performance and exercise tolerance.239 240 However these positive findings were not 
supported in the larger INHERIT trial which demonstrated that Losartan treatment at 
1 year did not result in a difference in LV mass and the extent and de novo occurrence 
of LGE. This study argues against the benefit of angiotensin antagonism in those with 
established disease.241 The role of targeting this pathway in sarcomeric mutation 
carriers with no or early phenotypic expression is in process.   
2.4.3 Endothelin 1  
 
The endothelin group of proteins are well established vasoconstrictors that play a role 
in cardiovascular disease including systemic and pulmonary hypertension. Endothelin-
1 has also been shown to be a mediator of fibrosis which may act downstream of TGF-
β and angiotensin II.185 Endothelin-1 binds to two distinct receptors, ET-A and ET-B, 
which are present in both cardiac fibroblasts and myocytes respectively.242 243 
Endothelin-1 promotes fibroblast proliferation, expression of the myofibroblast 
phenotype and enhance collagen synthesis.243-246 In animal models ET-1 induced 
myocardial fibrosis whilst antagonism of endothelin was served a protective role in 
myocardial fibrosis.247-249 Levels of myocardial and circulating ET-1 are elevated in 
patients with chronic heart failure but long-term antagonism of the endothelin 
receptor does not alter the course of the disease.250 251  
 
2.4.4 Platelet derived growth factor 
 
Four platelet derived growth factors (PDGF A to D) ligands have been identified which 
form homodimers (PDGF-AA, PDGF-BB, PDGF-CC, PDGF-DD) and heterodimers (PDGF-
AB). All forms of PDGF bind to tyrosine kinase receptors, PDGFR a and β. All known 
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PDGF isoforms can generate cardiac fibrosis and hypertrophy when overexpressed 
from cardiomyocytes. However, the degree and location of fibrosis vary between the 
different ligands, which are likely a result of differential activation of the two PDGF 
receptors.252-254 In rodent models of myocardial infarction increased PDGF-A, PDGF-D 
and PDGFR levels are coincident with angiogenesis, and inflammatory and fibrogenic 
responses.255 Levels of PDGF-B and PDGF-C were reduced.255 Similarly, cardiac-specific 
overexpression of PDGF A, C and D, but not PDGF B have been shown to enhance TGF-
β1 transcription and promote the development of cardiac fibrosis.256 In the infarcted 
myocardium, perivascular cells demonstrate activation of the PDGF-B/PDGFR- β 
pathway and may be a potential source of myofibroblast.257 However, in a rodent 
model of ischaemic reperfusion injury, recombinant human PDGF-B upregulated 
messenger RNA expression of anti-mesenchymal transition factor BMP-7.258 
Antagonism of PDGF receptors by Imatinib results in reduced expression of fibrogenic 
mediators including TGF-β, reduced collagen type I expression and scar formation.259  
2.4.5 Transforming growth factor-beta  
 
Transforming growth factor β is a cytokine which exerts a pleotrophic effect on all cell 
types involved in cardiac injury, repair and remodelling. In vitro and in vivo studies 
have established its central role in mediating myocardial fibrosis and hypertrophy.260 
261 Three distinct isoforms of TGF-β (TGF- β1, 2 and 3) exist and exhibit distinct patterns 
of regulation.262 TGF- β1 is the most prevalent isoform in the cardiovascular system 
and much of our knowledge relating to TGF- β and myocardial fibrosis relates to this 
isoform.  
 
Transforming growth factor β is synthesized as a precursor molecule and is 
incorporated into the ECM in a latent form following association with its latency-
associated pro-peptide (LAP) and latent TGF-β1-binding protein (LTBP-1).263 Only a 
small proportion of TGF- β requires activation from its latent state to exert a maximal 
cellular effect.264 TGF- β is activated by TSP-1, integrins, Ang II, proteases including 
MMP2, 9 and plasmin as well as changes in the pH of the local environment.124 220 264-
269 
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Active TGF- β binds to TGF- β  type II receptor (TGF- βR2) which in turn results in the 
recruitment and phosphorylation of TGF- β type 1 receptor (TGF- βR1).270 271 The TGF- 
βR1 is a kinase, and in the case of fibroblasts, it is termed activin-linked kinase 5 (ALK5). 
Subsequent phosphorylation of Smad 2 and 3 by ALK5 results in the formation of 
heterodimers with Smad 4 which can translocate into nucleus and directly promote 
pro-fibrotic gene expression. This process can be inhibited by Smad 7.262 271 272   
 
Independent of Smad mediated transcription, TGF-β activates additional signalling 
cascades including extracellular signal regulated kinase (Erk), c-Jun-N-terminal kinase 
(JNK), TGF-β-activated kinase 1 (TAK1), p38 Mitogen activated protein kinase (MAPK) 
and GTPase pathways.271 The pro-fibrotic actions of TGF- β in part also relate to its 
ability to strongly induce and synergistic interaction with CCN2. Elevated RNA and 
protein levels of CCN2 have been demonstrated in fibrotic disease in both animal 
models of cardiac disease and humans, including myocardial infarction, diabetes and 
heart failure.180 184  
 
A landmark study in 2007, demonstrated that endothelial - mesothelial 
transformation (End-MT) contributed to the development of myocardial fibrosis. The 
authors demonstrated that almost a third of myocardial fibroblasts were of 
endothelial origin. In cultured cells, they identified that the process of End-MT was 
driven by TGF- β and antagonised by BMP-7. Administration of BMP-7 was also able 
to reduce fibrosis via a reduction in End-MT in animal models of fibrosis.273 Parallels 
have identified in renal models of fibrosis.274 
 
Bone morphogenetic protein-7, is a member of the TGF-β superfamily. BMP-7 
signalling is regulated by Smad1, 5 and 8. The final common step involves Smad 4 
regulated translocation into the nuclear envelope.275 Recent studies have shown that 
BMP-7 can attenuate and facilitate reverse remodelling in animal models of AF and 
pressure overload induced fibrosis by antagonising the effects of TGF-β.276 277  
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Studies in HCM have been limited, but have demonstrated that myocardial TGF-β1 
messenger RNA and protein levels were 2.5 and 2.8 times higher in areas of 
hypertrophy relative to non-hypertrophied.278 Individuals with HCM have also been 
shown to demonstrate increased gene expression of TGF-β1 relative to those with 
aortic stenosis, stable angina and dilated cardiomyopathy.279 Elevated TGF-β  in those 
with HCM have been associated with increased brain natriuretic peptide (BNP), higher 
symptomatic status and adverse outcomes.280  
 
2.5 Histological evidence for myocardial fibrosis in hypertrophic 
cardiomyopathy 
2.5.1 Histology 
 
Histological analysis of the myocardium is the gold standard method for identifying 
and quantification of myocardial fibrosis. The observed patterns of myocardial fibrosis 
in HCM are described below.  
 
Replacement fibrosis, is the reactive deposition of collagenous scar in areas of 
myocyte death, figure 4. This type of fibrosis is synonymous with myocyte death 
following ischaemic insult but is also a prominent histological feature in HCM.21 22 The 
replacement scarring may be represented as small discrete foci, but multiple foci, 
confluent zones of fibrosis in the subendocardium and  transmural scar also occur.21 
24 Post-mortem examination of individuals with HCM who experienced sudden death 
revealed that chronic post-necrotic replacement fibrosis was a common finding in the 
absence of significant epicardial disease.27  
 
Diffuse interstitial myocardial fibrosis, is the expansion of the extracellular matrix by 
collagen, figure 4. An eight-fold increase in this form of collagen was identified in 
asymptomatic children and young adults with HCM who suffered sudden death 
compared to normal controls. Expansion of the interstitial compartment was also 
identified in infants and was independent of the organisation of the myocardial 
architecture.23 This study demonstrated that expansion of the interstitial collagen 
network commences at an early stage of the disease and continues during periods of 
	 39	
growth. Interstitial collagen accumulation is more prevalent in the dilating phase of 
HCM.281 This form of fibrosis appears to be predominantly seen in the mid wall of the 
myocardium although there is considerable heterogeneity.23 282 The histological 
evidence suggest that interstitial fibrosis may be an early and potentially reversible 
primary phenomenon that determines clinical phenotype and prognosis.  
 
Excessive collagen accumulation may also be seen surrounding the myocardial vessels, 
(perivascular fibrosis) and also in association with myocyte disarray (plexiform 
fibrosis).21 22 25 The latter is commonly identified in the septum at the insertion points.  	
 
 
Figure 4: Myocardial tissue stained with Azan Mallory trichrome demonstrating 
patterns of myocardial fibrosis (blue). A. Interstital fibrosis B. Replacement fibrosis. 
With permission from Galati et al, 2016.282 
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2.5.2 Techniques for tissue fibrosis quantification 
Dye Staining 	
Histological quantification of collagen can be performed by dye staining cut sections 
of either frozen or paraffin embedded tissue. The collagen volume fraction can be 
determined using automated image analysis software after selecting the region of 
interest. Several dyes have been established in their ability to stain collagen. 
 
Van Gieson’s stain is the most basic stain used for the identification of collagen. The 
combination of anionic dyes used in this technique produces differential binding of 
the dye to tissue components. The picric acid is able to penetrate and stain all the 
components of tissue whilst the larger molecules of fuschin acid is only able to enter 
the porous collagen network and displace the picric acid and ultimately results in the 
collagen network staining red and other components of tissue appearing yellow.  
 
Masson trichrome involves utilisation of three staining dyes with differing colours and 
size to again produce differential staining of tissue contents based upon the 
porousness of each tissue component. The exact composition of the stain can very but 
generally red blood cells, keratin and muscle stain red, cytoplasm and adipose tissue 
staining pink, cell nuclei appear brown or black and collagen appearing either green 
or blue.  
 
Picrosirius red binds to collagen and under bright field microscopy appears red. 
Picrosirius red also exaggerates the bifringency of collagen and under polarised light 
with collagen appearing green, red, orange or yellow on a black background. Some 
studies have shown that the appearance under polarised light may help to 
differentiate collagen type with type I collagen appearing red, orange or yellow and 
type III collagen appearing green.283 Other studies have however demonstrated that 
polarised colours are more reflective of fibre thickness and packing with larger 
collagen fibres appearing bright yellow or orange whilst thinner ones are green.284  
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Hydroxyproline 	
Collagen contains 12.2% w/w hydroxyproline which can be accurately quantified in 
homogenised tissue samples using either a commercially available colorimetric assay 
or by performing reverse-phase high performance liquid chromatography (HPLC).285  
 
To date the majority of studies in HCM which have utilised dye staining methods to 
quantify collagen volume fraction, however given the heterogeneity in the extent and 
distribution of fibrosis seen in HCM this method remains vulnerable to the influence 
of sampling error and may essentially influence the significance of clinical results.286 
Unlike staining methods, quantification of hydroxyproline does not provide any details 
relating to the pattern of collagen deposition but does provide accurate collagen 
quantification for an entire volume of tissue and thus eliminating sampling variability. 
285	
 
2.6 Detection and clinical significance of myocardial fibrosis in vivo 
2.6.1 Collagen biomarkers 
 
Several small-scale studies have evaluated collagen biomarkers in HCM and have been 
inconsistent in their findings.287-294 Ho et al,  provided the most significant study on 
collagen biomarkers in HCM.295 In this study the authors measured differences in 
levels of PICP, MMP-1, TIMP-1 and ICTP between individuals with pathogenic 
sarcomeric mutations with overt disease, subjects with proven pathogenic sarcomeric 
mutations without LVH and controls. Compared to controls those with overt disease 
demonstrated a significant elevation in PICP and its ratio with ICTP. No differences 
were identified in levels of MMP-1, TIMP-1 and ICTP. In those with overt disease there 
was no correlation between collagen biomarkers and clinical parameters including 
LGE.  However, the most significant finding of this paper was the discovery of raised 
levels in PICP in gene carriers without overt LVH or LGE on CMR when compared to 
controls. This finding demonstrates that enhanced collagen synthesis may represent 
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an early clinical manifestation of sarcomeric disease and provide a useful serological 
marker of genetic expression. 
2.6.2 Echocardiography 	
Myocardial scarring is characterised by increased acoustic brightness and integrated 
backscatter imaging was developed as a method to assess tissue reflectivity. 
Integrated backscatter which is calibrated relative to the pericardium and blood has 
been shown to correlate with histological fibrosis in those with myopathic and valvular 
cardiac disease.296-299 In HCM, integrated backscatter was higher in patients compared 
to controls and correlated with histological findings including disarray, interstitial 
fibrosis and myocyte non-homogeneity.300 Calibrated integrated backscatter has also 
been shown to be higher in sarcomeric mutation carriers relative to controls and an 
independent predictor of NSVT in those with the overt phenotype.301 302 Cyclic 
variation in integrated backscatter has previously been used to determine regional 
myocardial function but has been superseded by strain imaging as a clinical utility.303 
2.6.3 Contrast enhanced cardiac magnetic resonance imaging 
 
Contrast enhanced cardiac magnetic resonance (CMRI) imaging allows in vivo 
evaluation of myocardial fibrosis. The contrast agents employed are Gd based bound 
to a chelator such as diethylenetriamine pentaacetic acid (DTPA). Following 
administration into the intravascular compartment, Gd-DTPA can diffuse into the 
interstitial compartment of both normal and abnormal regions of myocardium. Due 
to increased volumes of distribution304-306 and differences in wash-in/washout time 
constants,305 307 abnormal myocardium accumulates higher concentrations of Gd-
DTPA and differences in image enhancement over time identify regions of fibrosis, late 
Gd enhancement (LGE).307  
 
The distribution of late enhancement in the diseased myocardium is not uniform. The 
distribution and extent of myocardial may help to establish an aetiology of both the 
dilated and hypertrophied heart.308 In ischaemic heart disease the presence of LGE 
has been shown to be an predictor of adverse outcomes.309 310 Furthermore, the 
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extent and degree of transmural LGE has been shown to predict a poor response to 
revascularisation, medical therapy and cardiac resynchronisation.311-314 In non-
ischaemic DCM, the pattern of LGE may help to identify the presence of infiltration 
and cardiac involvement as a part of a multisystem disease and the presence of LGE 
in DCM has been shown to be an adverse prognostic marker. In patients with an LVEF 
<35%, the presence of LGE was shown to result in a 8 fold increased risk of 
experiencing a composite end point of a heart failure admission, appropriate ICD 
therapy or cardiac death.315 In another study involving 472 patients, the presence of 
midwall fibrosis was found to be an independent predictor beyond LV function for all 
cause and cardiovascular mortality.316 
 
In the hypertrophied heart, the distribution of LGE and Gd kinetics may help to identify 
clinical phenocopies of sarcomeric disease. The presence of abnormal gadolinium 
kinetics and circumferential sub-endocardial late enhancement is specific to cardiac 
amyloidosis whilst localised posterior wall LGE may be a cardiac feature of Anderson-
Fabry disease.89-92 There is strong correlation between LGE and histological 
replacement fibrosis in HCM, figure 5.86-88 317 Gadolinium enhancement is not uniform 
and an array of patterns have been described in HCM and are likely to reflect the 
morphological varieties of fibrosis described above and varying extent of interstitial 
expansion.318  
 
	 44	
 
 
Figure 5:  Comparison of (a) in vivo diastolic cine image, (b) in vivo gadolinium-
enhanced cardiovascular magnetic resonance, (c) gross specimen of sections from an 
explanted heart, and (d) histologic sections stained with sirius red. Regions of 
gadolinium enhancement correlate with regions of macroscopic unstained pale 
myocardium and regions of red-stained collagen. A representative mesocardial region, 
which is well defined, is marked by an arrow. Figure and caption with permission from 
Moon et al 2004.86 
Techniques for quantification of late enhancement  	
Studies have utilised a variety of techniques for LGE quantification. Techniques for LGE 
quantification including manual quantification (which requires the operator to draw 
regions of interest in areas of LGE) and a variety of thresholding techniques whereby 
the scar is defined at a specific signal intensity above the normal myocardium. The 
defined signal intensity can be set to 2 – 6 standard deviations above the normal 
myocardium or alternatively by using a technique called full width half maximum 
	 45	
(FWHM), whereby the threshold is set to half the maximal signal within an area of 
scar. Flett et al, demonstrated that in their cohort of patients with ischaemic heart 
disease and HCM, LGE volumes were comparable when using manual quantification, 
FWHM, 5 and 6 standard deviation methods. The 2-standard deviation technique 
produced LGE volumes which were almost double those generated by the manual, 6 
standard deviation and FWHM techniques. The FWHM technique was the most 
reproducible, however reproducibility was the worst for the HCM group.319 A 
subsequent study focusing on LGE quantification in patients with HCM concluded that 
although the FWHM technique was the most reproducible, it also resulted in 
consistent underestimation when compared to manual quantification. The authors of 
this study found that thresholding with 3 standard deviations was the most accurate 
with acceptable reproducibility.320   
Clinical Significance of late gadolinium enhancement in hypertrophic 
cardiomyopathy 
 
Several studies have evaluated the clinical significance of LGE upon clinical outcomes. 
In a study published by Maron et al in 2008, 202 patients underwent a CMRI with a 
mean follow up of 681 ± 249 days. The authors identified that the presence of LGE was 
more prevalent in those with HF symptoms and that the extent of LGE was an inverse 
and independent predictor of left ventricular EF. The annualised adverse 
cardiovascular event rate, which included appropriate ICD therapy, SCD and 
progressive heart failure symptoms was not statistically different between those with 
and without LGE.321 
 
A later study from Rubinshtein et al, 2010 included 424 patients who underwent CMRI 
followed by manual LGE quantification. The authors demonstrated that during follow 
up (mean 43 +/- 14 months) 8 patients experienced SCD (n = 4) or appropriate ICD 
therapy (n = 4) and 2 patients experienced heart failure related deaths. All cardiac 
deaths occurred in patients with LGE. LGE remained an independent predictor of ICD 
therapy and SCD after adjustment of other risk factors. Although the presence of LGE 
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was not associated with symptomatic status, LGE was inversely correlated to EF and 
patients with LGE had a higher burden of ectopy and NSVT.322  
 
In the same year, O’Hanlon and colleagues published a study which had enrolled 217 
patients to undergo CMRI with a mean follow up of 3.1 years. The authors used the 
FWHM technique to quantify LGE and demonstrated that LGE was associated with a 
composite primary outcome of cardiovascular deaths, cardiovascular admissions, 
sustained ventricular arrhythmias, appropriate ICD therapy or SCD. The presence and 
extent of LGE was an independent predictor of heart failure related events but did not 
remain an independent predictor for the arrhythmic end point after adjusting for the 
presence of NSVT.88 In the same journal, Bruder et al, also published a follow up study 
of  220 patients who underwent CMRI with a mean follow up of 1,090 days. During 
the follow up period, 20 patients died and 2 experienced appropriate ICD therapy. Six 
patients died of cancer, 9 experienced SCD and 2 died of heart failure. The presence 
of LGE remained a univariate predictor of all cause and cardiac mortality, whilst the 
extent of LGE was associated with SCD and all cause cardiac mortality. The presence 
of LGE remained an independent predictor for all-cause mortality after considering 
the presence of 1-2 conventional risk factors.323  
 
Each of these published studies was limited by a combination of incomplete risk 
evaluation, selection and referral bias as well as differences in scanning protocols. A 
meta-analysis of these studies concluded that LGE was associated with all-cause 
mortality (OR 4.46, CI 1.53 to 13.01, p=0.006), cardiovascular death (OR 2.92, CI 1.01 
to 8.42, p=0.047) and heart failure related death (OR 5.68, CI 1.04 to 31.07, p=0.045). 
A trend for sudden or aborted SCD was observed but statistical significance was not 
reached (OR 2.39, CI 0.87 to 6.58, p=0.091).324   
 
Since the publication of this meta-analysis additional studies examining the influence 
of LGE on long term outcomes have been published. Ismail et al, examined the role of 
LGE in risk stratification. The study followed 711 patients who had undergone CMRI 
for a median follow up of 3.5 years. LGE was quantified by the FWHM technique. The 
authors identified that the extent, but not the presence of LGE was a strong 
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univariable predictor of the primary end-point of sudden or aborted SCD (event rate 
3.1%). Following multivariable analysis, the association between the extent of fibrosis 
and the primary end-point did not remain significant after adjusting for LV-EF. The 
extent of LGE was also found to be a univariable predictor of all-cause mortality but 
again did not remain significant after the adjusting for the influence of LV-EF and 
NSVT.325 A second study by Chan et al which enrolled 1,293 patients identified that 
the presence and extent of LGE by percent LV mass was strongly associated with 
sudden cardiac death (adjusted hazard ratio, 1.46 per 10% increase in LGE; P=0.002) 
and the development of LV systolic dysfunction (adjusted hazard ratio, 1.80 per 10% 
increase in LGE; P=0.03). The authors demonstrated that a LGE burden of >15% of LV 
mass was associated with 2-fold increase in the risk of sudden death and concluded 
that extensive fibrosis was an adverse prognostic marker.326  
A more contemporary meta-analysis of 3,067 patients including the above studies 
concluded that LGE was associated with all cause (OR 1.80, 95% CI 1.21 to 2.67, 
p=0.003) and cardiovascular mortality (OR 2.78, 95% CI 1.41 to 5.47, p=0.003), sudden 
cardiac death (OR 2.52, 95% CI 1.44 to 4.4, p=0.001) with a strong trend being 
observed towards heart failure associated deaths (OR 2.47, 95% CI 0.98 to 6.24, 
p=0.06). Late enhancement in this meta-analysis was both associated with adverse 
cardiovascular outcomes which in part may relate to the inclusion of patients with 
small volumes of fibrosis (<10%) in 5 of the 6 studies utilized.327  
Together, these studies suggest that fibrosis as detected by late enhancement imaging 
contributes the development of LV systolic dysfunction and associated symptoms and 
clinical outcomes. Late enhancement may also serve as a risk marker for SCD and 
overall adverse cardiac outcomes, however its value once other conventional clinical 
parameters including NSVT and EF are accounted for remains questionable.  
Extracellular volume 
 
Cardiac MRI with LGE enhancement has limitations in quantification of fibrosis as it 
fails to detect diffuse fibrosis. Techniques measuring myocardial longitudinal 
relaxation time constant (T1) and its spatial resolution (T1 mapping) pre- and post-
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contrast may overcome this and allow for a true estimation of myocardial ECV.  Several 
methods have been developed to overcome the confounding effect of contrast 
kinetics that alongside advancements in T1 mapping sequences have allowed for more 
robust and clinically applicable whole heart quantification of global ECV. 328-330 ECV 
has been shown to correlate consistently with myocardial collagen fraction assessed 
histologically across a range of cardiac pathologies.286 330-334 Flett et al, evaluated the 
correlation between ECV and histological collagen fraction in patients with HCM 
undergoing surgical myomectomy.286 Using the primed equilibrium contrast CMR (EQ-
CMR) technique, the authors identified a positive correlation between ECV and 
histological myocardial collagen volume. The correlation however was not as strong 
at that observed in aortic stenosis (r2 0.86 versus 0.62) and did not achieve statistical 
significance (p=0.08). The authors postulated that this reflected the heterogeneous 
and patchy nature of cardiac fibrosis in HCM. White et al, subsequently compared the 
EQ-CMR technique and the dynamic equilibration achieved by delayed post-bolus 
imaging upon ECV quantification derived from T1 mapping. The authors found that 
the correlation with histological collagen fraction and ECV using the bolus technique 
(r2 = 0.69, p < 0.01) was comparable to that with EQ-CMR technique (r2 = 0.71, p < 
0.01). Furthermore, the authors found that across a spectrum of health and disease 
that ECV values obtained by both techniques demonstrated a high level of correlation 
but the bolus technique consistently gave a higher value when ECV exceeded 0.4.331  
 
Subsequent evolution of T1 mapping techniques have resulted in the emergence of 
modified Look Locker inversion recovery (MOLLI) pulse sequences and a shortened 
MOLLI (ShMOLLI) pulsed sequence. MOLLI merges images from three consecutive 
inversion recovery experiments and allows T1 determination at the same phase of the 
cardiac cycle providing a more accurate measurement with less heart rate 
dependence. ShMOLLI confers an additional benefit of allow generating rapid and 
high-resolution myocardial T1-maps in a single short breath-hold over only 9 heart 
beats.335 Fontana and colleagues demonstrated that single breath hold T1 mapping to 
quantify ECV using the ShMOLLI protocol was better tolerated amongst patients, 
provided a better correlation with histological collagen volume and trended towards 
a greater reproducibility when compared to a multibreath-hold technique.330 A recent 
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meta-analysis identified 9 studies that have quantified ECV using a range of contrast 
protocols and TI mapping techniques. The pooled r for these nine studies describing 
the overall estimated correlations between collagen volume and ECV was 0.88 (95% 
CI:0.854, 0.914) and was not notably heterogeneous (chi-squared = 7.44, P = 0.489 for 
the Q test and I2 = 0.00%). Together, these studies demonstrate that CMR using T1 
mapping provides a reliable, consistent and reproducible method for ECV 
quantification.336  
 
Sado et al, 2012 evaluated ECV across a variety of cardiac pathologies and healthy 
controls. Cardiac ECV values were found to be similar between controls and patients, 
however the ECV in patients with HCM, DCM and aortic stenosis were comparable and 
significantly higher than in the control population. The amyloid and infarcted 
myocardium had a significantly higher ECV when compared to health and the other 
forms of non-ischaemic cardiomyopathies.337 Extracellular volume has also been 
shown to correlate to age and in patients with heart failure and preserved EF ECV has 
been shown to be a predictor passive LV stiffness.338 339 Extracellular volume is also 
higher in hypertensive patients although only in association with the development of 
LVH.340   
 
In 2013, Ho et al identified that patients with HCM demonstrated a higher ECV than 
controls. Within the HCM cohort those with sarcomeric mutations had a higher 
burden of LGE and elevated ECV even in areas without late enhancement when 
compared to patients in whom sarcomeric mutations were not identified. The authors 
further demonstrated that sarcomeric mutation carriers also had a higher ECV even in 
the absence of LVH when compared to controls, albeit not to the extent seen in those 
with overt disease. Extracellular volume was also found to correlate with NT-ProBNP 
and global E’ velocity.93  
 
The significance of ECV expansion as detected by CMRI on clinical phenotype is yet to 
be fully established. A study involving 45 patients found that ECV was significantly 
associated with parameters of diastolic dysfunction, diastolic strain rate and was 
inversely proportion to peak oxygen consumption.341 Another study demonstrated 
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that in HCM patients with preserved or mildly impaired systolic function, ECV 
correlated with impairment in both peak circumferential strain and early diastolic 
strain rate.342 These studies suggest that expansion of the extracellular compartment 
influences myocardial function. ECV has also been shown to be shown a useful utility 
in identifying individuals at identifying patients considered to be at intermediate or 
high risk of SCD (ESC risk score of >4%). Using a combination of ECV in addition to the 
ESC risk model increased the diagnostic accuracy of identifying patients with syncope 
or NSVT.343 However, in patients considered at high arrhythmic risk that carried ICD’s, 
ECV as quantified by computed tomography did not predict the occurrence of 
malignant ventricular arrhythmia.344 
2.6.4 Computed tomography and myocardial fibrosis 	
The development of multi-detector computed tomography (MDCT) has provided the 
ability to perform tissue characterisation using cardiac CT. Following the 
administration of iodinated contrast agent, delayed enhancement imaging with CT has 
been shown to accurately identify areas of established ischaemic scar on tissue 
histology and late enhancement on CMRI following myocardial infarction.345 346 
Studies in HCM have demonstrated a high burden of late enhancement in those 
considered to be at high arrhythmic risk and correlates with the detection of 
ventricular arrhythmia in those carrying ICDs.347 348 Equilibrium contrast CT can also 
be used to quantify the ECV by measuring pre and post contrast attenuation. ECV 
quantification using this method has good correlation with CMRI based quantification 
of ECV and histological fibrosis across a variety of cardiac disease.349-351 CT provides 
many advantages over CMRI including availability, higher spatial resolution and the 
presence of a linear relationship between attenuation and iodine contrast; however 
the exposure to the radiation and access CMRI limits its clinical utility.352  
2.6.5 Myocardial deformation imaging as a surrogate for myocardial 
fibrosis.  
Speckle tracking echocardiography can be used to assess regional and global 
myocardial deformation. Patients with HCM can demonstrate a reduction in both 
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regional and global longitudinal strain.43 353 Longitudinal impairment of strain has been 
shown to relate to the extent of hypertrophy although several studies have also shown 
an association between the extent of LGE and both regional and global strain. 43 353-362 
In one such study, 48 patients underwent deformation analysis using speckle tracking 
and CMRI with LGE quantification. `The authors found that global longitudinal strain 
was lower in patients whom demonstrated LGE and at a regional level segments with 
LGE had significantly impaired systolic strain. In multivariate analysis including LVMI, 
early diastolic mitral annular velocity and propagation velocity, GLS was the strongest 
independent predictor of the extent of LGE (standard coefficient = 0.627, p = <0.001). 
Furthermore, a GLS of <12.9% was associated with adverse cardiac outcomes.  
Myocardial deformation can also be assessed with CMRI. Myocardial tagging imaging 
can be used to quantify myocardial displacement, strain and strain rates. Studies 
utilising this technique and have demonstrated that patients with HCM have reduced 
myocardial contraction in both areas of hypertrophy and non-hypertrophied areas 
compared to controls.363 364 Patients with HCM have also demonstrated asynchronous 
contraction and a generalised reduction in diastolic strain rate indicative of slow filling 
and diastolic impairment.363 364 Kim et al 2008, found that in 25 patients with HCM 
circumferential shortening as quantified by a myocardial tagging sequence was 
significantly lower in segments that displayed LGE and was more specific to areas with 
a focal nodular pattern of late enhancement relative to areas with poorly defined late 
enhancement.365 Both ECV and LGE have been shown to associate with impairment of 
circumferential strain using myocardial tagging but the significance did not remain 
following inclusion of wall thickness.342  
 
The use of myocardial tagging in daily practice has however been somewhat limited 
due to the complex and time-consuming acquisition and post-processing protocols. 
Feature-tracking CMR overcomes some of these challenges and allows the assessment 
of myocardial motion and strain on routine steady state in free-precession (SSFP) 
imaging which as a routine part of a clinical scan. Unlike echo-based strain imaging 
CMR does not allow tracking of the compact myocardium, however the bloods tissue 
contrast defines the endocardium and provides the ability to track endocardial 
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features through the cardiac cycle. Feature tracking is highly reproducible and has 
been validated against both myocardial tagging and echo strain imaging.366-368 In 
patients with HCM, feature tracking shows good agreement with speckle tracking 
derived longitudinal strain.369 Late enhancement and wall thickness have been shown 
to be independent predictors of attenuated circumferential, radial and feature 
tracking derived longitudinal strain in HCM.370 In this study abnormal global 
longitudinal, circumferential and radial strain were associated with all-cause mortality 
and secondary composite end point of heart failure hospitalisation, ventricular 
arrhythmias and cardiovascular death. In another study both LGE and ECV were shown 
to be a univariable associates of impaired circumferential and radial strain derived by 
feature tracking, a relationship which does not hold true after inclusion of wall 
thickness.342   
 
2.7 Aims of the thesis.  
 
Myocardial fibrosis is a prominent feature in HCM that may precede clinical 
phenotype93 295, contributing to disease progression and clinical outcome. The 
regulation of genes involved in collagen metabolism and the expression of genes 
involved in mediating myocardial fibrosis have yet to be studied at a myocardial level. 
Reverse transcription polymerase chain reaction (RT-PCR) allows generation of 
sensitive, specific and reproducible quantitative data with a wide dynamic range of 
detection. The RT² Profiler™ PCR fibrosis array provides the benefits of RT-PCR and 
combines it with the ability of arrays to profile the expression of a panel of genes 
relevant to a specific pathway. I therefore choose to utilise RT² Profiler™ PCR human 
fibrosis array to answer the following aims:  
 
Aim 1: To investigate myocardial expression of genes involved in collagen metabolism 
in HCM and association with myocardial collagen content. 
 
Aim 2: To determine the myocardial genetic expression of pro-fibrotic mediators. 
- TGF- β and associated signaling cascade in HCM.  
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- Thrombospondins, Endothelin-1, Platelet derived growth factor and connective 
tissue growth factor. 
 
Markers of collagen metabolism have consistently been shown to be altered in 
individuals with HCM. However, correlation between markers of collagen metabolism 
and clinical phenotype have been inconsistent. Furthermore, to date only a solitary 
study has evaluated the expression of collagen biomarkers in those with sarcomeric 
mutations prior to the development of clinical phenotype. I therefore sought to 
evaluate the expression of collagen biomarkers in those with HCM and mutation 
carriers relative to controls. I further aimed to determine a clinical correlation 
between collagen biomarkers and clinical features in a well characterised cohort of 
patients with HCM. 
 
Aim 3: To evaluate plasma markers of collagen metabolism in controls, asymptomatic 
sarcomeric gene carriers and patients with HCM. 
 
Aim 4: To evaluate the relationship between markers of collagen metabolism to clinical 
phenotype in patients with HCM.  
 
Myocardial fibrosis has been shown to be a determinant of progressive systolic 
dysfunction and the development of heart failure. However, the relative contribution 
of myocardial fibrosis in systolic performance is poorly defined. I sought to determine 
the association between myocardial fibrosis to systolic performance using 2D speckle 
tracking imaging.  
 
Aim 5:  To determine the between global and regional longitudinal myocardial 
deformation and left ventricular hypertrophy, replacement fibrosis and interstitial 
fibrosis.  
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3. Methods:  	
3.1 Summary of my role in the project 
 
Together with Professor Perry Elliott, I developed the idea for the research project 
presented in this thesis. I initially obtained ethics (outlined below) to allow the 
collection and storage of plasma and tissue required for the studies presented in 
chapters 4 and 5. I was subsequently responsible for patient recruitment and sample 
(plasma and tissue) collection for all the patients presented in these chapters between 
2010 and 2013. I established the collaborative partnerships that were required for 
performing the plasma and tissue experiments and took responsibility for sample 
preparation and delivery. Data collection, clinical profiling and offline 2D 
echocardiography assessment include strain analysis required for these chapters was 
performed by myself and a second observer where indicated.  Clinical profiling and 
offline analysis of 2D echocardiography including strain analysis relating to the 
patients presented in chapter 6 was performed by myself between 2010 and 2012. 
Statistical analysis presented throughout the thesis was performed by myself.  	
3.2 Funding 	
The work in this thesis was undertaken during my period as a Clinical Research Fellow 
at the Heart Hospital, University College London Hospital. During this period, I was 
funded by Human Genetic Therapies, Shire Pharmaceuticals Ltd 
Hampshire International Business Park, Basingstoke, Hampshire, RG24 8EP, UK. 
 
Additional funding was obtained from the Heart Hospital Charitable grants 
committee, 16-18 Westmoreland Street, London, W1G 8PH, UK for research 
consumables.  
 
This work was undertaken at UCLH/ UCL that received a proportion of funding from 
the U.K. Department of Health’s NIHR Biomedical Research Centre’s funding scheme. 	
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3.3 Ethics  	
3.3.1 Plasma and tissue 
Patients 	
Ethical approval for the plasma and tissue work performed in this thesis was obtained 
from the London Central Research Ethics Committee (REC 11/LO/0913)).  Appendix 2. 
Ethical approval allowed for: 
 
- Tissue samples to be obtained from patients undergoing surgical myomectomy and 
retention of redundant tissue undergoing cardiac surgery and myocardial biopsy for 
protein and RNA expression.  
 
- Blood and urine samples to be collected and stored from patients with HCM and 
gene carriers for biomarker analysis. 
Controls:  
 
Ethical approval for the collection, storage and biomarker analysis of plasma from 
controls was obtained from the London Central Research Ethics Committee (REC 
11/LO/0913)).  Appendix 2. Ethical approval allowed for: 
 
Ethical approval for the experiments performed utilising control tissue was obtained 
from the ethical committee of clinical investigation at Hospital Puerta de Hierro-
Majadahonda, Estudio de los mecanismo moleculares que regulan la insuficiencia 
cardiac: paper del splicing alternative; Principal Investigator: Dr Pablo Garcia Pavia. 
3.3.2 Cardiac MRI: 	
All patients included in chapter 6 had been provided consent for their involvement in 
a study quantifying diffuse myocardial fibrosis using cardiac MRI. Ethical approval for 
	 56	
this study was provided by London Harrow research Ethics Committee (REC 
07/H0715/101); Principle investigator Dr James Moon.  	
3.4 Study Population 
3.4.1 Patient recruitment 	
Tissue: Myocardial tissue from the LV septum was obtained from 24 consecutive 
individuals fulfilling diagnostic criteria for with HCM (MWT thickness ≥ 15mm in the 
absence of abnormal loading conditions or ≥13mm with a first degree relative) 
undergoing surgical myomectomy for the management of LVOTO. There was no 
evidence of obstructive coronary artery disease or significant valvular heart disease. 
All patients were under active follow up at The Heart Hospital, University College 
London, United Kingdom.  
 
Plasma: 113 patients who fulfilled current diagnostic criteria for HCM, (MWT thickness 
≥ 15mm in the absence of abnormal loading conditions or ≥13mm with a first degree 
relative) were recruited at The Heart Hospital, UCLH, London, UK between 28TH July 
2011 and 20th March 2013. Exclusion criteria were previous or co-existing cardiac 
disease (valvular dysfunction greater than grade 2, ischaemic heart disease and 
congenital heart disease), previous cardiac surgery or alcohol septal ablation, history 
of recent trauma (<6 months), malignancy, systemic or inflammatory disease, 
coagulative disorder and uncontrolled hypertension (BP >140/90). 
 
Cardiac MRI: 56 patients had undergone a CMR with quantification of extracellular 
volume at The Heart Hospital, UCLH, London, UK. These patients formed the cohort 
for the study presented in chapter 6.  
3.4.2 Healthy mutation carriers 
	
Plasma: 20 patients with confirmed pathogenic sarcomeric mutations (table 1) and a 
family history of HCM were identified for recruitment between 1st December 2011 
and 19th November 2012. All individuals had mutations in sarcomeric genes and were 
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identified during cascade screening. The mutations were confirmed using Sanger 
sequencing and have been previously published. No individual had a preceding 
medical diagnosis and demonstrated no electrocardiographic or echocardiographic 
features of HCM. 
3.4.3 Controls: 
 
Myocardial RNA: Myocardial tissue was obtained from deceased subjects. The 
modality of death was road traffic accident or suicide (asphyxiation or gunshot), table 
2. The individuals were not known to have a personal or family history of 
cardiovascular disease. Samples were obtained within 24 hours of death and all 
subjects underwent detailed autopsy and no evidence of cardiac disease was 
identified. Methods undertaken for RNA extraction are described below. The samples 
were provided by Dr Pablo Pavia Garcia and Dr Enrique Lara, Hospital Puerta de 
Hierro-Majadahonda,  
 
Table 1: Confirmed pathogenic mutations in the gene carrier group 
 
Case Gene Mutation Case Gene Mutation 
1 MYBPC3 Trp792fs 11 MYBPC3 Glu542Gln 
2 MYH7 Val606Leu 12 MYBPC3 Glu619Lys 
3 TPM1 Glu192Lys 13 MYH7 Arg663His 
4 TNNI3 Ala157Val 14 ACTC Arg314Cys 
5 TPM1 Ala183Val 15 MYH7 Alal797Thr 
6 MYBPC3 Arg502Gln 16 MYH7 Alal797Thr 
7 MYBPC3 Arg502Gln 17 MYH7 Alal797Thr 
8 TNNI3 Ala157Val 18 TNNT2 Arg278Cys 
9 TNNT2 Arg278Cys 19 TNNT2 Arg278Cys 
10 MYBPC3 Glu619Lys 20 MYBPC3 IVS9-1G>C 
MYBPC	3	=	Myosin-binding	protein	C,	MYH7	b	=	Myosin	heavy	chain,	TPM1	=	a-tropomyosin,	TNNI3	=	Cardiac	troponin	I,		TNNT2	=	Cardiac	troponin	T		
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Plasma: 20 healthy controls were recruited between 24th October 2012 and 27th 
February 2013. These were family members and healthy volunteers. Family members 
included for the study did not meet the diagnostic criteria for HCM and tested 
negative for sarcomeric mutations implicated in their family. Healthy volunteers were 
individuals with no active medical problems, medical treatment or family history of 
HCM.  
 
Table 2: Demographics and information of control samples 
 
 
cm = centimetres, kg = kilograms, hrs = hours, g = grams 
 
3.5 Clinical profiling:  	
The following demographics were recorded in all individuals recruited in this study:  - Hospital ID - Sex - Date of birth - Date of recruitment - BP - BMI - Body surface area (BSA) 
 
Participants who were recruited for the studies involving tissue and plasma 
underwent additional clinical profiling to include the following parameters:  - NYHA functional class 
Gender 
Age 
(years) 
Height 
(cm) 
Weight 
(kg) 
Ischaemic 
Time (h) Modality of Death 
Heart 
Weight (g) 
Male 30 165 72 8 Road traffic accident 325 
Female 37 151 52 20 Suicide (Hanging) 250 
Male 17 181 69 17 Suicide (Gunshot) 275 
Male 31 190 115 5 Suicide (Hanging) 533 
Male 47 167 85 10.5 Suicide (Hanging) 361 
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- Medical therapy 
o Beta blocker 
o Calcium channel antagonist 
o Disopyramide 
o Amiodarone 
o Spironalactone 
o Other diuretic use 
o PPAR gamma inhibitors 
o Aspirin  
o Warfarin 
o Statin 
 - Presence of systolic dysfunction defined as EF <55% - History of AF - History of LVOTO (Resting gradient >30mmHg and provocable gradient 
>50mmHg) - Presence of pacemaker or ICD - Risk factor profiling 
o  MWT > 3cm 
o Presence of NSVT (three or more consecutive ventricular extrasystoles 
at a rate of ≥120 beats per minute (bpm)) 
o Abnormal BP response to exercise (Systolic BP drop >20mmHg) 
o Family history of SCD 
o History of unexplained syncope.   
 
3.6 Sample collection and storage 
3.6.1 Tissue  	
Myocardial tissue was collected at time of surgical myomectomy from patient with 
HCM. Tissue was either snap frozen in liquid nitrogen and subsequently stored at -80 
degrees or collected in RNA laterTM and frozen 24 hours later at -80 degrees. Control 
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biopsy samples from the left ventricular free wall were obtained during autopsy. 
Tissue was collected in RNA laterTM and frozen 24 hours later at -80 degrees.  
3.6.2 Plasma 	
Phlebotomy was performed in an upright position. Whole blood was collected into 
commercially available Ethylenediaminetetraacetic acid (EDTA) and lithium heparin 
(LiH) treated tubes. Dietary intake was not modified prior to sampling. Centrifugation 
was performed immediately for 15 minutes at 2,400 x g (5702R centrifuge, Eppendorf, 
Germany). The resulting supernatant was equally aliquoted into 2 clean polypropylene 
tubes (A and B samples) using a Pasteur pipette. Samples were stored at -40°C prior 
to transfer on dry ice for long term storage at -80°C. 
 
Routine laboratory blood sampling for N-terminal pro b-type natriuretic peptide (NT-
Pro BNP), liver function test, full blood count, erythrocyte sedimentation rate, urea 
and electrolytes, creatine kinase (CK) and C-reactive protein (CRP) was performed sin 
patients with HCM and gene carriers. 	
3.7 Echocardiography 
3.7.1 2-Dimensional echocardiography 	
All patients underwent detailed transthoracic echocardiographic examination in 
accordance with current BSE guidelines as a part of routine clinical assessment.371 
Pulsed wave Doppler and tissue Doppler imaging were used to measure mitral valve 
inflow and lateral mitral annular velocities to allow the calculation of the E/EA ratio. 
Left ventricular outflow tract gradient was assessed using continuous wave Doppler; 
LVOTO was defined as a resting LVOTG of ≥30mmHg or ≥50mmHg on physiological 
provocation (Valsalva or exercise). Echocardiograms were analysed offline using 
Echopac PC work- station (GE Medical Systems) by 2 observers (myself and Dr Joel 
Salazar, a cardiologist trained in echocardiography and cardiomyopathy). An average 
over 3 consecutive cycles was utilised for individuals with AF. The following 
parameters were recorded: 
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 - Distribution of LVH - Measurement of maximal left ventricular wall thickness (MWT)  - LA dimensions  
o Parasternal long axis diameter (mm)  
o Area (cmsq) from apical 4 chamber - Left ventricular dimensions at end-systole and end-diastole were measured 
(mm) - Indexed LV mass (g/msq) - EF was calculated using Simpson’s biplane method.   - Fractional shortening (%) - Peak left ventricular outflow tract gradient was measured using continuous 
wave Doppler - Transmitral E:A Ratio - E/Ea Lateral wall  - Severity of valvular dysfunction. 
3.7.2 Strain imaging 
	
Two-dimensional longitudinal strain was assessed retrospectively by two observers 
(myself and Dr Joel Salazar, a cardiologist trained in echocardiography and 
cardiomyopathy) who were blinded to the CMRI data. Apical views with high frame 
rates (range 28-110 fps) were analysed using a speckle-tracking algorithm 
incorporated into an Echopac work- station (GE Medical Systems). The endocardium 
was manually defined in the apical 3 chamber, 2 chamber and 4 chamber acquisitions. 
Automated tracking was performed with manual adjustment of tracked sectors to 
ensure that the myocardium was appropriately defined to achieve optimal tracking 
through the cardiac cycle. End-systole was defined by aortic valve closure in the apical 
3 chamber view. Strain profiles were obtained from the three apical views and a bull's-
eye display of left ventricular myocardial deformation was generated, figure 6. Peak 
longitudinal strain was recorded for each of myocardial segments using a 17-segment 
model to include basal anterior, basal anteroseptum, basal inferoseptum, basal 
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inferior, basal inferolateral, basal lateral, mid anteroseptum, mid inferoseptum, mid 
inferior, mid inferolateral, mid lateral, apical anterior, apical septum, apical inferior 
and apical inferolateral walls and apical cap; global LV longitudinal strain was 
calculated from the mean strain values from each segment. Individuals with imaging 
which was either prohibitive to strain analysis or resulted in greater than a total of 
four segments that failed to track, were excluded from analysis.  
 
Figure	6	Strain	profiles	from	the	apical	3	chamber	view	(A),	apical	2	chamber	view	
(B),	apical	4	chamber	view	(C)	and	a	bull's-eye	display	of	left	ventricular	myocardial	
deformation	(D)	
 
 
3.8 Cardiac MRI 
	
CMRI was performed in a 1.5 Tesla scanner (Avanto, Siemens, Erlangen, Germany). 
Retrospective image for the data presented in chapter 5 and 6 was performed by Dr 
Gaby Captur (chapter 5) and Dr Daniel Sado (chapter 6), cardiologist trained in CMRI 
respectively.  
A B 
C D 
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3.8.1 Pilot All	studies	started	with	single	shot	pilot	images	with	the	following	settings	:	repeat	time	(TR):	3.39ms,	echo	time	(TE):	1.7ms,	slice	thickness,	5mm,	field	of	view	(FOV)	360	x	360mm,	read	matrix	256	and	flip	angle	60o	.		
3.8.2 Cine imaging 
 Steady	state	free	precession	(SSFP)	cine	imaging	was	then	undertaken,	firstly	in	the	long	axis	planes	with	a	short	axis	cut	through	the	aortic	valve.	A	standard	LV	short	axis	stack	was	then	acquired	using	a	slice	thickness	of	7mm	with	a	gap	of	3mm.	Retrospective	ECG	gating	was	used	with	25	phases.	Typical	 fast	 imaging	with	steady	state	precession	(FISP)	imaging	parameters	were	TE:	1.6ms,	TR:	3.2	ms,	in	plane	pixel	size	2.3	x	1.4mm,	slice	thickness	7mm,	flip	angle	60	°	 .	These	settings	were	optimised	accordingly	if	the	subject	was	unable	to	breath	-	hold,	or	had	arrhythmia.	Cine	images	were	acquired	and	used	to	measure	wall	thickness,	left	 ventricular	mass	 and	 chamber	 dimensions.	 EF	was	 calculated	 by	 standard	thresholding	using	CMR	tools. 
3.8.3 Late gadolinium enhancement imaging 	
Intravenous Gadoterate meglumine (gadolinium - DOTA, marketed as Dotarem® 
Guerbet, S.A, France) was then administered as a 0.1mmol/kg dose via a pressure 
injector at a rate of 3ml/sec, with a 25ml normal saline flush. LGE assessment was then 
undertaken using a FLASH IR sequence with slice thickness 8 mm, TR: 9.8ms, TE: 4.6ms, 
α: 21 o , FOV 340 x 220 mm (transverse plane), sampled matrix size 256 x 115 - 135, 
21 k – space lines acquired every other RR interval (21 segments with linear reordered 
phase encoding), spatial resolution 1.3 x 2.1 x 8 mm, no parallel imaging, pre - 
saturation bands over cerebrospinal fluid and any pleural effusions .  
These parameters were optimised according to individual patient characteristics. The 
TI was manually set to achieve nulling of the myocardium between 300 and 440 ms. 
When LGE was observed, images were acquired in phase swap and cross cut to ensure 
artefact elimination. Where the LGE distribution appeared particularly diffuse, a TI 
scout was used to ascertain the specific parts of myocardium with the highest 
	 64	
concentration of gadolinium. If the participant was struggling with the breath - hold, 
FISP imaging or inversion recovery - SSFP imaging (single shot or segmented) was used 
as an alternative sequence.  
LGE quantification was performed using a semi-quantitative method (chapter 5) and 
using the full width at half maximum technique (chapter 6).319 
3.8.4 Extracellular volume 
Myocardial and blood T1 was assessed at baseline and at 15 minutes after the contrast 
bolus in a basal, mid and apical short axis slice using the shortened modified look 
locker inversion recovery sequence (Sh-MOLLI).335 For the ShMOLLI mapping, typical 
setting were: FOV 340 x 340mm, FOV phase 69.8%, flip angle 35o , TR 1095msec, TE 
1.05msec, slice thickness 8mm, 107 phase encoding steps, interpolated voxel 
size=0.9x0.9x8mm, base resolution 193 and phase resolution 100. Acquisition time 
was 206msec for a single image with a cardiac (trigger) delay time (TD) of 500ms; 
where necessary, to avoid misgating, the TD was decreased by 100ms for every 10 
beats per minute above a resting heart rate of 80 beats per minute.  
Blood haematocrit was assessed prior to the CMRI study. This information allows 
calculation of the ECV using the formula: 
 
ECV = (1-haematocrit) x  ΔR1 myocardium 
               -----------------------  
                     ΔR1 Blood 
Where ΔR1 = (1/T1post contrast – 1/T1pre contrast) 
A ROI was then drawn in the mid myocardium of each segment without reference to 
the LGE imaging and ECV was calculated for the basal anterior, basal anteroseptum, 
basal inferoseptum, basal inferior, basal inferolateral, basal lateral, mid 
anteroseptum, mid inferoseptum, mid inferior, mid inferolateral, mid lateral, apical 
anterior, apical septum, apical inferior and apical inferolateral wall using a 16-segment 
model.  
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3.9 Tissue RNA  
3.9.1 Extraction and quantitative polymerase chain reaction 
 
Performed by:  
Tepnel Pharmaceutical Services , Gen-Probe Life Sciences Ltd.  Oaks Business Park,  
Crewe Road, Wythenshawe, Manchester, M23 9HZ  
 
RNA was extracted from 24 HCM tissue samples using the Qiagen RNeasy fibrous 
tissues Mini Kit. Up to 30mg of tissue was used as the input material. The tissue was 
disrupted and homogenised in lysis buffer using the Qiagen Tissuelyser II and stainless-
steel beads. The homogenised samples were incubated for 10 minutes with 
Proteinase K to remove excess protein. The samples were bound to the Qiagen RNeasy 
columns following the standard protocol. The samples were then washed on column 
and genomic DNA was removed using DNase I in an on column digestion. The RNA was 
eluted from the columns in two 30µl aliquots of RNase Free water. 
 
RNA from control tissue (n = 8) was extracted by Dr Enrique Lara, Hospital Puerta de 
Hierro-Majadahonda, Madrid, Spain. The homogenised tissue was not incubated with 
Proteinase K but the methods were otherwise the same. RNA samples where sent on 
dry ice.  
 
All RNA elution’s were quantified by optical density using the nanodrop 
spectrophotometer. The first elution was also run on the Agilent bioanalyzer using 
RNA 6000 nano chips to assess the integrity of the RNA and a RNA integrity number 
(RIN) value was generated where possible.   
 
Quantitative PCR (qPCR) was performed on the extracted RNA using a RT² Profiler™ 
PCR Array, Qiagen, Hilden, Germany. The human fibrosis RT2 profilerTM PCR array 
profiles the expression of 84 key genes involved in dysregulated tissue remodelling 
during the repair and healing of wounds, table 3. 
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3.9.2 Analysis protocol: 	
32 samples were analysed using two- step RT-PCR on the Qiagen RT² Profiler PCR 
Array, Human, Fibrosis 384-well format. Prior to reverse transcription 1µg of RNA was 
treated with genomic DNA elimination solution to remove any residual DNA. The 
treated RNA was converted to cDNA using the Qiagen RT2 First Strand Kit. The cDNA 
was added to the RT² Profiler PCR Array with 2x RT2 SYBR Green Mastermix according 
to the manufacturers protocol and run on the 7900HT real time PCR instrument using 
the cycle times specified in the protocol. Four samples were processed on each array 
one of which being a control sample. The qPCR data was viewed in the 7900HT SDS 
Version 2.3 software and the cycle threshold was adjusted to the optimum point in 
the exponential phase of amplification. The cycle threshold values were exported into 
a Microsoft excel file and reformatted for input into the Qiagen web-based software 
RT2 Profiler PCR Array Data Analysis version 3.5.  
 
From the panel of 84 genes available, I shortlisted the genes involved in collagen 
synthesis and metabolism, genes involved in TGF- β mediated signalling and genes   of 
other established fibrotic mediators.  
 
The following genes involved in collagen synthesis and metabolism were analysed:  
COL3A1 (Collagen, type III, alpha 1), COL1A2 (Collagen, type I, alpha 2), MMP2 (Matrix 
metallopeptidase 2), MMP3 (Matrix metallopeptidase 3), MMP8 (Matrix 
metallopeptidase 8), MMP9 (Matrix metallopeptidase 9), MMP13 (Matrix 
metallopeptidase 13), MMP14 (Matrix metallopeptidase 14), TIMP1 (Tissue  
metallopeptidase inhibitor 1), TIMP2 (Tissue metallopeptidase inhibitor 2), TIMP3 
(Tissue metallopeptidase inhibitor 3), TIMP4 (Tissue metallopeptidase inhibitor 4). 
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Table	3:	The	Human	Fibrosis	RT²	Profiler™	PCR	Array	profiles	the	expression	of	84	key	genes	involved	in	human	fibrosis		
Symbol	 Description	 Symbol	 Description	ACTA2	 Actin,	alpha	2,	smooth	muscle,	aorta	 LOX	 Lysyl	oxidase	
AGT	 Angiotensinogen		 LTBP1	 Latent	transforming	growth	factor	beta	binding	protein	1	
AKT1	 V-akt	murine	thymoma	viral	oncogene	homolog	1	 MMP1	 Matrix	metallopeptidase	1		BCL2	 B-cell	CLL/lymphoma	2	 MMP13	 Matrix	metallopeptidase	13		BMP7	 Bone	morphogenetic	protein	7	 MMP14	 Matrix	metallopeptidase	14		CAV1	 Caveolin	1	 MMP2	 Matrix	metallopeptidase	2		CCL11	 Chemokine	(C-C	motif)	ligand	11	 MMP3	 Matrix	metallopeptidase	3		CCL2	 Chemokine	(C-C	motif)	ligand	2	 MMP8	 Matrix	metallopeptidase	8		CCL3	 Chemokine	(C-C	motif)	ligand	3	 MMP9	 Matrix	metallopeptidase	9		CCR2	 Chemokine	(C-C	motif)	receptor	2	 MYC	 V-myc	myelocytomatosis	viral	oncogene	homolog		
CEBPB	 CCAAT/enhancer	 binding	 protein	(C/EBP),	beta	 NFKB1	 Nuclear	factor	of	kappa	light	polypeptide	gene	enhancer	in	B-cells	1	COL1A2	 Collagen,	type	I,	alpha	2	 PDGFA	 Platelet-derived	growth	factor	alpha	polypeptide	COL3A1	 Collagen,	type	III,	alpha	1	 PDGFB	 Platelet-derived	growth	factor	beta	polypeptide	
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CCN2	 Connective	tissue	growth	factor	 PLAT	 Plasminogen	activator,	tissue	CXCR4	 Chemokine	(C-X-C	motif)	receptor	4	 PLAU	 Plasminogen	activator,	urokinase	DCN	 Decorin	 PLG	 Plasminogen	ET-1	 Endothelin	1	 SERPINA1	 Serpin	peptidase	inhibitor,	clade	A		EGF	 Epidermal	growth	factor	 SERPINE1	 Serpin	peptidase	inhibitor,	clade	E	ENG	 Endoglin	 SERPINH1	 Serpin	peptidase	inhibitor,	clade	H	FASLG	 Fas	ligand		 Smad2	 Smad	family	member	2	GREM1	 Gremlin	1	 Smad3	 Smad	family	member	3	HGF	 Hepatocyte	growth	factor		 Smad4	 Smad	family	member	4	IFNG	 Interferon,	gamma	 Smad6	 Smad	family	member	6	IL10	 Interleukin	10	 Smad7	 Smad	family	member	7	IL13	 Interleukin	13	 SNAI1	 Snail	homolog	1	(Drosophila)	IL13RA2	 Interleukin	13	receptor,	alpha	2	 SP1	 Sp1	transcription	factor	IL1A	 Interleukin	1,	alpha	 STAT1	 Signal	transducer	and	activator	of	transcription	1,	91kDa	
IL1B	 Interleukin	1,	beta	 STAT6	 Signal	 transducer	 and	 activator	 of	 transcription	 6,	interleukin-4	induced	IL4	 Interleukin	4	 TGF-β1	 Transforming	growth	factor,	beta	1	IL5	 Interleukin	5		 TGF-β2	 Transforming	growth	factor,	beta	2	ILK	 Integrin-linked	kinase	 TGF-	β3	 Transforming	growth	factor,	beta	3	
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INHBE	 inhibin,	beta	E	 TGF-βR1	 Transforming	growth	factor,	beta	receptor	1	ITGa1	 Integrin,	alpha	1	subunit	 TGF-βR2	 Transforming	growth	factor,	beta	receptor	II		ITGa2	 Integrin,	alpha	2	subunit	 TGIF1	 TGF-β-induced	factor	homeobox	1	ITGa3	 Integrin,	alpha	3	subunit	 TSP-1	 Thrombospondin	1	ITGaV	 Integrin,	alpha	V	subunit	 TSP-2	 Thrombospondin	2	ITGβ1	 Integrin,	beta	1	subunit	 TIMP1	 TIMP	metallopeptidase	inhibitor	1	ITGβ3	 Integrin,	beta	3	subunit	 TIMP2	 TIMP	metallopeptidase	inhibitor	2	ITGβ5	 Integrin,	beta	5	subunit	 TIMP3	 TIMP	metallopeptidase	inhibitor	3	ITGβ6	 Integrin,	beta	6	subunit	 TIMP4	 TIMP	metallopeptidase	inhibitor	4	ITGβ8	 Integrin,	beta	8	subunit	 TNFa	 Tumour	necrosis	factor	alpha	JUN	 Jun	proto-oncogene	 VEGFA	 Vascular	endothelial	growth	factor	A			 	
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The following genes involved in TGF-β mediated signalling were analysed:  
TGF-β family, associated proteins and receptors: TGF-β1 (Transforming growth factor, 
beta 1), TGF-β2, (Transforming growth factor, beta 2), TGF-β3 (Transforming growth 
factor, beta 3), BMP7 (Bone morphogenetic protein 7), LTBP1 (Latent, transforming 
growth factor beta binding protein 1), TGF-βR1 (Transforming growth factor, beta 
receptor 1) and TGF-βR2 (Transforming growth factor, beta receptor 2) 
 
Smad Signalling cascade: Smad2 (Smad family member 2), Smad3 (Smad family 
member 3), Smad4 (Smad family member 4), Smad6 (Smad family member 6) and 
Smad7 (Smad family member 7) 
 
Cardiac integrins: ITGaV (Integrin, alpha V), ITGβ3 (Integrin, beta 3), ITGβ5 (Integrin, 
beta 5). 
 
The following pro-fibrotic mediators were also analysed:  
- CCN2(Connective tissue growth factor) 
- TSP-1 (Thrombospondin 1) and TSP-2 (Thrombospondin-2) 
- PDGF-A (Platelet-derived growth factor alpha) and PDGF-B (Platelet-derived 
growth factor beta) 
- ET-1 (Endothelin-1)		
3.10 Tissue collagen quantification 	
In this study we elected to measure the levels of hydroxyproline as a marker of tissue 
collagen. Given the heterogeneous and patchy nature of fibrosis seen, this was 
considered the most accurate mean of determining total collagen myocardial collagen 
content eradicating any potential bias introduced by tissue sampling inherent to 
staining methods. We collaborated with Dr Chris Scotton, Principal Research Fellow 
based in the Centre for Inflammation and Tissue Repair, who had considerable 
experience and expertise in performing HPLC for hydroxyproline quantification. Tissue 
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preparation and HPLC was performed using an established protocol (detailed below) 
at University College London, Rayne Institute, 5 University Street, London WC1E 6JF. 
3.10.1 Protocol 	
Total myocardial collagen was determined by measuring hydroxyproline content in 
aliquots of pulverised myocardial. Collagen contains 12.2% w/w hydroxyproline, 
which is detected and quantified by reverse-phase high performance liquid 
chromatography (HPLC) of 7-chloro-4-nitrobenzo-oxa-1,3-diazole (NBD-Cl) -
derivatised acid hydrolysates. Hydroxyproline is a secondary amino acid that reacts 
with NBD-Cl to generate a chromophore detected at 495 nm wavelength. The 
specificity of the reaction is further ensured by keeping the derivatisation time to 20 
minutes at 37°C, a time-point that has been confirmed experimentally to be maximal 
for up to 20 mmol hydroxyproline.         
 
For each sample, approximately 20 mg of myocardial powder was weighed and 
hydrolysed in 2 ml 6 M hydrogen chloride (HCl) for 16 hours at 110°C in a Pyrex tube. 
Hydrolysates were decolourised with activated charcoal, filtered through 0.65 μm 
filter (Millipore Ltd., UK) and diluted 1 in 50. Aliquots (200 μl) of diluted hydrolysate 
were transferred to a microfuge tube and evaporated to dryness under vacuum on a 
Speedvac (Thermo Electron Corporation, UK). The resulting residue was reconstituted 
in 100 μl HPLC-grade water, buffered with 100 μl of 0.4 M potassium tetraborate (pH 
9.5) and reacted with 100 μl 36 mM NBD-Cl (in methanol) to a final concentration of 
12 mM NBD-Cl. The samples were then incubated in a hot block at 37°C for 20 minutes. 
The reaction was stopped by addition of 50 μl 1.5 M HCl. At this point 150 μl of 3.33x 
buffer A as described below was also added. Samples were then filtered through an 
HPLC low dead-volume filter (0.22 μm, Millipore Ltd., UK) into a polypropylene insert 
within an Amber Snap Seal vial (Laboratory Sales Ltd., UK). These vials were then 
loaded onto the HPLC apparatus and the samples were sequentially injected onto the 
HPLC column and eluted with acetonitrile gradient.  
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Chromatography conditions  
 
The HPLC apparatus used for measurements was Agilent series 1100 (Agilent 
Technologies, USA) with a reverse-phase cartridge column (LiChroCART LiCrospher, 
250mm length x 4 mm diameter, 5 μm particle size, 100 Rp-18; BDH/Merck, UK) 
protected by a directly coupled pre-column (LiChrosorb 4 mm x 4 mm, 5 μm particle 
size, 100 Rp-18; BDH/Merck, UK). The column was continuously maintained at 40°C in 
a heated column oven. At the beginning of each batch of samples, the HPLC system 
was equilibrated in running buffer A for minimum of 40 minutes. Hydroxyproline 
standards (50 pM, Sigma) were processed alongside the samples and inserted at equal 
intervals throughout the run. NBD-Cl-treated samples and standards were individually 
injected onto the column and eluted with an acetonitrile gradient, which was achieved 
by changing the relative proportions of running buffers A and B over time.  
 
Post-column detection was achieved by monitoring absorbance at 495nm using a 
flow-through variable wavelength monitor. Hydroxyproline elutes as a discreet peak 
between five and seven minutes following sample injection on the column, between 
glutamine (3.5 minutes) and serine (seven to nine minutes). The column running and 
regeneration time for each sample was 25 minutes.  
 
The hydroxyproline content in each sample was determined by comparing peak areas 
of individual sample chromatograms with the average of the standard peak areas. This 
value represents the hydroxyproline level in the fraction of the acid hydrolysates of 
the pulverised myocardial and was used to calculate total myocardial collagen based 
on the hydroxyproline content of collagen, dilution factors at the processing steps, the 
weight of myocardial powder and the total myocardial weight. 
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3.11 Biomarker analysis 
3.11.1 Initial experiments performed in Naples 
 
Initial efforts to quantify levels of PICP, PIIINP, ICTP, MMP1, MMP2, MMP9 and TIMP1 
were performed as a part of collaborative project with Dr Giuseppe Limongelli, 
Monaldi Hospital, AO Colli, Second University of Naples, Naples, Italy.  
 
In preparation for the experiments I sourced the following ELISA kits using 2B Scientific 
Ltd, UK: 
 
Source: Antibodies-online 
PICP: Code ABIN414990 
PIIICP: Code ABIN414778 
 
Source: Biovendor Research and Diagnostic Products, Czech Republic.  
TIMP 1: Code RBMS2018R 
MMP 1: Code BBT0458R 
MMP 2: Code BBT0459R 
MMP 9: Code RBMS2016/2R 
 
Source: USCN Life Sciences Inc, USA 
ICTP: E90665Hu 
 
Samples were couriered on dry ice alongside the ELISA kits to Naples using World 
Courier, USA. The experiments were subsequently conducted by Dr. Valeria 
Maddaloni, Medical genetics specialist, Department of Cardiothoracic and Respiratory 
Sciences, Monaldi Hospital, AO Colli, Second University of Naples, Naples, Italy. 
Following completion of the experiments it became apparent that the samples had 
been incorrectly processed resulting in sample concentrations which differed by 10 – 
100-fold relative to previously published results. The source of the error was not 
identifiable, and the results were therefore considered unreliable and decision to re-
run the experiments using the stored B samples was taken.   
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3.11.2 Re-run of experiments with KingsPath 	
Once the decision to re-run the experiments was made, competitive quotes were 
sought from industry and a decision to run the experiments with KingsPath was made. 
The B samples were transported on dry ice and biomarker analysis was performed at 
KingsPath, King’s College London, Bessemer Wing, Denmark Hill, London, SE5 9RS, UK. 
The following markers of collagen metabolism were measured in serum using 
commercially available kits: 
 
C terminal telopeptide of type 1 collagen (ICTP): Levels were measured in EDTA plasma 
using a competitive radioimmunoassay (RIA) assay manufactured by Orion 
Diagnostica, Finland. The minimal detectable level was 0.4ug/L. 
MMP1: Levels were measured in EDTA plasma by Quantakine ELISA kit distributed by 
R & D systems, Europe. Minimal detectable level of 0.021ug/L. 
MMP3: Levels were measured in EDTA plasma by Quantakine ELISA kit distributed by 
R & D systems, Europe. Minimal detectable level of 0.009ug/L. 
MMP9: Levels were measured in EDTA plasma by Quantakine ELISA kit distributed by 
R & D systems, Europe. Minimal detectable level of 0.156ug/L. 
Carboxy-terminal propeptide of procollagen type I (PICP): Levels were measured in 
EDTA plasma by sandwich enzyme linked immunosorbent assay (ELISA) KIT 
manufactured by USCN Life Science Inc, Democratic Republic of China). The minimal 
detectable level of 26.6pg/mL. 
Amino terminal peptide of type III procollagen (PIIINP): Levels were measured in EDTA 
plasma using a competitive radioimmunoassay (RIA) assay manufactured by Orion 
Diagnostica, Finaland. The minimal detectable level was 0.3ug/L. 
Tissue inhibitor of metalloproteinases 1 (TIMP-1): Levels were measured in EDTA 
plasma by Quantakine ELISA kit distributed by R & D systems, Europe. Minimal 
detectable level of 0.08ug/L. 
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3.12 Statistics: 	
3.12.1 General statistics 	
Statistical comparisons were carried out using either SPSS Statistics, version 21.0 (IBM, 
USA) or Analyse-it (version 2.26, Analyse-it software Ltd, Leeds, UK). A p value <0.05 
was considered significant in all analyses.  
Continuous data that were normally distributed either pre- or post-logarithmic 
transformation are expressed with mean and s.d. Non-normally distributed data were 
expressed as median and interquartile range (IQR). Categorical variables are shown as 
frequencies and percentages. Comparisons between groups were performed using 
independent T test (parametric data) or Mann Whitney U test (non-parametric data). 
Frequencies were compared using Fisher’s exact test. Correlations were quantified by 
simple linear regression with Pearson (parametric) or Spearman (non-parametric) 
correlation.  
Multivariable analysis with backward elimination was used to identify predictors of 
echocardiogram-derived strain in chapter 6. The model included factors that were 
considered predictors of global strain rate, including age, LVMI (CMRI derived), global 
LGE % and ECV.  
To assess the association between regional wall thickness and regional ECV to regional 
longitudinal strain in chapter 6, we utilised a mixed effect model to account for data 
correlation arising from related outcome measures being obtained from subjects.  
3.12.2 Analysis of RNA data 
 
The Microsoft excel file containing the cycle threshold values obtained from the qPCR 
analysis was uploaded to the Qiagen web-based software RT2 Profiler PCR Array Data 
Analysis version 3.5. The control and disease groups were pre-selected. β2-
Microglobulin was selected as the housekeeping gene. The software generates the 
following:  
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Average Ct, defined as the number of cycles required for the fluorescent signal to cross 
the threshold  
 
Delta Ct : Ct for the gene of interest (GOI) – Ct for the housekeeping gene (HKG) 
 
Delta-Delta Ct: Average Ct disease – Average Ct control  
 
Fold change = Describes the relative change in quantity between the disease group 
and controls and is calculated by 2(-Delta-Delta Ct).  
Fold regulation: For genes which are upregulated with a fold change of greater than 
1, the fold regulation value will be numerically identical. The software transforms fold 
change values less than 1 (down regulated) by returning the negative inverse ( i.e. -
1/fold change). Thus, if gene X has a fold change value of 0.2, this is the equivalent of 
having a fold regulation of - 5-fold.  
P value: The p values are calculated based on a Student’s t-test of the replicate 2^(-Delta 
Ct) values for each gene in the control group and treatment groups, and p values less 
than 0.05 are considered significant. 
 
To allow intra-group analysis of RNA expression for each mediator in the HCM group, 
the relative regulation of RNA for each HCM sample was normalised to the control 
groups.  
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4. Genetic regulation of myocardial fibrosis in hypertrophic 
cardiomyopathy 
 
4.1 Background: 
 
Despite elucidation of the genetic basis of HCM, the mechanisms underlying 
development and progression of the clinical phenotype are poorly understood. 
Although numerous pathological triggers can result in myocardial dysfunction, 
myocardial fibrosis is likely to be one common final pathway responsible for 
progressive ventricular remodelling.  Despite a growing body of evidence highlighting 
the entity of myocardial fibrosis in HCM and its role in clinical phenotype the pathways 
responsible for myocardial fibrosis have yet to be elucidated. The role of pro-fibrotic 
mediators and their association with myocardial fibrosis has yet to be evaluated in 
patients with HCM, A large number of mediators have been shown to role in 
promoting and regulating myocardial fibrosis however it is widely accepted that TGF-
β mediated signalling has a central role in mediating myocardial fibrosis in 
cardiovascular disease. Elevated expression of TGF-β has been demonstrated in 
patients with HCM, however, to date the genetic regulation of TGF-β and factors 
which are responsible for regulating TGF-β controlling its signalling cascade in 
mediating myocardial fibrosis in the HCM myocardium has yet to be evaluated.278 
 
In this study we sought to utilise a multiplex approach to examine the genetic 
regulation of pathways associated with fibrosis with a central focus on TGF-β in a well 
characterised cohort of patients undergoing myomectomy. We aimed to compare 
RNA expression of TGF-β, its associated proteins and other recognised mediators of 
fibrosis in the HCM myocardium relative to controls and their association with 
myocardial collagen content.  
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4.2 Aims:  
 
1: To investigate myocardial expression of genes involved in collagen metabolism in 
HCM and association with myocardial collagen content. 
2: To determine the myocardial genetic expression of pro-fibrotic mediators. 
 
4.3 Results: 
 
The final study cohort comprised 22 HCM samples and 5 controls. Prior to analysis 2 
HCM samples were excluded as the patients had undergone previous ASA and 3 
controls were excluded due to the presence of RNA degradation. The modality of 
death, ischaemic time and weight of the heart for the controls are shown in table 2.  
 
4.3.1 Demographics 
 
The HCM cohort was comprised of 12 males (55%) and 10 females (45%), whilst the 
control group consisted of 4 males (80%) and 1 female (20%). The HCM group was 
significantly older (47 ± 12 vs. 32 ± 11 y, p=0.02) than the controls group but with a 
comparable BMI (29 ± 5 vs. 27 ± 5 kg/m2, p=0.37), table 4. In the HCM group the mean 
MWT was 19.5 ± 4mm and the mean LVOTG was 113 ± 25 mmHg. The mean FS was 
40 ± 8 %. LA and left ventricular cavity dimensions are shown in table 4. Results of 
tissue RNA regulation are shown in table 5 and figure 7.    
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Table 4 Demographics of the study cohort 
  HCM           Controls           p value 
n 22           5             
Male 12 (54.6%)           4 (80%)           0.3 
  Mean s. d Min Max Median IQR Mean s. d Min Max Median IQR p value 
Collagen* 13.51 8.08 7.3 46.9 11.2 9.48- 15.03               
Age (yrs) 47 12 24 68 49 36 - 55 32 11 17 47 31 24 - 42 0.02 
BMI (kg/msq) 29 5 21 46 28 26 - 31 27 5 21 32 26 22 - 31 0.37 
MWT (mm) 19.5 4 14 29 18.5 17 - 22               
LVOTG (mmHg) 11 25 64 177 108 98 - 123               
LA (mm) 45 7 32 59 45 39 - 51               
LVEDD (mm) 45 5 34 56 45 42 - 48               
LVESD (mm) 27 5 19 38 28 22 - 30               
FS (%) 40 8 28 59 40 34 – 45               
E/A 1.49 0.81 0.63 4.29 1.26 1.05 - 1.63               
 
HCM = Hypertrophic cardiomyopathy, s.d = standard deviation, min = minimum, max = maximum, IQR = interquartile range; BMI = Body mass index, MWT = Maximal wall 
thickness, LVOTG = Left ventricular outflow tract gradient, LA = Left atrial diameter, LVEDD = Left ventricular end diastolic dimension, LVESD = Left ventricular end systolic 
dimension, FS = Fractional shortening, E/A = transmitral E to A ratio. *Total myocardial collagen content ug/mg of cardiac tissue,  yrs = years,  kg/m2 = kilogram per metre 
squared, mm  = millimetre, mmHg = millimetre of mercury, % = percent
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Table 5 Tissue RNA regulation of mediators involved in collagen synthesis, metabolism 
and TGF-β related pathways, HCM vs Controls.  
Gene Fold Change 95% CI Fold Regulation p value 
COL1A2 1.493 ( 1.09 - 1.89 ) 1.493 0.081 
COL3A1 2.037 ( 1.51 - 2.57 ) 2.037 0.013 
MMP1 0.786 (0.00 - 1.91 ) -1.272 0.564 
MMP2 0.896 ( 0.60 - 1.19 ) -1.116 0.775 
MMP3 0.672 ( 0.49 - 0.85 ) -1.487 0.029 
MMP8 0.555 ( 0.37 - 0.74 ) -1.801 0.002 
MMP9 1.433 ( 0.03 - 2.83 ) 1.433 0.588 
MMP13 0.702 ( 0.51 - 0.90 ) -1.425 0.087 
MMP14 0.928 ( 0.77 - 1.08 ) -1.077 0.617 
TIMP1 1.748 ( 1.23 - 2.27 ) 1.748 0.064 
TIMP2 0.987 ( 0.75 - 1.23 ) -1.013 0.990 
TIMP3 0.900 ( 0.67 - 1.13 ) -1.111 0.583 
TIMP4 1.522 ( 0.78 - 2.26 ) 1.522 0.110 
TGF-β1 1.017 ( 0.78 - 1.25 ) 1.017 0.778 
TGF-β2 4.761 ( 0.22 - 9.30 ) 4.761 0.008 
TGF-β3 1.153 ( 0.88 - 1.42 ) 1.153 0.318 
TGF-βR1 0.990 ( 0.75 - 1.23 ) -1.010 0.961 
TGF-βR2 0.944 ( 0.82 - 1.07 ) -1.060 0.576 
LTBP1 1.697 ( 0.90 - 2.49 ) 1.697 0.020 
Smad2 1.137 ( 0.91 - 1.37 ) 1.137 0.287 
Smad3 1.078 ( 0.78 - 1.38 ) 1.078 0.521 
Smad4 1.329 ( 0.79 - 1.87 ) 1.329 0.085 
Smad6 1.108 ( 0.70 - 1.52 ) 1.108 0.502 
Smad7 1.028 ( 0.79 - 1.27 ) 1.028 0.714 
ITGaV 1.787 ( 1.11 - 2.47 ) 1.787 0.001 
ITGb3 1.162 ( 0.89 - 1.44 ) 1.162 0.316 
ITGb5 1.159 ( 0.83 - 1.49 ) 1.159 0.267 
BMP7 0.265 ( 0.11 - 0.42 ) -3.780 0.015 
TSP-1 0.874 ( 0.00 - 1.82 ) -1.145 0.123 
TSP-2 1.225 ( 0.79 - 1.66 ) 1.225 0.310 
CCN2 2.921 ( 1.15 - 4.70 ) 2.921 0.022 
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PDGF-A 0.803 ( 0.65 - 0.96 ) -1.245 0.136 
PDGF-B 0.508 ( 0.22 - 0.79 ) -1.970 <0.001 
ET-1 0.826 ( 0.54 - 1.11 ) -1.211 0.371 
 
CI = Confidence interval 
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Figure 7: Tissue RNA regulation of mediators involved in collagen synthesis, 
metabolism and TGF-β related pathways, HCM vs controls. * = p <0.05 
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4.3.2 Collagen content 
 
In the HCM group the mean level of collagen was 13.51 ± 8.08 ug/mg of cardiac tissue, 
with a range of 7.3 – 46.9 ug/mg of cardiac tissue. When compared to controls, the 
RNA expression of type III procollagen was significantly up-regulated by a factor of 
2.0365, p=0.013 in the HCM group. Type 1 procollagen was upregulated by a factor of 
1.4928 although this failed to reach statistical significance, p=0.081.  
 
Within the HCM group, there was a significant correlation (r = 0.494, p=0.02) between 
levels of myocardial collagen and the fold regulation of type III procollagen (relative 
to the control group). The correlation between type I procollagen and myocardial 
collagen did not reach significance (r = 0.343, p=0.118) 
4.3.3 Matrix metalloproteinase 
 
Expression MMP3 (-1.4873 fold, p=0.029) and MMP8 (-1.8009, p=0.002) were 
significantly downregulated in the HCM group. Expression of MMP 1 (-1.2723 fold, 
p=0.56), MMP 2 (-1.1158 fold, p=0.77) MMP 9 (-1.4334 fold, p=0.59) MMP 13 (-1.425 
fold, p=0.09) and MMP 14 (-1.0772 fold, p=0.62) were also downregulated but 
statistical significance was not achieved.  
4.3.4 Tissue inhibitors of metalloproteinase 
 
Tissue RNA expression of TIMP 1 (1.7483 fold, p=0.064), TIMP 2 (-1.0131 fold, p =0.99) 
TIMP 3 (-1.1112 fold, p=0.58) and TIMP 4 (1.522 fold, p=0.11) were not significantly 
altered between controls and the HCM group.  
4.3.5 TGF-β family, associated protein and receptors 
 
Tissue expression of TGF-β2 showed a significant upregulation in the HCM samples 
when compared to the control group (4.7608 fold, p=0.008). No difference in the 
expression of TGF-β1 (1.0166 fold, p=0.78) and TGF-β3 (1.1529 fold, p=0.32) was 
observed. BMP7 was significantly downregulated in the HCM group (-3.7798, 
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p=0.015), LTBP1 was also significantly upregulated in HCM (1.6966 fold, p=0.02). No 
difference in the expression of TGF-βR1 (-1.01 fold, p=0.96) and TGF-βR2 (-1.0596, 
p=0.58) receptors was observed.  
 
Within the HCM group, there was a significant correlation between fold regulation 
relative to the control group of TGB1 (r = 0.570, p=0.006; r = 0.528, p=0.012), TGF-β2 
(r = 0.569, p=0.006; r = 0.514, p=0.014) and TGF-β3 (r = 0.738, p <0.001; r = 0.496, 
p=0.019) to the fold regulation of type 1 and 3 procollagens respectively. No 
correlation was observed for BMP7.  
4.3.6 Smad signalling cascade 
 
Expression of Smad 2 (1.1371 fold, p=0.29), Smad 3 (1.0782 fold, p=0.52), Smad 4 
(1.3291 fold, p=0.09), Smad 6 (1.1075 fold, p=0.50) and Smad 7 (1.0283, p=0.71) 
proteins were not significantly altered in the HCM group when compared to controls. 
4.3.7 Cardiac integrins  
 
In the HCM group, the expression of ITGav subunit was significantly upregulated 
(1.7871 fold, p=0.0007) whilst no statistical difference was identified in the expression 
of the ITGb3 (1.1617 fold, p=0.32) and b5 (1.1586 fold, p=0.27) subunits.  
4.3.8 Thrombospondins, Endothelin-1, Platelet derived growth factor and 
Connective tissue growth factor.  
 
When compared to controls, CCN2 was significantly upregulated (2.9207 fold, 
p=0.021) whilst. Levels of TSP 1 (-1.1445 fold, p=0.12), TSP-2 (1.2248 fold, p=0.31), ET-
1 (-1.2105 fold, p=0.37) and PDGF-A (-1.245 fold, p=0.14) were not significantly 
different between the 2 groups. PDGF-B was significantly down regulated in the HCM 
group (-1.97 fold, p=<0.001). 
 
Within the HCM group, there was a significant correlation between fold regulation 
relative to the control group of CCN2 (r = 0.841, p <0.001; r = 0.634, p=0.002), PDGF A 
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(r = 0.545, p=0.009; r = 0.485, p=0.022) and TSP-2 (r = 0.871, p <0.001; 0.785, 
p=<0.001) to the fold regulation of type 1 and 3 procollagens respectively. No 
correlation was observed for TSP-1, ET-1 and PDGF B.  
 
 
4.4 Discussion 
Collagen synthesis 
 
In this study, we identified a significant upregulation in the RNA expression of type III 
collagen in the HCM myocardium relative to controls. There was also a trend towards 
significance for elevated RNA expression of type I collagen. The extent of collagen as 
quantified by hydroxyproline varied greatly, however there was a significant 
correlation between myocardial collagen and the extent of collagen III genetic 
upregulation suggesting that collagen synthesis is an active process in HCM. 
Collagen metabolism 
 
The expression of MMP 1, 2, 9, 13 and 14 in the HCM myocardium was not significantly 
altered relative to controls. MMP 3 and MMP 8 were significantly down-regulated. No 
significant differences were identified in the expression of TIMP 1, 2, 3 and 4. 
Degradation of mature collagen is regulated by MMPs which are inhibited by TIMPs. 
These findings demonstrate that the up-regulation in collagen synthesis is not 
counterbalanced with increased expression of genes involved in collagen metabolism 
at a myocardial level.  
TGF-β mediated signalling and cardiac integrins 
 
In this study, I identified a 4.8 fold up-regulation in the RNA expression of TGF-β2 
isoform in the HCM myocardium. Regulation of all three TGF-β isoforms also 
correlated with the regulation of both procollagen I and III.  RNA levels of Smad 
signalling cascade were not significantly altered in the HCM myocardium. 
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Previous studies have established the role of TGF-β in promoting myocardial fibrosis 
and hypertrophy.260 261 Individuals with HCM have also been shown to demonstrate 
increased gene expression TGF-β1 relative to those with aortic stenosis, stable angina 
and dilated cardiomyopathy.279 Elevated levels of myocardial TGF-β1 messenger RNA 
and protein levels have also been shown to be 2.5 and 2.8 times higher in areas of 
hypertrophy relative to non-hypertrophied.278 Elevated levels TGF-β in those with 
HCM have been identified associate with increased BNP, higher symptomatic status 
and more adverse outcomes.280  
 
Smad signalling is a fundamental signalling pathway involved in response to TGF-β.262 
271 272  Independent of Smad mediated transcription, TGF-β activates additional 
signalling cascades including Erk, JNK, TAK1, MAPK and GTPase pathways.271 The 
results of this study suggest that TGF-β signalling does not directly regulate the 
expression of Smad proteins but its effects may be mediated through enhanced 
activation of pre-formed Smad or via Smad independent pathways.  
 
TGF-β has been shown to be a stimulator of endothelial - mesothelial transformation 
(Endo-MT), a process which is antagonised by BMP-7.273 BMP-7 has been shown to 
facilitate reverse fibrotic remodelling in cardiac disease.276 277   I was able to 
demonstrate that RNA levels of BMP-7 are downregulated in the HCM myocardium.  
 
Together, these data suggest that TGF-β is an important mediator of myocardial 
fibrosis and that Smad independent signalling may play an important role in TGF 
mediated signalling in HCM. The balance of TGF-β to BMP-7 is in favour of promoting 
endo-mesothelial transformation and unopposed TGF-β driven fibrosis.   
 
I identified a significant up-regulation in the integrin av subunit suggesting that cardiac 
integrins may play a role in TGF-β activation. Integrins are transmembrane receptors 
that are composed of an α and β subunits and facilitate cell–ECM connections and 
cell–cell interactions. Integrin dependent mechanical activation of TGF-β has been 
well described in epithelial cells which contains the αvβ6 integrin receptor.124 Epithelial 
cells are not expressed in the heart, but elevated levels of the mesenchymal integrins 
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αvβ5 and αvβ3 have been identified in animal models of fibrotic cardiac disease and 
have been shown to play an important role in controlling human myofibroblast 
differentiation via TGF-β activation.134 Integrin αvβ8, has also been shown to activate 
TGF-β in a proteinase dependent manner, although its role in cardiac fibrosis is yet to 
be established.135  
CCN family 
 
CCN2 is pro-fibrotic mediator which acts downstream of TGF-β. I found a 2.9 fold 
upregulation in CCN2 and this was strongly correlated with the regulation of both 
procollagen I and III RNA.  The CCN gene family consists of six members, of which the 
matricellular protein CCN2 has been most studies and implicated in cardiac disease. 
CCN2 expression is strongly driven and dependent on TGF-β partially through Smad 
dependent signalling.179 180 183 Elevated RNA and protein levels of CCN2 have been 
demonstrated in fibrotic disease in both animal models of cardiac disease and 
humans, including myocardial infarction, diabetes and heart failure.180 184 Despite its 
association with myocardial fibrosis, CCN2 on its own is considered a weak promotor 
of fibrosis, and requires TGF-β and other fibrogenic stimuli to produce a sustained and 
profound fibrotic response.180 185 The findings in this study would therefore suggest 
that CCN2 in synergy with TGF-β plays a role in mediating fibrosis in HCM. 
Thrombospondins 
 
Thrombospondin regulation was not significantly altered in the HCM group, but the 
level of TSP-2 regulation strongly correlated with the regulation of procollagen I and 
III RNA suggesting a role in modulation of fibrosis. Thrombospondin-1, is a angiostatic 
mediator that also plays an important role in TGF-β activation and inhibition of MMP 
activation.220 221 It is upregulated in the infarcted and pressure overloaded ventricle 
and is considered an important mediator of matrix preservation and preventing 
progressive ventricular dilatation.215 222 TSP-2 has also been shown to play a role in 
matrix preservation by inhibiting MMPs whilst TSP-4 null animal models have shown 
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accelerated fibrosis suggests an anti-fibrotic role.217 223 TSP-2 is able to bind but not 
activate TGF-β and thus may present as competitive inhibitor of TSP-1.220  
Endothelin 1 
 
In this study, no difference in the regulation of ET-1 or association with procollagen 
RNA was identified. Endothelin-1 has been shown to be a mediator of fibrosis which 
may act downstream of TGF-β and angiotensin II.185 ET-1 has been shown to promote 
fibroblast proliferation, promote the expression myofibroblast phenotype and 
enhance collagen synthesis.243-246 In animal models ET-1 induced myocardial fibrosis 
whilst antagonism of endothelin was served a protective role in myocardial fibrosis.247-
249 Elevated levels of myocardial and circulating ET-1 are elevated in patients with 
chronic heart failure but long-term antagonism of the endothelin receptor does not 
alter the course of the disease.250 251 The findings in this study suggest that ET-1 may 
not play a significant role in mediating fibrosis in HCM.  
Platelet derived growth factor 
 
The regulation of PDGF A was not upregulated in the HCM group but did correlate 
with the RNA expression of procollagen I and III. PDGF B was significantly down 
regulated with no correlation with the regulation of procollagen. All four PDGF (A-D) 
ligands have been associated with the ability to generate myocardial fibrosis and 
hypertrophy different ligands, which are likely a result of differential activation of the 
two PDGF receptors.252-254  PDGF A, C and D have been shown to increase expression 
of TGF-β and promote myocardial fibrosis.256 PDGF-B, may also demonstrate some 
protective properties by promoting the expression of anti-mesenchymal transition 
factor BMP-7.258 These findings suggest that PDGF may have a role in mediating 
fibrosis and potentially regulating mesenchymal transition. 
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4.5 Limitations 
 
The HCM samples were obtained from the interventricular septum of patients with 
left ventricular outflow tract obstruction and may not reflect gene regulation in those 
without obstruction. When considering the results of this study the small sample size 
must be considered. Furthermore, the control group was significantly younger than 
the patient group and the results may in part reflect processes associated with ageing. 
 
When aiming to compare genetic expression it was felt that the use of these samples 
would provide the best control relative to tissue biopsy from patients with cardiac 
disease undergoing surgery. The use of samples from patients with cardiac disease has 
its own inherent limitations and activation of common pathways such as myocardial 
fibrosis in cardiac disease would limit their value in such study.    
 
There are also several considerations to consider with relation to the control samples:  
(i) Samples were taken from the LV free wall and therefore may be a directly 
comparable to processes occurring in the intraventricular septum,  
(ii) The ischaemic time for the control samples are also likely to alter the 
genetic regulation. However, one would anticipate that myocardial 
ischaemia would trigger a pro-fibrotic response in a similar to one observed 
in myocardial infarction and thus should not deter from the positive 
findings of this study. 
(iii) A number of samples were taken from patients who had committed 
suicide. These individuals may have had neuro-hormonal activation 
associated with stress which may also alter cardiac genetic expression. 
(iv) Tissue collection and storage also varied amongst subjects and groups. This 
may influence the relative preservation of RNA. However, I feel that this is 
unlikely to alter the validity of the results as all the samples included in the 
final analysis passed quality checks to ensure that the RNA was not 
degraded.  
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RNA levels may degrade overtime and the differences observed in the study may be 
influenced as a result and enhanced RNA expression may not necessarily translate into 
enhanced protein synthesis.   
 
4.6 Conclusion:  
 
Genetic expression of procollagen is significantly upregulated in patients with HCM 
relative to controls. TGF-β and CCN2 mediated signalling appear to be key mediators 
in promoting collagen expression.  
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Chapter 5 Plasma markers of collagen turnover in patients 
with hypertrophic cardiomyopathy and preclinical carriers of 
sarcomere protein gene mutations 
 
5.1 Background  
 
Assessment of myocardial fibrosis in clinical practice is largely dependent on patients 
undergoing CMRI. Although CMRI remains a valuable tool in clinical evaluation it has 
some limitations and may not identify activation of pro-fibrotic pathways prior to the 
development of established fibrosis. Furthermore, cost, access and its unsuitability for 
certain patient groups provide additional challenges. Plasma collagen biomarkers may 
serve to be a useful clinical utility that allows for direct assessment of collagen 
synthesis and degradation in a timely and cost-effective manner.  
  
Studies analysing plasma markers of collagen have been small but have shown that 
collagen turnover is increased in HCM. However, the association between markers of 
collagen metabolism and clinical phenotype have been inconsistent. 287-290 
Furthermore, markers of collagen synthesis have been shown to precede the 
development of clinical phenotype and therefore may serve as useful clinical utility in 
identifying mutation carriers at risk of developing the clinical phenotype and may 
facilitate the implementation early targeted therapy.295  
 
In this study we sought to compare markers of collagen synthesis and degradation in 
plasma between patients with HCM, sarcomeric mutation carriers and healthy 
controls. Furthermore, we looked to correlate markers these markers to clinical 
phenotype in patients displaying the overt phenotype.  
 
5.2 Aims 
 
1: To evaluate plasma markers of collagen metabolism in controls, asymptomatic 
sarcomeric gene carriers and patients with HCM. 
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2: To evaluate the relationship between markers of collagen metabolism to clinical 
phenotype in patients with HCM.  
 
Results 
5.3.1 Demographics  
 
The final study cohort comprised 102 patients with HCM, 20 gene carriers and 20 
controls. 11 patients were excluded at the time of analysis due to the presence of 
exclusion criteria. The demographics of the study cohort are shown in table 6. The 
HCM cohort had a greater predominance of males compared to both gene carriers 
(p=0.02) and controls (p=0.02). The controls were younger (40 ± 11 vs. 49 ± 14 yrs, 
p=0.016) and had lower BMI compared to the HCM cohort (28 ± 5 vs. 25 ± 5, p=0.035). 
The age and BMI of the gene carrier cohort were comparable to both HCM and 
controls.  
5.3.2 Medical therapy: 
 
None of the controls were receiving cardioactive medications. Of the gene carriers, 1 
(5%) individual was treated with a beta blocker, 1 (5%) was being treated with a 
calcium channel antagonist and 2 (10%) patients were taking a loop or thiazide diuretic 
for the management of hypertension. In the HCM group 12 (11.8%) were on 
disopyramide, 54 (52.9%) on beta blockers, 8 (7.8%) on amiodarone, 25 (24.5%) on 
calcium channel antagonists, 10 (9.9%) on angiotensin converting enzyme inhibitors 
or angiotensin II receptor antagonist, 21 (20.6%) on warfarin, 9 (8.8%) on 
spironolactone, 8 (7.8%) on loop or thiazide diuretics and 29 (28.4%) on aspirin.  
5.3.3 Collagen metabolism 
 
Levels of PICP were higher in HCM compared to controls (75.95 ± 12.23 vs 62.94 ± 
17.18ug/L, p=0.002). There was no difference between the HCM group and gene 
carriers (74.74 ± 19.72ug/L, p=1.0), but a trend towards higher levels in gene carriers 
relative to the control group was observed (p=0.056), figure 8.  PIIINP levels were 
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higher in HCM (5.70 ± 2.15ug/L, p =0.027) and gene carriers (5.50 ± 1.04ug/L, p=0.024) 
when compared to controls (4.35 ± 1.52ug/L), figure 9. Levels of ICTP were higher in 
gene carriers when compared to controls. No significant difference in levels of ICTP 
were observed between the HCM group and the control and gene carrier group. 
Furthermore, no significant differences were noted between the PICP:ICTP ratio 
between any of the groups. No statistical differences were observed between the 
groups in levels of MMP1, MMP3, MMP9 and TIMP 1. Table 7. 
5.3.4 Control group 
 
In the control group MMP3 levels were significantly higher in men (21.63 ± 8.56 vs. 
10.01 ± 2.41ug/L, p = 0.003). Levels of PIIINP correlated with age, whilst BMI was found 
to have a negative correlation with MMP1 (r -0.580, p = 0.007) and positive correlation 
with ICTP (r 0.472, p = 0.035). No other significant gender differences or association 
with age and BMI were identified.  
5.3.5 Hypertrophic cardiomyopathy group 
 
In the HCM group no clinical correlation existed between levels of PICP and PIIINP with 
age, BMI, MWT, LVMI, LA area, EF, E/Ea ratio, LV dimensions, GLS, LGE and LVOTG. 
MMP 1 correlated with LA area (r = 0.22, p=0.026). MMP3 correlated with age (r = 
0.236, p=0.017), LVEDd (r = 0.255, p=0.01) and E/Ea (r = -0.21, p=0.05). TIMP-1 
correlated with age (r = 0.298, p=0.002), LA area (r = 0.315, p=0.001) and LVOTG (r = 
0.211, p=0.036). ICTP correlated with E/Ea (r = 0.214, p=0.046). Table 8. 
Left ventricular outflow tract obstruction 
 
When the HCM group was dichotomised by those with and without LVOTO, the non-
obstructive group contained more males (p=0.011) and a greater proportion were 
receiving either ACE inhibitors, mineralocorticoid antagonist or both (p=0.037). The 
obstructive group had a higher LVMI (139 ± 48 vs. 111 ± 4 g/msq, p=0.008) and a 
greater proportion were receiving beta-blocker and/or disopyramide therapy. No 
significant difference in age, BMI, ALT or Creatinine were observed between the 
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groups and comparable levels of amiodarone therapy and calcium channel 
antagonists were being received between the groups.   
 
In the HCM group levels of PICP was higher in those without LVOTO (70.32 ± 14.77 vs. 
77.98 ± 17.76ug/L, p=0.05). PIIINP levels were comparable between individuals with 
and without LVOTO. MMP1 levels were higher in individuals with LVOTO (0.82 ± 0.40 
vs. 0.60 ± 0.37ug/L, p=0.006). MMP3, MMP9, ICTP, PICP:ICTP ratio and TIMP-1 were 
comparable between those with and without obstruction. Table 9. 
Non-sustained ventricular tachycardia 
 
When the HCM group was dichotomised by those with and without NSVT, gender, 
age, LVMI, BMI, ALT and Creatinine levels were comparable between those with and 
without NSVT. Amiodarone, beta-blocker and calcium channel antagonist use was 
comparable in those with and without NSVT. The use of disopyramide was higher in 
those without NSVT.  
 
PICP levels were higher in individuals with NSVT compared to those with no evidence 
of NSVT (81.08 ± 16.05 vs. 71.39 ± 17.20ug/L, p=0.002). PIIINP levels were comparable 
between individuals with and without NSVT, figure 10. Levels of MMP1, MMP3, 
MMP9, ICTP, PICP:ICTP ratio and TIMP-1 were comparable between those with and 
without NSVT. Table 9. 
Left ventricular systolic dysfunction 
 
When the HCM group was dichotomised by those with and without an EF <55%, those 
with an EF <55% contained a higher proportion of patients receiving ACE inhibitors 
and/or a mineralocorticoid antagonist. Gender, age, BMI, Creatinine, ALT, LVMI were 
comparable between those with an EF < 55% and those with an EF ≥ 55%. The use of 
amiodarone, beta-blockers, disopyramide and calcium channel antagonists were 
comparable.  
 
	 95	
PICP and PIIINP levels were comparable between those with an EF < 55% and those 
with an EF ≥ 55%. Levels of MMP1, MMP3, MMP9, ICTP, PICP:ICTP ratio and TIMP-1 
were comparable between those with an EF < 55% and those with an EF ≥ 55%. Table 
9. 
Atrial fibrillation 
 
When the HCM group was dichotomised by those with and without AF, gender, BMI, 
Creatinine, ALT and LVMI were comparable. The use of amiodarone, beta-blockers, 
disopyramide and calcium channel antagonists were comparable between the groups. 
A greater proportion of patients with AF were receiving ACE inhibitors and/or 
mineralocorticoid antagonists. The AF group were older (59 ± 8 vs 46± 14yrs, p=0.002) 
and had a greater LA area (33 ± 9 vs 25 ± 5cmsq, p=<0.001). EF and E/EA were 
comparable.  
 
PICP and PIIINP levels were comparable between those with and without AF. MMP 9 
(51.76 ± 33.44 vs. 46.73 ± 69.33ug/L, p=0.04) and TIMP-1 (96.92 ± 23.01 vs. 84.17 ± 
15.21ug/L, p=0.004) were higher in individuals with AF. No differences in ICTP, 
PICP:ICTP ratio and MMP3 were observed. Table 9. 
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Table 6: Demographics of the study cohort.  
  HCM  Gene Carriers  HCM vs. GC Controls  
HCM vs. 
Control 
GC vs. Control 
n 102 20 p 20 p p 
Male 74 9 0.02 9 0.02 1 
Age (years) 49 ± 14 43 ± 17 0.176 40 ± 11 0.016 1 
BMI (kg/msq) 28 ± 5 26 ± 5 0.237 25 ± 5 0.035 1 
MAP (mmHg) 91 ± 9 86 ± 10 0.022       
ALT (IU/L) 36 ± 19 27 ± 15 0.044       
Creatinine (µmol/L) 84 ± 15 74 ± 18 0.021       
Hb (g/dL) 14.8 ± 1.1 14.1 ± 1.3 0.013       
NT-ProBNP 
(pmol/L) 
145 ± 180 13 ± 13 <0.001 
      
CK (IU/L) 167 ± 124 120 ± 62 0.024       
MWT (mm) 18 ± 4 9 ± 2 <0.001       
Rest LVOTG 
(mmHg) 
6 [4.00 - 23] 4 [3 - 5] <0.001 
      
LVEDD (mm) 47 ± 6 47 ± 4 0.945       
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HCM = hypertrophic cardiomyopathy, GC = Gene carriers, BMI = body mass index, MAP=mean arterial pressure, ALT = alanine transaminase, Hb = haemoglobin, NT-ProBNP=N-
terminal pro-brain natriuretic peptide, CK = Creatine kinase, MWT = maximal wall thickness, LVOTG = left ventricular outflow tract gradient, LVEDD = left ventricular end 
diastolic dimension, LVMI – Indexed left ventricular mass, LA = left atrial, EF = ejection fraction, FS = Fractional shortening, GLS = global longitudinal strain, E:A = transmitral 
E to A ratio, E/Ea = transmitral E to early diastolic velocity of the lateral wall, LGE = late gadolinium enhancement.   
 
kg/msq = kilogram per metre squared, mm  = millimetre, mmHg = millimetre of mercury, % = percent, IU/L = international units per litre, µmol/L =  micromoles per litre,  g/dL 
= grams per decilitre, pmol/L = picomoles per litre, g/msq = grams per metre squared, cmsq = centimetre squared. 
 
LVMI (g/msq) 119 ± 36 66 ± 17 <0.001       
LA Diameter (mm) 45 ± 8 35 ±5 <0.001       
LA area (cmsq) 27 ±  18 ± 4 <0.001       
EF (%) 66 [63 - 70.0] 66 [63 - 68] 0.335       
FS (%) 37 [33 - 42] 35 [33 - 39] 0.234       
GLS (%) -14 ± 4 -22 ± 2 <0.001       
E:A 1.25 [0.84 - 1.60] 1.14 [0.85 - 1.75] 0.77       
E/Ea 8.66 [6.30 - 12.16] 6.10 [4.40 -7.35] 0.001       
LGE (%) 16 ± 14           
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Figure 8: Levels of PICP in hypertrophic cardiomyopathy (HCM), gene carriers and 
controls. 
 
PICP=Carboxyterminal propeptide of type I procollagen, ug/L = microgram per litre, CI = confidence 
intervals 
 
 
 
 
 
 
 
 
 
 
 
p=1.0 
p=0.002 
p=0.056 
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Figure 9 Levels of PIIINP in hypertrophic cardiomyopathy (HCM), gene carriers and 
controls.  
 
PIIINP=Aminoterminal propeptide of type III procollagen, ug/L = microgram per litre, CI = confidence 
intervals 
 
 
p=0.972 
p=0.027 
p=0.024 
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Table 7 Plasma levels of collagen biomarkers in hypertrophic cardiomyopathy (HCM), gene carriers (GC) and controls. 
Biomarker HCM GC Controls 
HCM vs GC 
p value 
HCM vs 
Controls  
p value 
GC vs 
Controls 
p value 
n 102 20 20 
   
PICP (ug/L) 75.95 ± 17.29 74.76 ± 19.72 62.94 ± 17.18 1 0.002 0.056 
PIIINP (ug/L) 5.70 ± 2.16 5.50 ± 1.04 4.35 ± 1.52 0.972 0.027 0.024 
PICP:ICTP 26.89 ± 14.90 21.90 ± 9.33 23.72 ± 6.05 0.268 1 0.999 
MMP1 (ug/L) 0.66 ± 0.39 0.62 ± 0.32 0.76 ± 0.52 1 1 1 
MMP3 (ug/L) 16.74 ± 7.46 14.82 ± 6.59 15.24 ± 8.31 0.887 1 1 
MMP9 (ug/L) 47.91 ± 62.64 46.65 ± 74.23 47.29 ± 31.28 1 1 0.993 
ICTP (ug/L) 3.32 ± 1.54 3.71 ± 0.9 2.70 ± 0.54 0.18 0.247 0.017 
TIMP-1 1 
(ug/L) 87.17 ± 18.07 89.78 ± 16.33 81.88 ± 10.74 1 0.83 0.49 
 PICP=Carboxyterminal	propeptide	of	type	I	procollagen,	PIIINP=Aminoterminal	propeptide	of	type	III	procollagen,		MMP=Matrix	metalloproteinase,	TIMP=Tissue	inhibitors	of	metalloproteinases,	ICTP=Carboxyterminal	telopeptide	of	type	I	collagen,	ug/L	=	micrograms	per	l
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Table 8 Correlation of collagen of biomarkers to clinical parameters in hypertrophic cardiomyopathy 
 
 
PICP 
(ug/L) 
 
PIIINP 
(ug/L) 
 
PICP : 
ICTP 
 
MMP1 
(ug/L) 
 
MMP 9 
(ug/L) 
 
MMP 3 
(ug/L) 
 
ICTP 
(ug/L) 
 
TIMP1 
(ug/L) 
 
 r p r p  r p r p r p r p r p  r p 
Age 0.146 0.143 -0.045 0.655 0.034 0.733 0.179 0.072 0.094 0.346 0.236 0.017 0.043 0.670 0.298 0.002 
BMI 
(kg/msq) 
0.131 0.190 0.061 0.539 0.001 0.989 0.013 0.897 -0.165 0.097 -0.004 0.966 0.073 0.465 0.171 0.086 
MWT 
(mm) 
-0.41 0.683 -0.015 0.881 -0.079 0.433 -0.007 0.942 -0.09 0.366 -0.11 0.272 0.07 0.484 -0.043 0.667 
LVMI 
(g/msq) 
0.065 0.513 -0.071 0.478 -0.099 0.324 0.100 0.317 -0.098 0.328 -0.037 0.710 0.155 0.120 0.115 0.248 
LAA 
(cmsq) 
0.135 0.177 0.025 0.807 0.129 0.2 0.222 0.026 0.106 0.29 0.182 0.068 -0.055 0.585 0.315 0.001 
EF (%) -0.166 0.096 -0.043 0.665 -0.119 0.232 0.03 0.767 -0.015 0.88 -0.14 0.162 0.03 0.765 -0.164 0.099 
E/Ea -0.167 0.119 0.174 0.106 -0.246 0.021 0.292 0.006 0.052 0.632 -0.21 0.05 0.214 0.046 0.194 0.07 
LVEDD 
(mm) 
0.162 0.104 0.006 0.953 0.128 0.199 -0.062 0.535 -0.078 0.438 0.255 0.01 -0.06 0.547 0.09 0.371 
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GLS (%) -0.58 0.656 -0.142 0.274 0.15 0.247 0.057 0.664 -0.083 0.526 -0.025 0.847 -0.167 0.2 0.045 0.733 
LGE (%) 0.153 0.345 0.123 0.451 0.117 0.474 -0.179 0.27 -0.09 0.579 0.128 0.432 -0.035 0.828 0.015 0.923 
Rest 
LVOTG 
(mmHg) 
-0.058 0.569 0.104 0.305 -0.16 0.114 0.12 0.238 -0.015 0.879 -0.139 0.169 0.182 0.072 0.211 0.036 
 
PICP=Carboxyterminal propeptide of type I procollagen, PIIINP=Aminoterminal propeptide of type III procollagen, MMP=Matrix metalloproteinase, TIMP=Tissue inhibitors of 
metalloproteinases, ICTP=Carboxyterminal telopeptide of type I collagen 
BMI = body mass index, MWT = maximal wall thickness, LVMI = Indexed left ventricular mass, LAA = left atrial area, LVOTG = left ventricular outflow tract gradient, EF = 
ejection fraction, E/Ea = transmitral E to early diastolic velocity of the lateral wall, LVEDD = left ventricular end diastolic dimension, GLS = global longitudinal strain, LGE = late 
gadolinium enhancement.   
kg/msq = kilogram per metre squared, mm = millimetre, mmHg = millimetre of mercury, % = percent, g/msq = grams per metre squared, cmsq = centimetre squared, ug/L = 
micrograms per litre.  
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Table 9 Collagen biomarkers in hypertrophic cardiomyopathy dichotomised by clinical phenotype 
 
Biomarker LVOTO      NSVT   
 
EF < 55%    
 
AF   
 
  No  Yes  p No  Yes  p No  Yes  p No  Yes  p 
N 75 27  54 48  95 7  78 24  
PICP (ug/L) 
77.98 ± 
17.76 
70.32 ± 
14.77 
0.04
9 
71.39 ± 
17.20 
81.08 ± 
16.05 0.002 
76.38 ± 
17.25  
70.16 ± 
18.12 0.320 
74.76 ± 
17.27 
79.81 ± 
17.14 0.189 
PIIINP (ug/L) 
5.64 ± 
2.22 
5.84 ± 
2.01 0.59 
5.62 ± 
2.36 
5.78 ± 
1.93 0.44 
5.69 ± 
2.22 
5.74 ± 
1.05 0.65 
5.61 ± 
1.96 
5.98 ± 
2.73 0.719 
PICP:ICTP 
27.23 ± 
11.47 
25.94 ± 
22.05 0.2 
25.61 ± 
17.22 
28.33 ± 
11.77 0.07 
27.17 ± 
15.26 
23.06 ± 
8.41 0.059 
26.42 ± 
15.11 
28.43 ± 
14.39 0.56 
MMP1 (ug/L) 
0.6 ± 
0.37 
0.82 ± 
0.40 
0.00
6 
0.66 ± 
0.42 
0.65 ± 
0.35  0.95 
0.66 ± 
0.42  
0.63 ± 
0.39 0.87 
0.62 ± 
0.31  
0.76 ± 
0.57 0.578 
MMP3 (ug/L) 
17.32 ± 
7.10 
15.13 ± 
8.31 
0.19
2 
16.72 ± 
7.80 
16.77 ± 
7.14 0.975 
16.65 ± 
7.64  
17.97 ± 
4.41 0.653 
16.33 ± 
7.66 
18.08 ± 
6,74 0.318 
MMP9 (ug/L) 
45.18 ± 
50.95 
55.51 ± 
88.16 0.81 
35.03 ± 
20.92 
62.41 ± 
86.80 0.114 
49.19 ± 
64.61 
30.59 ± 
16.43  0.403 
46.73 ± 
69.33 
51.76 ± 
33.44 0.038 
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 	PICP=Carboxyterminal	propeptide	of	type	I	procollagen,	PIIINP=Aminoterminal	propeptide	of	type	III	procollagen,	MMP=Matrix	metalloproteinase,	TIMP=Tissue	inhibitors	of	metalloproteinases,	ICTP=Carboxyterminal	telopeptide	of	type	I	collagen,	ug/L = micrograms per litre.  
LVOTO = left ventricular outflow tract obstruction, NSVT = non-sustained ventricular tachycardia, EF = ejection fraction, AF = atrial fibrillation.  
 
 
 	
 
 
 
 
 
 
 
ICTP (ug/L) 
3.26 ± 
1.58 
3.48 ± 
1.44 
0.68
2 
3.45 ± 
1.81 
3.18 ± 
1.17 0.649 
3.33 ± 
1.59 
3.16 ± 
0.65 0.939 
3.28 ± 
1.34 
3.45 ± 
2.10 0.957 
TIMP1 (ug/L) 
83.54 ± 
18.54 
91.99 ± 
16.03 0.07 
87.45 ± 
19.16  
86.85 ± 
19.96  0.881 
87.36 ± 
18.49 
84.54 ± 
11.53 0.798 
84.17 ± 
15.21 
96.92 ± 
23.01  0.004 
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Figure 10 Levels of (A) PICP and (B) PIIINP in HCM patients with and without non-sustained ventricular tachycardia  
 PICP=Carboxyterminal	propeptide	of	type	I	procollagen,	PIIINP=Aminoterminal	propeptide	of	type	III	procollagen,	ug/L = micrograms per litre, NSVT = non-sustained 
ventricular tachycardia.
00 
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5.4 Discussion: 
5.4.1 Collagen synthesis 
 
In this study, I identified a significant elevation in plasma levels of both procollagen I 
and pro-collagen III in patients with HCM when compared to controls. Plasma 
expression of PIIINP was also significantly elevated in gene carriers when compared to 
controls and comparable to those seen in HCM. Levels of PICP showed a trend towards 
increased levels in gene carriers (p =0.056).  Levels of ICTP were also elevated in gene 
carriers without any significant differences seen in the PICP:ICTP ratio between the 
groups. These findings demonstrate that enhanced collagen synthesis and turnover is 
an early, active process present in mutation carriers that is likely to contribute to the 
development and progression of the clinical phenotype.  
 
Several investigators have identified elevated levels of markers of collagen type I (PICP 
and PINP) and type III (PIIINP) synthesis in HCM whilst others have been unable to 
demonstrate differences compared to controls.287-290 Ho et al measured differences in 
levels of PICP, MMP-1, TIMP-1 and ICTP between individuals with pathogenic 
sarcomeric mutations with evidence overt disease, subjects with proven pathogenic 
mutation without LVH and controls.295 Compared to controls, those with overt disease 
demonstrated a significant elevation in PICP and its ratio with ICTP. No differences 
were identified in levels of MMP-1, TIMP-1 and ICTP. In those with overt disease there 
was no correlation between collagen biomarkers and clinical parameters including 
LGE.  However, the most significant finding of this paper was the discovery of raised 
levels in PICP in gene carriers without overt LVH or LGE on CMRI when compared to 
controls. This finding demonstrates that enhanced collagen synthesis may represent 
an early clinical manifestation of sarcomeric disease and provide a useful serological 
marker of genetic expression.  
 
An association between markers of collagen synthesis and markers of diastolic 
dysfunction has been reported, whilst an elevated PICP or PINP to ICTP ratio (which 
represent the ratio of collagen type I synthesis to degradation) has been shown to 
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consistently correlate to markers of diastolic and systolic dysfunction at rest across 
several studies.287-289 A correlation between markers of collagen synthesis and other 
clinical markers of disease has been inconsistent amongst studies.  
 
When evaluating the association of plasma collagen markers and clinical phenotype, I 
identified elevated levels of PICP in patients with NSVT. These findings may point 
towards an association between collagen synthesis and ventricular arrhythmias. In 
this study, I also identified that the group with LVOTO had lower levels of PICP when 
compared to patients without obstruction, despite the non-obstructive group having 
a higher proportion of men, a lower LVMI and greater use of ACE inhibitors and/or 
mineralocorticoid antagonists. These findings suggest that myocardial fibrosis is an 
intrinsic process in HCM and not driven by increased afterload as observed in 
hypertension and aortic stenosis. No other clinical correlation between PICP and 
PIIINP were identified, including the extent of LGE. The lack of significant clinical 
correlations may in part relate to the relatively small sample size or may reflect the 
chronic nature of the process.  
 
5.4.2 Regulation of collagen degradation  
 
MMP2 has consistently been shown to be elevated in HCM and correlate with levels 
of BNP.289 291-293 Furthermore, levels of MMP2 are highest in those with systolic 
dysfunction, severe heart failure symptoms and in patients with AF.291-293 Elevated 
levels of MMP2 levels were also shown to be significantly associated with an adverse 
heart failure related outcome.293 MMP9 has been shown in 2 studies to be elevated 
in HCM whilst no significant difference was identified in another.289 291 292 Roldan et al, 
demonstrated that MMP9 was associated with LGE on CMRI and correlated with both 
exercise incapacity and LVOTG.292 In another study MMP9 was shown to predict future 
LV dysfunction.294 MMP1 has been shown to be reduced or undetectable in HCM. 
Other studies have not found any significant difference in levels of MMP1, MMP3 or 
MMP9 between controls and HCM.287 289 291 292 Tissue inhibitors of metalloproteinase, 
TIMP1 and TIMP2 are also elevated in HCM with the latter being elevated in patients 
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with HCM with LV systolic dysfunction when compared to those without LV 
dysfunction and controls.287 289 291-293  
 
In this study, we found no significant difference in the levels of MMP 1, MMP 3, MMP 
9 and TIMP-1 between the HCM group, gene carriers and controls. Within the HCM 
cohort, MMP 1 was higher in the obstruction group although no correlation was 
identified with LVOT gradient. MMP 1 correlated with both LAA and E/Ea. MMP-9 was 
higher in those with AF and MMP 3 correlated positively with LV dimensions. TIMP-1 
levels associated positively with LAA and rest LVOT gradient. These findings suggest 
that a complex interaction between collagen synthesis and degradation contributes 
to disease pathophysiology and cardiac remodelling.     
 
5.5 Limitations 
 
The study is in part limited by its power and population size. Although strict inclusion 
and exclusion criteria were employed, the expression of biomarkers may be 
influenced by non-cardiac pathophysiological processes and we are unable to 
conclude whether markers of collagen synthesis are proportional to the activity of pro-
fibrotic pathways and collagen synthesis at a myocardial level.  
 
Another limitation of this study was that the control samples were not matched with 
regards to gender, age and BMI. Although many of the markers did not correlate to 
these parameters in the HCM and control group the differences in the group may be 
a confounding factor.   
 
5.6 Conclusions 
 
Plasma biomarkers of collagen synthesis are increased in patients with HCM and 
sarcomeric mutation carriers in the absence of overt disease. Enhanced collagen 
synthesis is an early, active process likely to be involved in disease development and 
long-term outcomes.  
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6. Relationship between myocardial hypertrophy, fibrosis and 
myocardial deformation in hypertrophic cardiomyopathy 
 
6.1 Background: 
 
Patients with HCM often have supra-normal EF which is in part related to the small 
ventricular geometry. However, in most patients, HCM is characterised by slow 
progression to systolic and diastolic LV impairment which can result in death from heart 
failure or cardiac transplantation.372 The mechanisms of this gradual decline in cardiac 
performance are only partly understood, but almost certainly reflect a complex and 
dynamic interplay between cardiomyocyte dysfunction and progressive changes in the 
myocardial interstitium.  
 
Assessment of myocardial deformation allows for the assessment of global and regional 
systolic performance and several studies have shown that longitudinal myocardial 
deformation is abnormal in HCM, 43 353-356 373 The contribution of interstitial fibrosis to 
cardiac dysfunction is not known and a greater understanding of this interaction could 
direct therapy in patients with early left ventricular dysfunction.  
 
In this study, we sought to determine the relationship between myocardial deformation, 
diffuse and replacement myocardial fibrosis using a combination of two-dimensional 
echocardiographic deformation imaging and contrast cardiac magnetic resonance 
imaging 
 
6.2 Aim:  
1: To determine the between global and regional longitudinal myocardial 
deformation and left ventricular hypertrophy, replacement fibrosis and interstitial 
fibrosis.  
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6.3 Results 
6.3.1 Baseline characteristics 
The study sample comprised 37 patients (79% male) with a mean age of 48 ± 14 years. 
19 patients were excluded due to suboptimal echocardiographic imaging which was 
prohibitive to strain analysis. Twenty-five (65.8%) had asymmetrical septal 
hypertrophy, 1 (2.6%) had concentric LVH and 12 (31.6%) had an apical distribution of 
hypertrophy. Baseline characteristics of the study population are shown in table 10.  
Examples of strain maps obtained from patients with different distributions of 
hypertrophy are shown in figure 11.  
6.3.2 Correlations with global strain rate 
 
The results obtained from CMRI and echocardiography are displayed in table 11. The 
mean GLS in the cohort was -14 ± 5%. There was a significant correlation between the 
GLS and CMRI derived LVMI (r = 0.71, p=<0.001), EF (r = -0.36, p=0.027), mean LV wall 
thickness (r = 0.75, p=<0.001), MWT (r = 0.43, p=0.008) and % LGE (r = 0.43, p=0.008), 
figure 12. The correlation between GLS and global ECV failed to reach statistical 
significance (r = 0.25, p=0.138). There was no correlation between GLS, LVOTG and LA 
dimensions. There was a significant correlation observed between GLS and both E/Ea 
(r = 0.37, p=0.027) and NT-Pro BNP (r = 0.41, p=0.012). 
In a multivariable model including predictors of global strain rate, the combined R 
squared of the model which factored age, LVMI, global LGE % and ECV was 0.57. LVMI 
(B 0.076, p=<0.001, CI 0.048 – 0.104, b = 0.65) remained an independent predictor.  
Global LGE % showed a weak trend towards significance (B 0.14, p=0.076, CI -0.016 – 
0.295, b = 0.218). 
In previous work from our department we documented the healthy volunteer range 
of ECV to be 0.20 – 0.34.330 Individuals where global ECV was greater than 0.35 had 
impaired GLS, EF and a trend towards higher NT-Pro BNP. There was no significant 
difference between wall thickness, LVOTG, LA dimensions and E/Ea. Table 12 and 
Figure 13.  
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Figure 11: Longitudinal strain bullseye plot in patients with (a) asymmetrical 
hypertrophy, (b) apical hypertrophy and (c) concentric hypertrophy.  
GLPS_LAX = mean longitudinal strain from apical 3 chamber, GLPS_A4C = mean longitudinal strain from 
apical 4 chamber, LGPS_A2C = mean longitudinal strain from apical 2 chamber, GLPS_Avg = mean global 
longitudinal strain. 
 
 
 
 
a b 
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Table 10: Baseline characteristic of the study population (n = 37). All results displayed 
as frequencies and mean ± s.d 
Age (years) 48 ± 14 
Male 28 (76%) 
Distribution of LVH 
 
Asymmetrical septal hypertrophy 24 (64.9%) 
Concentric 1 (2.7%) 
Apical 12 (32.4%) 
LVOTO 9 (24.3%) 
Height (cm) 173 ± 9 
Weight (kg) 84 ± 14 
Body mass index (kg/msq) 28 ± 4 
  
LVH = left ventricular hypertrophy, LVOTO = left ventricular outflow tract obstruction, cm = centimetres, 
kg = kilogram, kg/msq = kilogram per metre squared. 
 
Figure 12: Association between late gadolinium enhancement (LGE) and global 
longitudinal strain (GLS).  
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Table 11: Characteristics of the study population and associated correlation coefficient 
with global longitudinal strain. All data displayed as mean ± standard deviation or 
median and interquartile range.  
n = 37 
mean ± s.d 
median [IQR] 
Correlation 
Coefficient p 
Age (years) 48 ± 14 -0.12 0.493 
NT Pro BNP (pmol/L) 64 [28 - 109] 0.41 0.012 
CMRI Parameters       
LV Mass (g) 251 ± 83 0.77 <0.001 
LVMI (g/msq) 114 [85 - 161] 0.71 <0.001 
EF (%) 75 ± 8 -0.36 0.027 
LA Area (cmsq) 31 ± 7 -0.01 0.955 
LA Area Indexed 
(cm/msq) 15 ± 4 -0.09 0.608 
Mean WT (mm) 10 ± 3 0.75 <0.001 
Maximal WT (mm) 18 ± 5 0.43 0.008 
Global LGE (%) 7 [1 – 12] 0.43 0.008 
Global ECV 0.32 ± 0.04 0.25 0.138 
Echo Parameters       
LVOTG (mmHg) 7 [4.00 – 39] 0.133 0.433 
E/Ea 8.3 [6.2 - 13.7] 0.368 0.027 
GLS (%) -14 ± 5     
 
 
NT-ProBNP=N-terminal pro-brain natriuretic peptide, LVMI – Indexed left ventricular mass, EF = 
ejection fraction, LA = left atrial, WT = wall thickness, LGE = late gadolinium enhancement, ECV = 
extracellular volume, LVOTG = left ventricular outflow tract gradient, E/Ea = transmitral E to early 
diastolic velocity of the lateral wall, GLS = global longitudinal strain.  
pmol/L = picomoles per litre, g = grams, mm = millimetre, g/msq = grams per metre squared, cmsq = 
centimetre squared, cm/msq = centimetre per metre squared, mmHg = millimetres of mercury.  
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Table 12: Group descriptive by global ECV. All data displayed as mean ± s.d unless 
stated. 
 
ECV <0.35 ECV ≥ 0.35 p 
n 29 8 
 
Age (years) 50 ± 14 41 ± 14 0.114 
NT Pro BNP (pmol/L) 56 [20 - 104] 105 [60 – 162] 0.086 
CMRI Parameters 
   
MWT (mm) 18 ± 5 19 ± 6 0.510 
EF (%) 77 ± 5 67 ± 9 0.020 
LA Area (cm2) 30 ± 7 34 ± 9 0.120 
LA Area Indexed 
(cmsq/m) 15 ± 3 17 ± 5 0.221 
LVMI  113 [83 – 14] 130 [98 – 192] 0.354 
Echo Parameters 
   
LVOTG (mmHg) 7 [4.0 – 37] 6 [5 – 65] 0.651 
LA Area (cmsq) 27 ± 6 30 ±  0.268 
LA Area Indexed 
(cmsq/m) 12 ± 3 13 ± 4 0.357 
EF Simpsons (%) 69 ± 5 61 ± 7 0.001 
E/Ea 8.1 [6.1 – 14.8] 9.5 [8.2 – 11.8] 0.537 
GLS (%) -15.30 ± 4.54 -11.49 ± 4.81 0.045 
 
NT-ProBNP=N-terminal pro-brain natriuretic peptide, LVMI – Indexed left ventricular mass, EF = 
ejection fraction, LA = left atrial, WT = wall thickness, LGE = late gadolinium enhancement, ECV = 
extracellular volume, LVOTG = left ventricular outflow tract gradient, E/Ea = transmitral E to early 
diastolic velocity of the lateral wall, GLS = global longitudinal strain.  
pmol/L = picomoles per litre, g = grams, mm = millimetre, g/msq = grams per metre squared, cmsq = 
centimetre squared, cm/msq = centimetre per metre squared, mmHg = millimetres of mercury.  
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Figure 13: Segmental longitudinal strain by segmental Extracellular volume (ECV).  
6.3.3 Correlation with regional strain 
 
Segmental echocardiographic derived regional strain was correlated with regional 
CMRI derived wall thickness and ECV over 16 segments excluding the apical cap. 
Echocardiographic derived regional strain and its correlation with CMRI derived wall 
thickness and ECV is displayed in table 13.  
 
The association of regional wall thickness and ECV on RLS was investigated using a 
mixed effect model. The mixed effect found the intra-cluster correlation within each 
subject was 24% and the random component of the mixed effect model was 
statistically significant (p<0.001), suggesting appropriate choice of this approach for 
analysing the data. The model demonstrated a significant relationship between both 
WT (estimated regression coefficient 0.48, CI 0.37- 0.58, p <0.001) and ECV (estimated 
regression coefficient 18.64, CI 9.49 – 27.78, p <0.001) to RLS. 
 
00 
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Table 13: Relationship between regional wall thickness  and regional ECV to regional 
longitudinal strain.   
 
Regression 
coefficient 
Confidence 
interval 
p 
Regional wall 
thickness  
0.48 0.37- 0.58 <0.001 
ECV 18.64 9.49 – 27.78 <0.001 
 
 
6.4 Discussion: 
 
In this current study we identified that LGE was a univariate predictor of GLS with a 
trend being observed in a multivariable model suggesting that progressive 
replacement fibrosis may contribute to impaired systolic performance.  The 
relationship between global ECV and GLS did not reach statistical significance, 
however, an association between ECV and longitudinal strain at a segmental level was 
observed. Expansion of the extracellular compartment beyond that seen in healthy 
controls was also associated with a significant reduction on global strain rate even 
after correcting for the influence of left ventricular hypertrophy.  
 
Speckle tracking echocardiography can be used to assess regional and global 
myocardial deformation. HCM is characterized by a regional and global reduction in 
longitudinal deformation prior to the development of overt systolic dysfunction.43 353  
An impairment in GLS has been demonstrated to be an independent predictor of 
adverse cardiac outcomes including heart failure related admissions and  deaths. 357 
358 Consistent with these findings we found that study GLS correlated inversely with 
EF and directly with levels of NT-Pro BNP.  
 
The findings of this study were also consistent with previously published studies that 
have demonstrated longitudinal strain to be lower in patients with HCM exhibiting 
LGE with GLS correlating inversely with the extent of LGE.355 359-362 The results of this 
study also suggest that progressive expansion of the extracellular volume with 
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interstitial fibrosis contributes towards progressive systolic impairment. The role of 
ECV in myocardial dysfunction has been poorly described but in accordance with 
findings of this study, ECV has been shown to be a univariable associate of impaired 
circumferential and radial strain and correlate with levels of NT-ProBNP.93 342  
 
Ejection fraction is considered a poor surrogate for systolic function in the context of 
LVH and  impairment of longitudinal deformation has been shown to be most marked 
in regions of hypertrophy.43 353-356 Consistent with these studies, the current study also 
demonstrates that global strain is influenced primarily by the degree of hypertrophy.  
Impaired longitudinal deformation in the hypertrophied myocardium and may reflect 
a combination of direct sarcomeric dysfunction and the sub-endocardial distribution 
of myocyte disarray directly influencing longitudinal function.374 375 Furthermore, 
myocardial ischaemia in areas of hypertrophy may also impair systolic performance.  
 
6.5 Limitations:  
 
The study is limited by the relatively small sample size. Although echocardiographic 
studies were not performed on the same day as the CMRI, the mean gap between the 
studies was 5 months and this believe that the results allow a fair comparison.  
Furthermore, the strain analysis was performed on scans acquired during routine 
clinical scans. Despite stringent criteria for inclusion and exclusion there was a wide 
range of frame rates and the images had not been optimised for strain acquisition. 
 
6.6 Conclusion. 
 
LV strain correlates with the extent of hypertrophy and focal fibrosis in HCM. 
Expansion of the ECV was associated with segmental systolic dysfunction and GLS 
when the ECV exceeded the range observed in the normal population. Together these 
findings suggest that the myocardial fibrosis contributes towards impaired myocardial 
systolic performance.  
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7. Final conclusions 
 
Together, the findings of this thesis support the hypothesis that myocardial fibrosis is an 
early entity in HCM that precedes clinical phenotype. Myocardial fibrosis is associated 
with impaired systolic performance and may contribute to arrhythmic risk in HCM. 
Myocardial fibrosis is at least in part mediated by the TGF- β pathway.  
 
7.1 Collagen synthesis and turnover in hypertrophic cardiomyopathy 
 
In this thesis, I identified that genes involved in collagen synthesis are upregulated in 
myocardial tissue. There was a significant upregulation in the RNA expression of type 
III collagen in the HCM myocardium relative to controls. There was also a trend 
towards significance for elevated RNA expression of type I collagen. The relative 
genetic expression of type III collagen correlated to levels of myocardial collagen. This 
pattern is paralleled by a significant elevation in plasma levels of both procollagen I 
and pro-collagen III in patients with HCM relative to controls. 
 
The enhanced synthesis of collagen is not counteracted by enhanced collagen 
metabolism. Tissue gene expression and plasma levels of MMP’s were not significantly 
upregulated to counteract the increase in collagen synthesis resulting in unopposed 
development of myocardial fibrosis.  
 
7.2 Collagen metabolism in gene carriage 
 
Plasma markers of collagen synthesis are significantly altered in gene carriers and 
comparable to those seen in HCM. Levels of procollagen III are significantly increased 
when compared to controls. A strong trend for procollagen I was observed. Levels of 
ICTP were also increased in gene carriers relative to controls suggesting that both 
collagen synthesis and degradation are enhanced in gene carriers. These findings 
confirm that enhanced collagen synthesis and turnover is an early, active and 
continued process present in gene carriers that is likely to contribute to the 
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development and progression of the clinical phenotype. In this setting plasma markers 
of collagen synthesis may be a potential clinical utility for screening.  
 
7.3 Regulation of collagen synthesis 
 
In the HCM samples, expression of TGF-β2 and its downstream mediator CCN2 were 
markedly upregulated. Relative expression of all three TGF-β isoforms and CCN2 
correlated with procollagen I and III gene expression. Expression PDGF B was 
downregulated in HCM whilst expression of PDGF A and TSP-2 correlated with 
expression of procollagen. These findings suggest that TGF-β mediated signalling is a 
key determinant of promoting myocardial collagen synthesis. Furthermore, the 
relative balance between TGF-β and BMP-7 is in favour of promoting endo-
mesothelial transformation and unopposed TGF-β driven fibrosis 
 
7.4 Clinical correlation 
 
Plasma levels of PICP were higher in individuals with NSVT suggesting an association 
between myocardial fibrosis and the risk of sudden ventricular arrhythmias. The lack 
of consistent correlations between plasma markers of collagen turnover and other 
clinical markers of disease may be explained by the fact that myocardial fibrosis is an 
active and chronic process that is likely to influence the clinical phenotype over a long-
term period. 
 
Focal fibrosis identified by CMRI was associated with a reduction in systolic 
deformation. Furthermore, expansion of the extracellular volume by diffuse fibrosis 
beyond that seen in healthy controls resulted in a reduction in systolic longitudinal 
function.  
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7.5 Future directions  
 
The work performed in my thesis has identified that increased collagen synthesis in gene 
carriers and HCM is an active process that is likely to contribute towards disease 
development and clinical markers of disease. The work carried out in this thesis could be 
explored to overcome some of the limitations identified and to fully understand that 
impact of myocardial fibrosis in HCM.  
 
7.5.1 Genetic profiling  
 
The majority of patients included in this study had not undergone extensive genotyping 
and thus I was unable to look at the role of genetic mutations upon myocardial fibrosis. 
The contribution of genetic mutation on myocardial fibrosis would be best studied in a 
large cohort of patients that had undergone extensive genetic profiling with next 
generation sequencing.  
 
7.5.2 Tissue work 
 
I chose to use a RT-PCR array to evaluate to reliably determine the regulation of genes 
involved in myocardial fibrosis. This process allowed me to profile a wide selection of 
genes that were involved in collagen synthesis and metabolism. There were however 
limitations which may be overcome with future work: 
 
a. Sample size: The study cohort was small and under-representative of the diverse 
clinical phenotype seen in HCM. All samples were obtained from patients that 
has symptomatic LVOTO and samples were taken from the areas of septal 
hypertrophy. Future studies should:  
i. Aim to replicate the studies on larger scale in a group of genotyped 
patients,  
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ii. Utilise biopsy specimens from patients with no LVOTO, non-
hypertrophied regions and study samples from patients at different 
stages of their disease including those with severe systolic impairment. 
 
b. Protein expression and biological integration: Although the study highlighted the 
enhanced gene expression of TGF-β, we did not determine protein expression 
of TGF-β and its downstream mediators. Furthermore, the development and 
progression of myocardial fibrosis in HCM is likely to be complex interaction of 
cellular and molecular mediated signaling which is influenced by sarcomeric 
mutations, disease pathophysiology and the environment. The use and 
integration of microarrays and quantitative proteomics will in the future allow a 
greater understanding of the complex regulation of gene expression and protein 
synthesis that regulate myocardial fibrosis.  
 
7.3.5 Plasma work 
 
Future studies that would add scientific and clinical benefit would include: 
a. Biomarker analysis with longitudinal follow up of a large cohort of gene carriers. 
This type of study would help to determine the utility of collagen biomarkers in 
the identification of gene carriers and prediction of disease development.  
b. Longitudinal follow up of patients with HCM and correlation of clinical phenotype 
with collagen biomarkers. This study would provide further insight of the role of 
collagen turnover in disease progression and would help to determine the role 
of collagen biomarkers in risk prediction. 
 
7.3.6 Targeted therapies 
 
Enhanced understanding of disease pathophysiology and its association with genotype 
and clinical phenotype will ideally lead to individualised therapies for patients. 
Understanding the role of fibrosis in disease development and the contribution of TGF-
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β activation may potentially allow for targeted antagonism of these pathways and 
improve patient outcome.  
7.3.7 Current studies 
 
The hypertrophic cardiomyopathy registry is a large multicenter trial that is currently 
underway and is designed to help establish a clearer understanding of the clinical 
significance of fibrosis upon clinical outcomes in HCM. The trial aims to establish a large 
registry of patients that have undergone genetic profiling with a view of evaluating the 
impact of genetic, CMR and collagen biomarkers variables on clinical outcomes in HCM. 
The ultimate aim is to generate a risk prediction model based upon these parameters. 
The design of this study should overcome many of the limitations encountered in this 
body of work and will not only provide further insight in the role myocardial fibrosis upon 
clinical outcomes but will also aim to determine the clinical utility of collagen biomarkers 
in clinical practice.376	
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9. Appendix 
Appendix 1: Abbreviations 
 
ACCF American college of cardiology foundation 
ACE Angiotensin converting enzyme 
ACTA2 Actin, alpha 2, smooth muscle, aorta 
ACTC a-cardiac actin  
AF Atrial fibrillation 
AGT Angiotensinogen  
AHA American heart association 
AKT1 V-akt murine thymoma viral oncogene homolog 1 
ALK5 Activin-linked kinase 5 
Ang II Angiotensin II 
ASA Alcohol septal ablation 
ASH Asymmetrical septal hypertrophy 
AT-1 Angiotensin receptor type 1 
ATP Adenosine triphosphate  
AV Atrio-ventrincular 
BCL2 B-cell CLL/lymphoma 2 
bFGF Fibroblast growth factor basic 
BMI Body mass index 
BMP Bone morphogenetic protein 
BNP Brain natriuretic peptide 
BP Blood pressure 
bpm Beats per minute 
BSA Body surface area 
CAV1 Caveolin 1 
CCL11 Chemokine (C-C motif) ligand 11 
CCL2 Chemokine (C-C motif) ligand 2 
CCL3 Chemokine (C-C motif) ligand 3 
CCN2 Connective tissue growth factor 
CCN2 Connective tissue growth factor 
CCR2 Chemokine (C-C motif) receptor 2 
CEBPB CCAAT/enhancer binding protein (C/EBP), beta 
CF Cardiac fibroblasts 
CI Confidence intervals 
CK Creatine kinase 
cm Centimetre 
CMRI Cardiac magnetic resonance imaging 
cmsq Centimetre squared 
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COL1A2 Collagen, type I, alpha 2 
COL3A1 Collagen, type III, alpha 1 
CRP C-reactive protein 
CXCR4 Chemokine (C-X-C motif) receptor 4 
DCM Dilated cardiomyopathy 
DCN Decorin 
DTPA Diethylenetriamine pentaacetic acid 
Ea Early diastolic velocity at the mitral annulus 
Ea/Aa Ratio of the early to late diastolic velocities at the mitral annulus 
ECG Electrocardiogram 
ECM Extracellular matrix 
ECV Extracellular volume 
EDTA Ethylenediaminetetraacetic acid  
EF Ejection fraction 
EGF Epidermal growth factor 
End-MT Endothelial – mesothelial transformation 
ENG Endoglin 
EQ-CMR Equilibrium contrast cardiac magnetic resonance imaging 
Erk Extracellular signal regulated kinase  
ESC European society of cardiology 
ET-1 Endothelin 1 
ET-A Endothelin receptor type A 
ET-B Endothelin receptor type B 
FASLG Fas ligand  
FFA Free fatty acids  
FGF Fibroblast growth factor 
 
g/msq Grams per metre squared 
Gd Gadolinium 
GLS Global longitudinal strain 
GREM1 Gremlin 1 
HCl Hydrogen chloride 
HCM Hypertrophic cardiomyopathy 
HGF Hepatocyte growth factor  
HPLC High performance liquid chromatography  
ICD Implantable cardiac defibrillator 
ICTP Carboxyterminal telopeptide of type I collagen 
IFNG Interferon, gamma 
IIICTP Carboxyterminal telopeptide of type III collagen 
IL-1 Interleukin-1  
IL-6 Interleukin-6 
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IL10 Interleukin 10 
IL13 Interleukin 13 
IL13RA2 Interleukin 13 receptor, alpha 2 
IL1A Interleukin 1, alpha 
IL1B Interleukin 1, beta 
IL4 Interleukin 4 
IL5 Interleukin 5  
ILK Integrin-linked kinase 
INHBE inhibin, beta E 
ITGa1 Integrin, alpha 1 subunit 
ITGa2 Integrin, alpha 2 subunit 
ITGa3 Integrin, alpha 3 subunit 
ITGaV Integrin, alpha V subunit 
ITGβ1 Integrin, beta 1 subunit 
ITGβ3 Integrin, beta 3 subunit 
ITGβ5 Integrin, beta 5 subunit 
ITGβ6 Integrin, beta 6 subunit 
ITGβ8 Integrin, beta 8 subunit 
JNK c-Jun-N-terminal kinase  
JUN Jun proto-oncogene 
kg/msq Kilogram per metre squared 
LAP Latency-associated pro-peptide  
LGE Late gadolinium enhancement 
LiH Lithium heparin  
LOX Lysyl oxidase 
LTBP1 Latent transforming growth factor beta binding protein 1 
LV Left ventricle 
LVED left ventricular end diastolic 
LVH Left ventricular hypertrophy 
LVOTG Left ventricular outflow tract gradient 
LVOTO Left ventricular outflow tract obstruction 
MAPK p38 Mitogen activated protein kinase (MAPK) 
mm Millimetre 
mmHg Millimetre of mercury 
MMP Matrix metalloproteinase 
MMP1 Matrix metallopeptidase 1  
MMP13 Matrix metallopeptidase 13  
MMP14 Matrix metallopeptidase 14  
MMP2 Matrix metallopeptidase 2  
MMP3 Matrix metallopeptidase 3  
MMP8 Matrix metallopeptidase 8  
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MMP9 Matrix metallopeptidase 9  
MYBPC 3 Myosin-binding protein C  
MYC V-myc myelocytomatosis viral oncogene homolog  
MYH6 a-myosin heavy chain  
MYH7 b Myosin heavy chain 
MYL2 Regulatory myosin light chain  
MYL3 Essential myosin light chain  
NBD-Cl 7-chloro-4-nitrobenzo-oxa-1,3-diazole  
NFKB1 Nuclear factor of kappa light polypeptide gene enhancer in B-cells 1 
NSVT Non-sustained ventricular tachycardia 
NYHA New York heart association 
OPN Osteopontin 
PCR Polymerase chain reaction  
PCr:ATP Phosphocreatine to adenosine triphosphate 
PDGF Platelet derived growth factor 
PDGFA Platelet-derived growth factor alpha polypeptide 
PDGFB Platelet-derived growth factor beta polypeptide 
PDGFR Platelet derived growth factor receptor 
PICP Carboxyterminal propeptide of type I procollagen 
PIIICP Carboxyterminal propeptide of type III procollagen 
PIIINP Aminoterminal propeptide of type III procollagen  
PINP Aminoterminal propeptide of type I procollagen  
PLAT Plasminogen activator, tissue 
PLAU Plasminogen activator, urokinase 
PLG Plasminogen 
qPCR Quantitative PCR 
RIN Ribonucleic acid integrity number 
RNA Ribonucleic acid 
s.d Standard deviation 
SAM Systolic anterior motion of the mitral valve 
SCD Sudden cardiac death  
SERPINA1 Serpin peptidase inhibitor, clade A  
SERPINE1 Serpin peptidase inhibitor, clade E 
SERPINH1 Serpin peptidase inhibitor, clade H 
Sh-MOLLI Shortened modified look locker inversion recovery sequence  
Smad2 Smad family member 2 
Smad3 Smad family member 3 
Smad4 Smad family member 4 
Smad6 Smad family member 6 
Smad7 Smad family member 7 
SNAI1 Snail homolog 1  
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SP1 Sp1 transcription factor 
SPARC Secreted protein acidic and rich in cysteine 
SSFP Steady state free precision 
STAT1 Signal transducer and activator of transcription 1 
STAT6 Signal transducer and activator of transcription 6 
TAK1 Transforming growth factor-β-activated kinase 1 
TD Delayed time 
TGF- β3 Transforming growth factor, beta 3 
TGF-ß Transforming growth factor beta 
TGF-ßR1 Transforming growth factor receptor type 1 
TGF-ßR2 Transforming growth factor receptor type 2 
TGF-β1 Transforming growth factor, beta 1 
TGF-β2 Transforming growth factor, beta 2 
TGF-βR1 Transforming growth factor, beta receptor 1 
TGF-βR2 Transforming growth factor, beta receptor II  
TGIF1 TGF-β-induced factor homeobox 1 
TIMP Tissue inhibitors of metalloproteinases 
TIMP1 Tissue inhibitor of metallopeptidase 1 
TIMP2 Tissue inhibitor of metallopeptidase 2 
TIMP3 Tissue inhibitor of metallopeptidase 3 
TIMP4 Tissue inhibitor of metallopeptidase 4 
TN-C Tenascin C 
TN-X Tenascin X 
TNF Tumour necrosis factor 
TNFa Tumour necrosis factor alpha 
TNNC1 Cardiac Troponin C  
TNNI3 Cardiac Troponin I  
TNNT2 Cardiac Troponin T  
TPM1 alpha-tropomyosin  
TSP Thrombospondin 
TSP-1 Thrombospondin 1 
TSP-2 Thrombospondin 2 
VEGF Vascular endothelial growth factor 
VEGFA Vascular endothelial growth factor A 
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Appendix 2: Patient and control information and consent forms.  
 
 
 
 
INFORMATION ABOUT THE RESEARCH 
 
Measuring Biomarkers in People with Inherited 
Cardiomyopathies (Adult information sheet and consent form 
for Blood and Urine) 
Chief Investigator: Dr. Perry Elliott, Department of Cardiology, The Heart 
Hospital, 16-18 Westmoreland Street, London. W1G 8PH 
 
We would like to invite you to take part in this research study. Before you decide 
if you wish to be enrolled in the study you need to understand why the research 
is being done and what it would involve for you. Please take time to read the 
following information carefully. Ask us if there is anything that is not clear or if 
you would like more information. Take time to decide whether or not you wish 
to take part.  
What is the purpose of the study?  
The aim of this research is to provide a greater understanding of the pathways 
that are involved in the development and progression of inherited 
cardiomyopathies. We also aim to identify markers of disease activity to help in 
routine clinical assessment and management. 
Why have I been invited?  
You have been asked to take part because you have a genetic predisposition 
or have been diagnosed with an inherited cardiomyopathy. 
Do I have to take part?  
There is no obligation on your part to enter this study. It is up to you to decide. 
We will describe the study and go through this information sheet, which we will 
then give to you. If you agree, we will then ask you to sign a consent form to 
show you have agreed to take part. You are free to withdraw at any time, 
without giving a reason. Participation or non participation will not affect the 
standard of care you receive in any way. 
What will happen to me if I take part?  
IMPORTANT: THIS IS NOT A TRIAL OF TREATMENT – YOUR TREATMENT 
DOES NOT CHANGE. 
The investigations and interventions in this research will be a part of the 
investigation and treatment that you would normally receive. The exception to 
this is that we will be required to take an additional sample of blood and urine 
for the purpose of further analysis and investigation.  
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Clinical Assessment and Tests 
Your symptoms will be assessed and recorded during your routine outpatient 
appointment. As a part of the study we will be recording the results of tests that 
you would have done as a routine part of your assessment.  
 
 
Blood and Urine Samples  
As a part of the study we will be analysing your blood and urine. In addition to 
the routine blood test that you normally have done we will require 2 additional 
small tubes of blood and a sample of urine.  
What will happen to any samples I give?  
Samples will be labelled with a unique patient study number. Samples will be 
stored securely and analysed at facilities with in UCLH, GOSH and UCL. 
Access to samples will be restricted to researchers involved in taking 
measurements from them. Samples for the purpose of this study may be sent 
to external laboratories which may be outside the UK. No patient identifiers will 
be sent. At the end of the study the samples may be stored in accordance with 
the Human Tissue Act. Samples will not be used without further consent. 
You may also wish to donate your blood and urine as an absolute and 
unconditional gift. If you do, you will retain no future rights to these samples and 
to any information that may be derived from them. No testing for serious 
communicable disease such as HIV or hepatitis B will be performed on these 
samples.  
Will any genetic tests be done?  
DNA is the hereditary material containing the genetic instructions for 
development and disease.  Analysis of your DNA will NOT be performed. We 
will NOT use these samples to obtain genetic information that may have 
implications for you or your family.  
 
RNA carries the genetic information and chemical “blueprint” that is essential 
for protein synthesis. With your consent we may measure the expression of 
RNA. 
 
What are the possible disadvantages and risks of taking part?  
All aspects of this study are safe.  
What are the possible benefits of taking part?  
To you as an individual, there is little direct benefit. However, the information 
we get from this study will help improve our understanding of the condition and 
will hopefully help us to improve the care we give our patients in the future. 
What if there is a problem?  
As a matter of routine, researchers have to inform all participants in all studies 
about their rights in the unlikely event that harm should occur. This project has 
been approved by an independent research committee who believe the risk to 
participants is minimal. Compensation for any injury caused by taking part in 
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this study is covered under the NHS indemnity scheme. Your right in law to 
claim compensation for injury where you can prove negligence is not affected. 
The ethics committee advises (as a matter of routine) that people with private 
health-care cover should inform their insurers about participation in research 
studies. 
What if I wish to make a complaint? 
Any complaint about the way you have been dealt with during the study or any 
possible harm you might suffer will be addressed. If you have a concern about 
any aspect of this study, you should ask to speak to the researchers who will 
do their best to answer your questions (Contact Dr. Perry Elliott on 
02034567898 ext 64801). If you remain unhappy and wish to complain formally, 
you can do this through the NHS Complaints Procedure. Details can be 
obtained from the hospital.  
Will my taking part in the study be kept confidential?  
Yes. We will follow ethical and legal practice and all information about you will 
be handled in confidence. All information which is collected about you during 
the course of the research will be kept strictly confidential, and any information 
about you which leaves the hospital/surgery will have your name and address 
removed so that you cannot be identified.  
What will happen if I don’t want to carry on with the study?  
We will not perform any further testing on the samples you have provided and 
no further information will be acquired for the research. Information that has 
already been collected may still be used.  
Will your GP be informed of your participation? 
We would routinely inform your GP unless there are any objections.  
What will happen to the results of the research study?  
We intend to publish the results of this study in a medical journal and present 
them at conferences.  
Your individual test results from investigation will be stored and analysed. A 
report of the investigations and the results will be recorded in your clinical notes. 
In the event that we identify a problem not already known about, your clinical 
care provider will be informed. 
Who is organising and funding the research?  
This study is being organised by Dr. Perry Elliott, Reader in inherited cardiac 
disease - The Heart Hospital, UCLH.  
Who has reviewed the study? 
All research in the NHS is looked at by independent group of people, called a 
Research Ethics Committee to protect your safety, rights, wellbeing and dignity. 
This study has been reviewed and given favourable opinion by London – 
Central UCLH Research Ethics Committee. 
Where can I obtain independent advice about whether to enter the study? 
You can ask the UCLH research and development office or consult your GP for 
general advice. 
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Patient Identification Number:   
Study Number: 11/LO/0913 
CONSENT FORM 
Title of Project: Measuring Biomarkers in People with Inherited 
Cardiomyopathies (Adult information sheet and consent form for Blood 
and Urine) 
Name of Researchers: Dr. Perry Elliott. 
 
 
________________    _____________      
_________________  
Name of Patient    Date     Signature  
 
_________________    _____________      _________________ 
Name of Person taking consent   Date     Signature  
When completed, 1 for patient; 1 for researcher site file; 1 (original) to be kept in medical notes  
 
 
 
I confirm that I have read and understood the information sheet 
dated 21/06/2012, version 4 for the above study. I have had the 
opportunity to consider the information, ask questions and have 
any queries answered satisfactorily. 
I understand that my participation is voluntary and that I am free 
to withdraw at any time without giving any reason, without my 
medical care or legal rights being affected.  
I give permission for my blood and urine to be stored indefinitely 
and for further research to be carried out using them with/without 
(delete appropriate) the need to contact me again. I understand 
that no research will be performed unless ethics committee 
approval has been obtained.  (If you do not agree, your sample 
will be destroyed at the end of the study) 
 
I give permission for the measurement and analysis of RNA  
 
I agree to take part in the above study. 
 
I agree that my GP may be informed of my involvement in the 
study. 
 
Please Initial  
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INFORMATION ABOUT THE RESEARCH 
 
Measuring Biomarkers in People with Inherited 
Cardiomyopathies (Adult information sheet and consent form 
for Myocardial Tissue - Controls) 
Chief Investigator: Dr. Perry Elliott, Department of Cardiology, The Heart 
Hospital, 16-18 Westmoreland Street, London. W1G 8PH 
 
We would like to invite you to take part in this research study. Before you decide 
if you wish to be enrolled in the study you need to understand why the research 
is being done and what it would involve for you. Please take time to read the 
following information carefully. Ask us if there is anything that is not clear or if 
you would like more information. Take time to decide whether or not you wish 
to take part.  
What is the purpose of the study?  
The aim of this research is to provide a greater understanding of the pathways 
that are involved in the development and progression of inherited 
cardiomyopathies. We also aim to identify markers of disease activity to help in 
routine clinical assessment and management. 
Why have I been invited?  
You have been asked to take part have because you DO NOT have a genetic 
predisposition or have NOT been diagnosed with an inherited cardiomyopathy 
and have undergone or are undergoing a cardiac biopsy or surgical procedure 
as a part of your routine investigation or treatment. 
Do I have to take part?  
There is no obligation on your part to enter this study. It is up to you to decide. 
We will describe the study and go through this information sheet, which we will 
then give to you. If you agree, we will then ask you to sign a consent form to 
show you have agreed to take part. You are free to withdraw at any time, 
without giving a reason. Participation or non participation will not affect the 
standard of care you receive in any way. 
What will happen to me if I take part?  
IMPORTANT: THIS IS NOT A TRIAL OF TREATMENT – YOUR TREATMENT 
DOES NOT CHANGE. 
The investigations and interventions in this research will be a part of the 
investigation and treatment that you would normally receive. The exception to 
this is that we will store and further analyse the heart tissue obtained at the time 
of biopsy or surgery.  
Clinical Assessment and Tests 
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Your symptoms will be assessed and recorded during your routine outpatient 
appointment. As a part of the study we will be recording the results of tests that 
you would have done as a routine part of your assessment.  
 
 
Cardiac Tissue Samples 
We would like to analyse samples of heart muscle that have been obtained 
during cardiac biopsy or cardiac surgery as a part of your ongoing care. We will 
not obtain extra tissue for the purpose of research.  
What will happen to any samples I give?  
Samples will be labelled with a unique patient study number. Samples will be 
stored securely and analysed at facilities with in UCLH, GOSH and UCL. 
Access to samples will be restricted to researchers involved in taking 
measurements from them. Samples for the purpose of this study may be sent 
to external laboratories which may be outside the UK. No patient identifiers will 
be sent.  At the end of the study the samples may be stored in accordance with 
the Human Tissue Act. Samples will not be used without further consent. 
You may also wish to donate your tissue as an absolute and unconditional gift. 
If you do, you will retain no future rights to your tissue and to any information 
that may be derived from them. No testing for serious communicable disease 
such as HIV or hepatitis B will be performed on these samples.  
Will any genetic tests be done?  
DNA is the hereditary material containing the genetic instructions for 
development and disease.  Analysis of your DNA will NOT be performed. We 
will NOT use these samples to obtain genetic information that may have 
implications for you or your family.  
 
RNA carries the genetic information and chemical “blueprint” that is essential 
for protein synthesis. With your consent we may measure the expression of 
RNA. 
 
What are the possible disadvantages and risks of taking part?  
There are no additional risks to taking part in the research. 
What are the possible benefits of taking part?  
To you as an individual, there is little direct benefit. However, the information 
we get from this study will help improve our understanding of the condition and 
will hopefully help us to improve the care we give our patients in the future. 
What if there is a problem?  
As a matter of routine, researchers have to inform all participants in all studies 
about their rights in the unlikely event that harm should occur. This project has 
been approved by an independent research committee who believe the risk to 
participants is minimal. Compensation for any injury caused by taking part in 
this study is covered under the NHS indemnity scheme. Your right in law to 
claim compensation for injury where you can prove negligence is not affected. 
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The ethics committee advises (as a matter of routine) that people with private 
health-care cover should inform their insurers about participation in research 
studies. 
What if I wish to make a complaint? 
Any complaint about the way you have been dealt with during the study or any 
possible harm you might suffer will be addressed. If you have a concern about 
any aspect of this study, you should ask to speak to the researchers who will 
do their best to answer your questions (Contact Dr. Perry Elliott on 
02034567898 ext 64801). If you remain unhappy and wish to complain formally, 
you can do this through the NHS Complaints Procedure. Details can be 
obtained from the hospital.  
 
Will my taking part in the study be kept confidential?  
Yes. We will follow ethical and legal practice and all information about you will 
be handled in confidence. All information which is collected about you during 
the course of the research will be kept strictly confidential, and any information 
about you which leaves the hospital/surgery will have your name and address 
removed so that you cannot be identified.  
What will happen if I don’t want to carry on with the study?  
We will not perform any further testing on the samples you have provided and 
no further information will be acquired for the research. Information that has 
already been collected may still be used.  
Will your GP be informed of your participation? 
We would routinely inform your GP unless there are any objections.  
What will happen to the results of the research study?  
We intend to publish the results of this study in a medical journal and present 
them at conferences.  
Your individual test results from investigation will be stored and analysed. A 
report of the investigations and the results will be recorded in your clinical notes. 
In the event that we identify a problem not already known about, your clinical 
care provider will be informed.  
Who is organising and funding the research?  
This study is being organised by Dr. Perry Elliott, Reader in inherited cardiac 
disease - The Heart Hospital.  
Who has reviewed the study? 
All research in the NHS is looked at by independent group of people, called a 
Research Ethics Committee to protect your safety, rights, wellbeing and dignity. 
This study has been reviewed and given favourable opinion by London - Central 
Research Ethics Committee. 
Where can I obtain independent advice about whether to enter the study? 
You can ask the UCLH research and development office or consult your GP for 
general advice. 
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Patient Identification Number:   
Study Number: 11/LO/0913 
CONSENT FORM 
Title of Project: Measuring Biomarkers in People with Inherited 
Cardiomyopathies 
(Adult information sheet and consent form for Myocardial Tissue - Controls) 
 
Name of Researchers: Dr Perry Elliott. 
 
 
________________    _____________      
_________________  
Name of Patient    Date     Signature  
 
_________________    _____________      _________________ 
Name of Person taking consent   Date     Signature  
When completed, 1 for patient; 1 for researcher site file; 1 (original) to be kept in 
 
I confirm that I have read and understood the information 
sheet dated 21/06/2012, version 1 for the above study. I 
have had the opportunity to consider the information, ask 
questions and have any queries answered satisfactorily. 
I understand that my participation is voluntary and that I am 
free to withdraw at any time without giving any reason, 
without my medical care or legal rights being affected.  
I give permission for my cardiac tissue to be stored 
indefinitely and for further research to be carried out using 
them with/without (delete appropriate) the need to contact 
me again. I understand that no research will be performed 
unless ethics committee approval has been obtained.  (If you 
do not agree, your sample will be destroyed at the end of the 
study) 
 
I give permission for the measurement and analysis of RNA  
 
I agree to take part in the above study. 
 
I agree that my GP may be informed of my involvement in 
the study. 
 
Please Initial  
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INFORMATION ABOUT THE RESEARCH 
 
Measuring Fibrosis (Scarring) in the Heart with MRI. 
 
Investigators: Dr. James Moon, Dr. Andrew Flett, Dr Dan Sado 
 
We would like to invite you to take part in a research study. Before you decide 
whether you wish to be enrolled in the study you need to understand why the 
research is being done and what it would involve for you. Please take time to 
read the following information carefully. Ask us if there is anything that is not 
clear or if you would like more information. Take time to decide whether or not 
you wish to take part.  
What is the purpose of the study?  
Heart muscle scarring, or fibrosis makes people breathless.  It is difficult to 
measure, especially when it is diffuse.  We want to develop a new technique of 
heart scanning (magnetic resonance scan) which will enable us to measure the 
amount of fibrosis (or scar tissue) in the heart.  
Why have I been invited?  
You have been chosen to take part because you have a condition that is known 
to cause fibrosis of the heart muscle (even though the amount of fibrosis may 
be very small).  
Do I have to take part?  
There is no obligation on your part to enter this study. It is up to you to decide. 
We will describe the study and go through this information sheet, which we will 
then give to you. We will then ask you to sign a consent form to show you have 
agreed to take part. You are free to withdraw at any time, without giving a 
reason. Participation or non participation will not affect the standard of care you 
receive in any way. 
What will happen to me if I take part?  
IMPORTANT: THIS IS NOT A TRIAL OF TREATMENT – YOUR TREATMENT 
DOES NOT CHANGE. 
We are developing a technique to measure fibrosis or scarring in the heart. To 
do this we need to ask you to have a heart scan and during this, some blood 
tests. 
Department of Cardiology 
The Heart Hospital 
16-18 Westmoreland Street 
London. W1G 8PH 
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1. ‘Heart’ scans.  
One of these is an echocardiogram (you may have had this already), a safe test 
using an ultrasound probe on your chest. The other scan is a cardiovascular 
magnetic resonance (CMR) scan. CMR uses a magnet and radio waves to form 
pictures of your heart; there are no known harmful effects (there are no x-rays). 
The scans are highly specialised, so they have to be done at The Heart hospital 
or Great Ormond Street hospital in London.  
What will happen when I come for the scan? 
We ask patients to arrive approximately 20 minutes before their actual CMR 
scan appointment time to do the paper work and get changed into a gown (there 
is a private changing area for this). It is important not to bring metal or jewellery 
into the scanner room (such as wiring or clasps in your bra, or zips, or buckles 
in other clothes). This is because metal interferes with the pictures. We will 
measure your height, and weight. A small cannula (drip) is inserted in to a vein 
in the arm by an experienced doctor/technician. This allows a blood sample to 
be taken and later a small amount of a dye to be given as part of the scan itself. 
This dye is called gadolinium; it is very widely used and usually has no side 
effects at all; very occasionally (less than 1/100 times) it causes a temporary 
mild headache or nausea. The scan itself takes just over an hour. It involves 
lying on your back inside a large open-ended tube (which is the magnet). An 
ECG (heart) monitor (3 sticky pads) is put on the chest and we will ask you to 
hold your breath (for between 2 and 15 seconds) when we are actually taking 
the pictures.  
Are there any side effects from the scan and will it hurt? 
The scanner is noisy but not at all painful. Some people experience feelings of 
claustrophobia during the scan, but there is constant contact via an intercom 
system so you can request the investigation be paused at any time. We can 
play the radio or music (bring your own CD if you wish).  
2. Blood and tissue samples  
We take extra blood when the cannula (‘drip’) is inserted for the dye with the 
heart scan. We need 2-3 small tubes (each about the same as a teaspoon). If 
you have had or are having a heart biopsy already, we would like to be able to 
analyse the histology slides. If this test is not required by your doctor then no 
biopsy will be performed. Participating in the study means you agree to donate 
your blood and tissue as an absolute and unconditional gift to UCL and that you 
will retain no future rights to your blood or to any information that may be 
derived from your blood. 
3. Other Tests 
If you have not had it done previously, we will perform an electrocardiogram 
(ECG). This test involves applying 12 sticky electrodes to your body and takes 
a few minutes to do. It is a perfectly safe test that allows us to assess the 
electrical function of your heart. 
If you have not previously had one, we will also ask you to perform a 
cardiopulmonary exercise test if possible. During this test, you will be asked to 
peddle on an exercise bicycle while breathing into a mask. This allows us to 
	 171	
assess the function of your heart and lungs. Again, this is a very safe test that 
is routinely performed on patients everyday in the NHS. 
What are the possible disadvantages and risks of taking part?  
The MRI scan is very safe.  Patients where there are potential or real problems 
(eg patients with a pacemaker, or severe kidney disease) will not be invited to 
participate in this project.   
What are the possible benefits of taking part?  
To you as an individual, there is little direct benefit except that it will give you 
an idea of how well your heart is functioning. However, the information we get 
from this study will help improve our understanding of heart disease and will 
hopefully help us to improve the care we give our patients in the future. 
 
 
What if there is a problem?  
As a matter of routine, researchers have to inform all participants in all studies 
about their rights in the unlikely event that harm should occur. This project has 
been approved by an independent research committee who believe the risk to 
participants is minimal. Compensation for any injury caused by taking part in 
this study is covered under University College London’s Indemnity Scheme; 
under this arrangement it is not necessary to prove fault/negligence. You are 
also covered against injury caused by negligence by the NHS indemnity 
scheme. Your right in law to claim compensation for injury where you can prove 
negligence is not affected. The ethics committee advises (as a matter of 
routine) that people with private health-care cover should inform their insurers 
about participation in research studies. 
What if I wish to make a complaint? 
Any complaint about the way you have been dealt with during the study or any 
possible harm you might suffer will be addressed. If you have a concern about 
any aspect of this study, you should ask to speak to the researchers who will 
do their best to answer your questions (Contact Andrew Flett / Daniel Sado on 
02075738888 ext 4910) If you remain unhappy and wish to complain formally, 
you can do this through the NHS Complaints Procedure. Details can be 
obtained from the hospital.  
Will my taking part in the study be kept confidential?  
Yes. We will follow ethical and legal practice and all information about you will 
be handled in confidence.  
What will happen if I don’t want to carry on with the study?  
Information collected may still be used. Any stored blood that can still be 
identified as yours will be destroyed if you wish.  
Will my taking part in this study be kept confidential?  
All information which is collected about you during the course of the research 
will be kept strictly confidential, and any information about you which leaves the 
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hospital/surgery will have your name and address removed so that you cannot 
be recognised. 
What will happen to any samples I give?  
We will need to collect blood samples during your MRI to measure the amount 
of contrast. Blood tests will be taken by an experienced researcher qualified to 
do so. Samples will be stored within UCLH. Access to samples will be restricted 
to researchers involved in taking measurements from them. Samples will 
remain in the UK at all times. 
Will any genetic tests be done?  
No 
What will happen to the results of the research study?  
We intend to publish the overall results of this study in a medical journal and 
present them at conferences.  
Your individual test results from the blood and heart scan will be stored and 
analysed. A report of the MRI will be generated and the results will be 
communicated to the doctor who referred you. In the event that the scan 
identifies a problem not already known about, your GP may be informed. Such 
conditions would include scarring from a previous heart attack.  
Who is organising and funding the research?  
This study is being organised by Dr. James Moon, Senior lecturer and Honorary 
Consultant in cardiology – The Heart Hospital. It is being funded by the British 
Heart Foundation charity. 
Who has reviewed the study? 
All research in the NHS is looked at by independent group of people, called a 
Research Ethics Committee to protect your safety, rights, wellbeing and dignity. 
This study has been reviewed and given favourable opinion by UCLH Research 
Ethics Committee. 
Where can I obtain independent advice about whether to enter the study? 
You can ask the UCLH research and development office or consult your GP for 
general advice. 
  
	 173	
 
Patient Identification Number:   
Study Number:  
CONSENT FORM 
Title of Project: Measuring fibrosis (scarring) in the heart with MRI scanning 
Name of Researchers: Dr. Andrew Flett, Dr Dan Sado, Dr. James 
Moon. 
  
1. I confirm that I have read and understand the information sheet 
dated 8/10/2010, version 5 for the above study. I have had the 
opportunity to consider the information, ask questions and have 
had these answered satisfactorily.  
2. I understand that my participation is voluntary and that I am free 
to withdraw at any time without giving any reason, without my 
medical care or legal rights being affected.  
3. I understand that relevant sections of my medical notes and data 
collected during the study may be looked at by members of the 
research team, where it is relevant to my taking part in this 
research. I give permission for these individuals to have access to 
my records.  
4. I give permission for my blood and tissue to be stored indefinitely 
and for further research to be carried out using them without the 
need to contact me again. I understand that no research will be 
performed unless ethics committee approval has been obtained.  
(If you do not agree, your sample will be destroyed at the end of 
the study) 
5. I agree to take part in the above study.  
 
6. I agree that my GP may be informed of my involvement in the 
study. 
 
_________________    _____________      _________________  
Name of Patient    Date     Signature  
 
_________________    _____________      _________________ 
Name of Person taking consent   Date     Signature  
 
 
When completed, 1 for patient; 1 for researcher site file; 1 (original) to be kept in medical notes  
 
Department of Cardiology 
The Heart Hospital 
16-18 Westmoreland Street 
London. W1G 8PH 
Please 
initial box 
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